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3PREFACE
The asbestos epidemic is far from being over. While the use of asbestos has 
been banned in many industrialized countries, and production has been 
stopped in some countries, the global production and use of asbestos remains 
at a high level.  Asbestos is still widely used in many newly industrialized, rap-
idly developing countries. Exposure to asbestos fibres (fibers) may also still oc-
cur in countries that have banned the new use of asbestos in, e.g., demolition 
and asbestos removal activities.  According to the most recent WHO estimate, 
more than 107 000 people die each year from asbestos-related lung cancer, 
mesothelioma and asbestosis resulting from exposure at work (1). 
The first ‘Asbestos, asbestosis, and cancer’ symposium convened in Helsinki 
in 1997 and included 19 participants from eight countries. The purpose of the 
meeting was to “discuss disorders in association with asbestos and to agree 
upon state-of-the-art criteria for diagnosis and attribution with respect to 
asbestos (2, 3), in addition to questions concerning the surveillance of asbes-
tos-exposed workers.” The resulting document was named the Helsinki Crite-
ria. A follow-up Expert Meeting on new advances in radiology and the screen-
ing of asbestos-related diseases was held in 2000 in Helsinki (4, 5).
Since 1997, a considerable amount of new knowledge regarding the diagnosis 
and screening of asbestos diseases has been accumulated. The Finnish Insti-
tute of Occupational Health therefore decided to  integrate this new data into 
the Helsinki Criteria. The updating of the Helsinki Criteria was carried out with 
the help of international experts over a period of two years, with a final  
meeting in Espoo, Finland, on 10–13 February 2014. The conference was 
organized by the Finnish Institute of Occupational Health in collaboration  
with the International Commission on Occupational Health, ICOH. 
The Consensus Report Asbestos, Asbestosis, and Cancer: Helsinki Criteria 
update 2014 (6) summarizes up-to-date information on methods for 
the management and elimination of asbestos-related diseases. We recom-
mend using the updates in programs and practices for the detection, diagno-
sis and attribution of asbestos-related diseases.
We wish to most cordially thank all the international and national experts for 
their important work, Ms. Solveig Borg for her technical assistance, the spon-
sors, The Finnish Work Environment Fund, the Federation of Finnish Learned 
Societies, the Federation of Accident Insurance Institutions, and the Finnish 
Cancer Society for their financial support.
Helsinki June 30th 2014
Harri Vainio and Panu Oksa
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7UPDATING THE HELSINKI CRITERIA
The Finnish Institute of Occupational Health (FIOH) was contacted in 2011 
about updating the Helsinki Criteria by incorporating new research findings 
and accommodating the changes in medical practices and classifications that 
had occurred during recent years. 
To evaluate the need for this, we sent a questionnaire to selected international 
contacts. In the questionnaire, we inquired about various aspects of the Crite-
ria, about policies regarding the surveillance of asbestos-exposed workers, and 
the opinion regarding the need for and focus on updates in the Criteria. 
The answers indicated a considerable variation of opinions, although some 
general trends could be seen. The questionnaires, the possible updates and the 
question of the desirability of an updating process were discussed at an initial 
meeting of international experts and FIOH staff on December 2nd, 2011. As a 
result, preparations for a new meeting began. 
The following subject areas were selected for updating:
1. CT screening for asbestos-related lung cancer
2. Diagnostics and follow-up of asbestos-related diseases
3. New asbestos-related disease entities
4. Pathology and biomarkers.
Subject area 1 is in response to recent research results suggesting that screen-
ing for lung cancer with CT may prevent cancer deaths.
Subject Area 2 is mostly a response to our findings from the questionnaires, i.e. 
that the follow-up of asbestos-related diseases differ substantially.
Subject Area 3 was inspired by the recent IARC review in which the classifica-
tions of some asbestos-related malignancies were upgraded.
Subject Area 4 was included because some classification pathology used in 
the old Criteria is now obsolete. In addition, there was an interest in staying 
abreast of the developments in biomarkers for asbestos-related diseases.
Most subject areas are additions to the old Criteria. Most of the original Cri-
teria remain unchanged. In its concept, this updating process is rather similar 
to the meeting in 2000. The selection of subject areas has thus been driven by 
the perceived need for updates, and this process is not a systematic re-evalua-
tion of the criteria in its entirety.
8For each area, a working group was assembled, with a chairman, one or two 
rapporteurs (members of FIOH staff with special expertise) and three to five 
members.
In the fall of 2012, it was decided that the updating process would be asso-
ciated with an asbestos-related conference, the International Conference on 
Asbestos Monitoring and Health Surveillance in Individuals (Helsinki Asbestos 
2014) on 11–13 February 2014 in Hanasaari Cultural Centre, Espoo, Finland. 
This provided an opportunity to hear views from a wider group of experts.
The conference was organized by the Finnish Institute of Occupational Health 
in collaboration with the InternationalCommission on Occupational Health, 
ICOH.
Each working group created an evidence-based review. The working groups 
first formulated two preliminary drafts, which were circulated among the en-
tire HCU group for comments and then revised. Based on this review, a set of 
recommendations for each subject area was formulated. The recommenda-
tions were then processed at the HCU group pre-conference meeting and the 
ensuing versions of the drafts were discussed at the workshops of the confer-
ence. The modified drafts were presented and discussed in a plenary session 
on the last conference day.   
Much of the original Criteria remain unchanged. In specific issues, some addi-
tions were made to the old Criteria by the Helsinki Criteria Update 2014 group. 
Table 1 summarizes the key points of the 1997 Helsinki criteria and its 2014 
updates. 
9Table 1. Comparison of Helsinki Criteria 1997 and its 2014 update.
Item Helsinki criteria 1997 2014 update 
General 
considerations
Guidelines for identifying asbes-
tos-exposed persons with struc-
tured interview and fibers from 
tissue and BAL specimen given. 
Guidelines for the diagnostics of 
asbestosis, pleural disorders, meso-
thelioma and lung cancer given.
Update concentrates on:
- screening for asbestos-related lung cancer
- follow-up of asbestos-exposed workers and 
  diagnosis of non-malignant asbestos diseases
- new asbestos-related disease entities
- pathology and biomarkers
Asbestos-related 
non-malignant diseases
Roggli-Pratt modification of the CAP 
NIOSH classification of asbestosis 
recommended. 
Radiology: small opacities with ILO 
grade of 1/0 in radiographs regard-
ed as early stage asbestosis, HRCT 
in selected cases. Development 
of standardized reporting of HRCT 
scans recommended.
New histology classification of asbestosis (2) 
adapted.
Criteria for the use of CT imaging in the diag-
nostics of asbestos-related diseases presented. 
Recommendation to use the international ICOERD 
CT classification in international studies.
Retroperitoneal fibrosis described as a new entity 
due to asbestos exposure (under certain condi-
tions).
Asbestos-related 
malignant diseases
• Lung cancer
• Mesothelioma
• Other malignancies
Four types of lung cancer associated 
with asbestos exposure defined. Cu-
mulative exposure of 25 fiber-years 
increases lung cancer risk two-fold. 
Risk estimates also related to tissue 
fiber levels and asbestos bodies in 
BAL fluid. 
Histopathological diagnosis 
discussed  
Discussed as research needs 
The current classification (WHO 1999) includes 
two additional types of lung cancer (sarcomatoid 
and adenosquamous). These are included as types 
of lung malignancies that may occur as a conse-
quence of asbestos exposure.
Additional recommendations for histopathological 
diagnosis given for epithelioid and sarcomatoid 
mesotheliomas, separate recommendations for   
peritoneal mesotheliomas.  
Laryngeal and ovarian cancers viewed as asbes-
tos-caused diseases.
Guidelines for attribution given.
Surveillance and 
screening
Possibilities for primary and 
secondary prevention (screening) 
discussed. Scientific studies on 
screening recommended. Technical 
requirements for HRCT described 
(Helsinki conference in 2000). 
Several research topics suggested.
Medico-legal surveillance (incl. spirometry) rec-
ommended according to the national regulation 
stratified according to the intensity, latency and 
duration of exposure.
Vaccination against influenza and pneumococcus 
recommended for asbestosis patients.
LDCT screening recommended for asbestos-ex-
posed workers with sufficiently high risk of lung 
cancer (see text for details). The importance of 
obtaining standardized data in an international 
setting is stressed.
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Screening for asbestos-related  
lung cancer
Tapio Vehmas, Finnish Institute of Occupational Health, Finland
Riitta Sauni, Ministry of Social Affairs and Health, Finland
Anthony B. Miller, Dalla Lana School of Public Health, University of Toronto, Canada
Kurt Straif, International Agency for Research on Cancer (IARC), France
Nea Malila, Finnish Cancer Register, Finland
Robert A. Smith, Cancer Control Department,  American Cancer Society, 
Atlanta, GA, USA
Objectives: Review the existing literature on the efficacy of lung cancer screen-
ing with low-dose computed tomography (LDCT) in asbestos-exposed workers 
in order to update the 1997 and 2000 Helsinki Criteria during the Internation-
al Conference of Monitoring and Surveillance of Asbestos-Related Diseases, 
10–13 February, Espoo, Finland
Methods: Two separate literature searches were conducted; the first focused 
on the evidence related to the effects of LDCT screening on lung cancer, and 
the second focused on original studies on screening for lung cancer in asbes-
tos-exposed workers.
Results: Three recent systematic reviews of screening for lung cancer with 
LDCT conclude that screening is associated with a reduced risk of lung cancer 
mortality, and that benefits outweigh harms. There is no evidence of benefit 
from screening with chest x-ray. Twelve studies of LDCT screening for lung 
cancer in asbestos-exposed workers principally were case series with a limited 
number of subjects, no control groups and little follow-up data on mortality, 
providing only weak if any inferential evidence about the efficacy of lung can-
cer screening specifically targeted to adults with a history of asbestos expo-
sure.
Conclusions: Adults with a history of exposure to asbestos who meet absolute 
lung risk criteria set by randomized trials and existing lung cancer screening 
guidelines should be offered screening. Study designs that allow for simultane-
ous enrollment of asbestos-exposed workers into a screening program while 
also collecting minimum but essential data are a high priority as are interna-
tional data pooling projects. 
1
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Introduction
Lung cancer is one of the most common and fatal cancers worldwide. 
While long-term exposure to tobacco smoke is the underlying cause of 
most lung cancer, lung cancer accounts for more than half of all occupa-
tional cancers, and it is estimated that between 5% and 7% of newly diag-
nosed cases are attributable to exposure to asbestos, which is by far the 
single most important occupational carcinogen. A greater than additive 
effect modification describes the association between asbestos and ciga-
rette smoke in causing lung cancer (1, 2).  The World Health Organization 
estimates 107 000 people die each year from occupational exposure to 
asbestos, and more than 125 million still are exposed to asbestos in the 
workplace (3).
Lung cancer is most often diagnosed at an advanced stage, which makes 
the prognosis poor. Despite observations of more favorable survival when 
lung cancer was diagnosed at an early stage, early randomized controlled 
trials (RCT) of lung cancer screening with chest X-rays (CXR) failed to 
demonstrate that screening reduced lung cancer mortality (4). The consid-
erable methodological limitations of the CXR RCTs conducted in the 1970s 
were among the reasons that CXR screening was included in the Prostate 
Lung Colorectal and Ovarian Cancer Screening Trial (PLCO), which enrolled 
adults during 1993–2001 (5).  Still, in the PLCO, the risk ratio for lung cancer 
mortality among average risk adults invited to receive four rounds of CXR 
screening was 0.99 (0.81-1.10) compared with the control group, again pro-
viding no evidence of a benefit from screening for lung cancer with CXR (6). 
A recent update of the Cochrane Collaboration review of lung screening 
concluded there was no evidence to justify screening with CXR or sputum 
cytology (7).
Interest in screening for lung cancer with low dose computed tomography 
(LDCT) began to increase during the mid-late 1990s, especially following 
the baseline results of the Early Lung Cancer Action Project (ELCAP), which 
demonstrated substantially better performance in the detection of small, 
favorable stage lung cancers with LDCT compared with CXR (8). Given the 
significantly better prognosis associated with the detection of lung cancers 
early in their natural history, and the superior performance of LDCT com-
pared with CXR, the accumulation of favorable observational evidence led 
to the initiation of RCTs in the U.S. and Europe. The largest RCT of LDCT 
screening conducted to date is the National Lung Screening Trial (NLST) (9), 
which recruited a high risk group of men and women who were current or 
former smokers (quit ≤ 15 years) ages 55–74 who had at least a 30 pack-
year smoking history. The NLST randomized approximately 57 000 study 
subjects to a LDCT arm vs. CXR arm for three rounds of annual screening.  
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At a median of 6.5 years of follow-up, there was a 20% reduction in lung 
cancer mortality in the LDCT arm compared to the CXR arm (95% CI 
6.8%‒26.7%) (9). Further, there also was a significant reduction in mortal-
ity from all causes of 6.7%, of which deaths from lung cancer accounted 
for about half of the difference. RCTs also have been conducted or still are 
underway in Europe. When the three good- or fair-quality trials (1 U.S. trial 
& 2 European trials) were combined in a random effects meta-analysis, the 
relative risk of lung cancer mortality was 0.81 (95% CI, 0.72‒0.91) (10).
While the new data on LDCT screening of smokers is promising, there is 
a need to clarify whether the same principles of LDCT screening could be 
applied to other groups at high risk for lung cancer, and in this context, 
specifically those with prior exposure to asbestos. This paper includes a 
systematic review on CT screening for asbestos-related lung cancer. It also 
reviews the current knowledge on lung cancer screening based on previous 
and recent systematic reviews, compares lung cancer risk-estimation cal-
culators that include asbestos exposure, and provides background data for 
recommendations accepted at the International Conference on Monitoring 
and Surveillance of Asbestos-Related Diseases at Hanasaari, Espoo, Finland 
in February 2014. 
Methods
Two separate literature searches were conducted. First, we searched for 
evidence on the effects of lung cancer screening with LDCT from system-
atic reviews (SR) and second, we searched for original studies on screening 
for lung cancer in asbestos-exposed workers.
PubMed database was searched for SRs on lung cancer screening between 
November 1, 2010 and March 7, 2014 using the following terms: “lung 
neoplasms”[Mesh] AND screening* [tw] AND “Tomography”[Mesh] OR 
tomograph*[tw] OR CT[tw] OR LDCT[tw] AND systematic review [tw] or 
evidence review [tw]. The Cochrane database also was searched using the 
term “lung cancer screening.” Other criteria included English language, 
inclusion of both CXR and LDCT studies, and reviews that met Institute of 
Medicine criteria (11). A total of 67 articles were identified, and three re-
cent SRs met the inclusion criteria (7, 10, 12).
In order to retrieve papers on CT screening for lung cancer among asbes-
tos-exposed workers, PubMed database was searched until Mar 3, 2014 
using terms “Tomography”[Mesh] OR tomograph*[tw] OR CT[tw] OR 
LDCT[tw] OR CECT[tw]) AND asbest* AND (“Lung Neoplasms”[Mesh] OR 
“lung cancer”[tw]. This search strategy yielded 158 articles. Original pa-
pers in English language describing primary lung cancer screening studies, 
whether case series or comparative studies, were accepted. 
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Review articles and case reports were excluded. Articles were first evalu-
ated by title, then by abstract and if not clear whether to include or not, by 
full text. The evaluation was carried out by two reviewers (RS and TV) in 
consensus. Twelve papers fulfilling the inclusion criteria were accepted.
Results
Three recent SRs of lung cancer screening that included LDCT studies and 
the recent U.S. NLST were identified. Two of the SRs were updates of prior 
SRs of lung cancer screening conducted for the Cochrane Collaboration 
(13) and the United States Preventive Services Task Force (USPSTF),(14), 
while the third was conducted principally by the American Society of Clin-
ical Oncology (ASCO) for a consortium of U.S. organizations preparing to 
issue lung cancer screening guidelines (12). The description of SRs is given 
in Table 1. One SR focused exclusively on RCTs of LDCT screening in adults 
at high risk of lung cancer due to smoking history (12), while the other SRs 
included RCTs and cohort studies of imaging exams (LDCT and CXR) as well 
as sputum cytology in average risk adults and adults at high risk based on 
smoking history (7, 10). None of the SRs addressed asbestos exposure as 
a risk factor for lung cancer, or screening outcomes in the context of as-
bestos exposure. The primary outcome in each SR was lung cancer specific 
mortality, although two SRs also included all-cause mortality (10, 12). The 
SRs also focused on secondary outcomes including cancer detection rate 
(CDR), nodule detection rate (NDR), recall rate, stage at diagnosis, survival, 
harms of screening (interval imaging, invasive procedures, complications, 
post-operative deaths, incidental findings), costs, quality of life, and the 
effect of screening on smoking cessation.
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Table 1: Systematic Reviews of Lung Cancer Screening with LDCT
Comparison
Systematic Reviews of Lung Cancer Screening
ACS, ACCP, ASCO, NCCN ( 2012)12 Cochrane (2013)7 USPSTF (2013)10
Update of previ-
ous review?
No Yes (1999, 2004,13 20107) Yes (200414)
Literature 
period
1996–4/2012 1996–5/2012 2000–2012
Literature 
sources
Ovid, EMBASE, Cochrane, refer-
ence lists; published data only.
EMBASE, MEDLINE, PREMED-
LINE, Cochrane, Lung Cancer 
(up to 2000); Contact with 
experts to identify other data 
sources
MEDLINE, Cochrane, Scopus, 
reference lists
Target popula-
tion
Individuals at elevated risk of 
developing lung cancer because 
of age and smoking history
Not specified Asymptomatic men and wom-
en at average risk or current 
and former smokers at high 
risk
Intervention(s) LDCT screening Alone or in combination--CXR, 
CT, sputum examinations
Alone or in combination-- 
LDCT, CXR, sputum cytology 
Target audience 
for 
the review
Physicians, allied professionals, 
and policy makers.
Not specified Not specified
Inclusion criteria RCTs and cohort studies of LDCT 
screening for lung cancer (English 
only)
RCTs of screening for lung 
cancer using sputum exam-
inations, chest radiography or 
chest CT
RCTs and cohort studies that 
evaluated screening or treat-
ment interventions for lung 
cancer and reported health 
outcome (English only)
Exclusion cri-
teria
Studies that only assessed screen-
ing among participants with risk 
factors other than smoking (eg, 
asbestos), meta-analysis or case 
series reports of outcomes only 
among patients diagnosed with 
lung cancer
Non-controlled trials, Studies, 
trials without disease specific 
mortality as an outcome, and 
trials with < 5 years follow-up. 
By Key Question: children, 
symptomatic, prior lung 
cancer, no screening, cost 
effectiveness, editorials, case 
reports, studies without com-
parison group, sample sizes 
< 1000, or < 500, < 5 years of 
follow-up
Asbestos ad-
dressed
No Some literature evident, but 
no focus on asbestos exposure
Described as a risk factor, and 
evident in excluded literature
Primary out-
come
Lung cancer mortality
All-cause mortality
Lung cancer mortality Lung cancer mortality
All-cause mortality
Lung cancer incidence
Other outcomes Nodule detection rate; Frequency 
of additional imaging; Frequency 
of invasive diagnostic procedures 
(e.g., needle or bronchoscopic 
biopsy, surgical biopsy, surgical 
resection); Complications from 
the evaluation of suspected lung 
cancer; Rate of smoking cessation 
or re-initiation.
Compliance with screening 
and follow up; Incidence of 
lung cancer; Five-year survival; 
Stage at diagnosis; Resection 
rate; Postoperative deaths; 
Harms of screening, including 
adverse outcomes from fur-
ther diagnostic testing in those 
who have a positive result on 
initial screening; Costs;
Quality of life
Reduction in lung cancer 
morbidity; 
five-year and ten-year surviv-
al rates; Impact on smoking 
cessation; 
Detection of other abnormal-
ities; Quality of life; Direct 
harms from screening and/or 
treatment interventions 
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Table 1: Systematic Reviews of Lung Cancer Screening with LDCT
Comparison
Systematic Reviews of Lung Cancer Screening
ACS, ACCP, ASCO, NCCN ( 2012)12 Cochrane (2013)7 USPSTF (2013)10
CONCLUSIONS—BENEFITS & HARMS
Disease specific 
mortality
“Low-dose computed tomogra-
phy screening may benefit individ-
uals at an increased risk for lung 
cancer, but uncertainty exists 
about the potential harms of 
screening and the generalizability 
of results.”
“Annual low-dose CT screening 
is associated with a reduction 
in lung cancer mortality in 
high-risk smokers but further 
data are required on the cost 
effectiveness of screening and 
the relative harms and benefits 
of screening across a range 
of different risk groups and 
settings.”
 “Strong evidence shows that 
LDCT screening can reduce 
lung cancer and all-cause 
mortality.”
Cost effective-
ness
Cost-effectiveness of LDCT screening for lung cancer was not addressed in any of the systematic 
reviews
False positives The review notes that the rate 
of harms associated with LDCT 
is high, although considerable 
variation was observed within and 
between study designs.
The review notes that false posi-
tive rates based on nodule cate-
gorization or screening protocols 
often are inconsistent—some-
times unclear if FP rates are based 
on newly identified nodules, or 
are assigned to the current round 
or to an earlier round if they can 
be seen retrospectively. Also, size 
thresholds for workup vary and 
are inconsistently reported, as 
are the potential denominators 
for estimating false-positive rates, 
such as per screening round or 
per person-year.
The review notes that the rate 
of false positive examinations 
associated with LDCT screen-
ing is high.
Range from 9.2% to 51%; (PPV 
ranging from 2.2% to 36%); 
Most FP resolved with addi-
tional imaging. 
Biopsy Rates described The biopsy rate associated 
with positive findings is rela-
tively low
Rates described, along with 
PPV. The majority of biopsies 
performed were for cancer, 
not benign disease, with 
positive predictive values for 
invasive procedures or biopsy 
ranging from 50 to 92 percent.
Harms due to 
interventions, 
including death
Described as low. The review 
notes that the only study de-
scribing complications from LDCT 
screening was the NLST
Described, but conclusion is 
that benefits likely exceed 
harms
Clear description of the bal-
ance of benefits and harms, 
concludes that benefits out-
weigh harms
Radiation risk Addressed, noting that benefit of 
screening exceeds possible inci-
dence/mortality association with 
radiation exposure
Described in discussion in con-
text of follow-up for positive 
findings, relies on Brenner’s 
estimates from 2004
Described in the discussion as 
a theoretical harm
Incidental 
findings
Not noted Not noted Noted as a harm, most com-
monly reported findings were 
emphysema and coronary 
artery calcifications
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Table 1: Systematic Reviews of Lung Cancer Screening with LDCT
Comparison
Systematic Reviews of Lung Cancer Screening
ACS, ACCP, ASCO, NCCN ( 2012)12 Cochrane (2013)7 USPSTF (2013)10
Anxiety Uncertain Not assessed Individuals with positive or 
indeterminate exams showed 
some short-term increases 
in anxiety and distress, but 
not long-term; patients with 
negative scans had a reduction 
in distress.
Smoking 
behavior
Insufficient evidence to conclude 
that screening contributes to 
higher quit rates
Insufficient evidence from lit-
erature to assess the impact of 
screening on smoking behavior
Individuals with positive or in-
determinate screens showed a 
trend toward reduced smoking 
or sustained abstinence
Quality of life The effect of LDCT on quality of 
life is uncertain
None of the studies included 
in the review assessed the 
impact of screening on quality 
of life.
Overall, LDCT screening did 
not appear to significantly 
impact overall health-related 
quality of life
Overdiagnosis The overdiagnosis rate for LDCT 
screening cannot yet be estimat-
ed; NLST data show a persistent 
gap of about 120 excess lung 
cancers in the LDCT group vs. 
the chest radiographs group, but 
further follow-up is needed.
Note…inappropriate to conclude 
that the gap is persistent, since 
this would imply that the entirety 
of the overdiagnosis was attribut-
able to the prevalent screen. 
Acknowledges possibility 
of overdiagnosis. Counsels 
against drawing conclusions 
from Mayo. Notes excess 
incidence in NLST 5 years 
after cessation of screening 
(119 cases), and further notes 
the excess number of BACs 
(adenocarcinoma in situ) in the 
CT arm (95 vs. 13), speculating 
that excess incidence may be 
mostly attributable to BAC 
lesions, which have very good 
survival, but also longer lead 
time. Also concludes NLST is 
not a good source of overdi-
agnosis estimates due to 
inclusion of CXR arm.
Magnitude is uncertain.
MAIN 
CONCLUSIONS
LDCT screening may benefit 
individuals at an increased risk 
for lung cancer, but uncertainty 
exists about the potential harms 
of screening and the generalizabil-
ity of results.
Conclusions from previous 
systematic reviews altered by 
new data from NLST and PLCO. 
Annual LDCT is associated with 
a reduction in lung cancer 
death in high risk smokers and 
former smokers. 
Further data are required 
on the cost effectiveness of 
screening, and the relative 
harms and benefits of screen-
ing across a range of different 
risk groups and settings. 
Good evidence shows LDCT 
can significantly reduce 
mortality from lung cancer. 
However, there are significant 
harms associated with screen-
ing that must be balanced with 
the benefits.
Abbreviations: ACS, American Cancer Society; ACCP, American College of Chest Physicians;  
ASCO, American Society of Clinical Oncology; NCCN, National Comprehensive Cancer Network; USPSTF, United States 
Preventive Services Task Force; LDCT, low dose computed tomography; CXR, chest x-ray; NLST, National Lung Screen-
ing Trial; PLCO, Prostate, Lung, Colorectal, and Ovarian Trial
Table 1: Systematic Reviews of Lung Cancer Screening with LDCT
Comparison
Systematic Reviews of Lung Cancer Scre ning
ACS, ACCP, ASCO, NCCN ( 2012)12 Cochrane (2013)7 USPSTF (2013)10
CONCLUSIONS—BENEFITS & HARMS
Disease specific 
mortality
“Low-dose computed tomogra-
phy scre ning may benefit individ-
uals at an increased risk for lung 
cancer, but uncertainty exists 
about the potential harms of 
scre ning and the generalizability 
of results.”
“Annual low-dose CT scre ning 
is as ociated with a reduction 
in lung cancer mortality in 
high-risk smokers but further 
data are required on the cost 
effectivenes  of scre ning and 
the relative harms and benefits 
of scre ning acros  a range 
of different risk groups and 
settings.”
 “Strong evidence shows that 
LDCT scre ning can reduce 
lung cancer and all-cause 
mortality.”
Cost effective-
nes
Cost-effectivenes  of LDCT scre ning for lung cancer was not addres ed in any of the systematic 
reviews
False positives The review notes that the rate 
of harms as ociated with LDCT 
is high, although considerable 
variation was observed within and 
betwe n study designs.
The review notes that false posi-
tive rates based on nodule cate-
gorization or scre ning protocols 
often are inconsistent—some-
times unclear if FP rates are based 
on newly identified nodules, or 
are as igned to the cur ent round 
or to an earlier round if they can 
be se n retrospectively. Also, size 
thresholds for workup vary and 
are inconsistently reported, as 
are the potential denominators 
for estimating false-positive rates, 
such as per scre ning round or 
per person-year.
The review notes that the rate 
of false positive examinations 
as ociated with LDCT scre n-
ing is high.
Range from 9.2% to 51%; (P V 
ranging from 2.2% to 36%); 
Most FP resolved with addi-
tional imaging. 
Biopsy Rates described The biopsy rate as ociated 
with positive findings is rela-
tively low
Rates described, along with 
P V. The majority of biopsies 
performed were for cancer, 
not benign disease, with 
positive predictive values for 
invasive procedures or biopsy 
ranging from 50 to 92 percent.
Harms due to 
interventions, 
including death
Described as low. The review 
notes that the only study de-
scribing complications from LDCT 
scre ning was the NLST
Described, but conclusion is 
that benefits likely exce d 
harms
Clear description of the bal-
ance of benefits and harms, 
concludes that benefits out-
weigh harms
Radiation risk Addres ed, noting that benefit of 
scre ning exce ds pos ible inci-
dence/mortality as ociation with 
radiation exposure
Described in discus ion in con-
text of follow-up for positive 
findings, relies on Brenner’s 
estimates from 2004
Described in the discus ion as 
a theoretical harm
Incidental 
findings
Not noted Not noted Noted as a harm, most com-
monly reported findings were 
emphysema and coronary 
artery calcifications
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Comparison
Systematic Reviews of Lung Cancer Screening
ACS, ACCP, ASCO, NCCN ( 2012)12 Cochrane (2013)7 USPSTF (2013)10
CONCLUSIONS—BENEFITS & HARMS
Disease specific 
mortality
“Low-dose computed tomogra-
phy screening may benefit individ-
uals at an increased risk for lung 
cancer, but uncertainty exists 
about the potential harms of 
screening and the generalizability 
of results.”
“Annual low-dose CT screening 
is associated with a reduction 
in lung cancer mortality in 
high-risk smokers but further 
data are required on the cost 
effectiveness of screening and 
the relative harms and benefits 
of screening across a range 
of different risk groups and 
settings.”
 “Strong evidence shows that 
LDCT screening can reduce 
lung cancer and all-cause 
mortality.”
Cost effective-
ness
Cost-effectiveness of LDCT screening for lung cancer was not addressed in any of the systematic 
reviews
False positives The review notes that the rate 
of harms associated with LDCT 
is high, although considerable 
variation was observed within and 
between study designs.
The review notes that false posi-
tive rates based on nodule cate-
gorization or screening protocols 
often are inconsistent—some-
times unclear if FP rates are based 
on newly identified nodules, or 
are assigned to the current round 
or to an earlier round if they can 
be seen retrospectively. Also, size 
thresholds for workup vary and 
are inconsistently reported, as 
are the potential denominators 
for estimating false-positive rates, 
such as per screening round or 
per person-year.
The review notes that the rate 
of false positive examinations 
associated with LDCT screen-
ing is high.
Range from 9.2% to 51%; (PPV 
ranging from 2.2% to 36%); 
Most FP resolved with addi-
tional imaging. 
Biopsy Rates described The biopsy rate associated 
with positive findings is rela-
tively low
Rates described, along with 
PPV. The majority of biopsies 
performed were for cancer, 
not benign disease, with 
positive predictive values for 
invasive procedures or biopsy 
ranging from 50 to 92 percent.
Harms due to 
interventions, 
including death
Described as low. The review 
notes that the only study de-
scribing complications from LDCT 
screening was the NLST
Described, but conclusion is 
that benefits likely exceed 
harms
Clear description of the bal-
ance of benefits and harms, 
concludes that benefits out-
weigh harms
Radiation risk Addressed, noting that benefit of 
screening exceeds possible inci-
dence/mortality association with 
radiation exposure
Described in discussion in con-
text of follow-up for positive 
findings, relies on Brenner’s 
estimates from 2004
Described in the discussion as 
a theoretical harm
Incidental 
findings
Not noted Not noted Noted as a harm, most com-
monly reported findings were 
emphysema and coronary 
artery calcifications
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Comparison
Systematic Reviews of Lung Cancer Screening
ACS, ACCP, ASCO, NCCN ( 2012)12 Cochrane (2013)7 USPSTF (2013)10
Anxiety Uncertain Not assessed Individuals with positive or 
indeterminate exams showed 
some short-term increases 
in anxiety and distress, but 
not long-term; patients with 
negative scans had a reduction 
in distress.
Smoking 
behavior
Insufficient evidence to conclude 
that screening contributes to 
higher quit rates
Insufficient evidence from lit-
erature to assess the impact of 
screening on smoking behavior
Individuals with positive or in-
determinate screens showed a 
trend toward reduced smoking 
or sustained abstinence
Quality of life The effect of LDCT on quality of 
life is uncertain
None of the studies included 
in the review assessed the 
impact of screening on quality 
of life.
Overall, LDCT screening did 
not appear to significantly 
impact overall health-related 
quality of life
Overdiagnosis The overdiagnosis rate for LDCT 
screening cannot yet be estimat-
ed; NLST data show a persistent 
gap of about 120 excess lung 
cancers in the LDCT group vs. 
the chest radiographs group, but 
further follow-up is needed.
Note…inappropriate to conclude 
that the gap is persistent, since 
this would imply that the entirety 
of the overdiagnosis was attribut-
able to the prevalent screen. 
Acknowledges possibility 
of overdiagnosis. Counsels 
against drawing conclusions 
from Mayo. Notes excess 
incidence in NLST 5 years 
after cessation of screening 
(119 cases), and further notes 
the excess number of BACs 
(adenocarcinoma in situ) in the 
CT arm (95 vs. 13), speculating 
that excess incidence may be 
mostly attributable to BAC 
lesions, which have very good 
survival, but also longer lead 
time. Also concludes NLST is 
not a good source of overdi-
agnosis estimates due to 
inclusion of CXR arm.
Magnitude is uncertain.
MAIN 
CONCLUSIONS
LDCT screening may benefit 
individuals at an increased risk 
for lung cancer, but uncertainty 
exists about the potential harms 
of screening and the generalizabil-
ity of results.
Conclusions from previous 
systematic reviews altered by 
new data from NLST and PLCO. 
Annual LDCT is associated with 
a reduction in lung cancer 
death in high risk smokers and 
former smokers. 
Further data are required 
on the cost effectiveness of 
screening, and the relative 
harms and benefits of screen-
ing across a range of different 
risk groups and settings. 
Good evidence shows LDCT 
can significantly reduce 
mortality from lung cancer. 
However, there are significant 
harms associated with screen-
ing that must be balanced with 
the benefits.
Abbreviations: ACS, American Cancer Society; ACCP, American College of Chest Physicians;  
ASCO, American Society of Clinical Oncology; NCCN, National Comprehensive Cancer Network; USPSTF, United States 
Preventive Services Task Force; LDCT, low dose computed tomography; CXR, chest x-ray; NLST, National Lung Screen-
ing Trial; PLCO, Prostate, Lung, Colorectal, and Ovarian Trial
Table 1: Systematic Reviews of Lung Cancer Screening with LDCT
Comparison
Systematic Reviews of Lung Cancer Scre ning
ACS, ACCP, ASCO, NCCN ( 2012)12 Cochrane (2013)7 USPSTF (2013)10
CONCLUSIONS—BENEFITS & HARMS
Disease specific 
mortality
“Low-dose computed tomogra-
phy scre ning may benefit individ-
uals at an increased risk for lung 
cancer, but uncertainty exists 
about the potential harms of 
scre ning and the generalizability 
of results.”
“Annual low-dose CT scre ning 
is as ociated with a reduction 
in lung cancer mortality in 
high-risk smokers but further 
data are required on the cost 
effectivenes  of scre ning and 
the relative harms and benefits 
of scre ning acros  a range 
of different risk groups and 
settings.”
 “Strong evidence shows that 
LDCT scre ning can reduce 
lung cancer and all-cause 
mortality.”
Cost effective-
nes
Cost-effectivenes  of LDCT scre ning for lung cancer was not addres ed in any of the systematic 
reviews
False positives The review notes that the rate 
of harms as ociated with LDCT 
is high, although considerable 
variation was observed within and 
betwe n study designs.
The review notes that false posi-
tive rates based on nodule cate-
gorization or scre ning protocols 
often are inconsistent—some-
times unclear if FP rates are based 
on newly identified nodules, or 
are as igned to the cur ent round 
or to an earlier round if they can 
be se n retrospectively. Also, size 
thresholds for workup vary and 
are inconsistently reported, as 
are the potential denominators 
for estimating false-positive rates, 
such as per scre ning round or 
per person-year.
The review notes that the rate 
of false positive examinations 
as ociated with LDCT scre n-
ing is high.
Range from 9.2% to 51%; (P V 
ranging from 2.2% to 36%); 
Most FP resolved with addi-
tional imaging. 
Biopsy Rates described The biopsy rate as ociated 
with positive findings is rela-
tively low
Rates described, along with 
P V. The majority of biopsies 
performed were for cancer, 
not benign disease, with 
positive predictive values for 
invasive procedures or biopsy 
ranging from 50 to 92 percent.
Harms due to 
interventions, 
including death
Described as low. The review 
notes that the only study de-
scribing complications from LDCT 
scre ning was the NLST
Described, but conclusion is 
that benefits likely exce d 
harms
Clear description of the bal-
ance of benefits and harms, 
concludes that benefits out-
weigh harms
Radiation risk Addres ed, noting that benefit of 
scre ning exce ds pos ible inci-
dence/mortality as ociation with 
radiation exposure
Described in discus ion in con-
text of follow-up for positive 
findings, relies on Brenner’s 
estimates from 2004
Described in the discus ion as 
a theoretical harm
Incidental 
findings
Not noted Not noted Noted as a harm, most com-
monly reported findings were 
emphysema and coronary 
artery calcifications
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The SRs all resulted in the conclusion that an invitation to annual lung can-
cer screening with LDCT in adults at high risk for lung cancer was associat-
ed with a reduction in lung cancer mortality (7, 10, 12), and all-cause mor-
tality (10, 12). The SRs that assessed the benefit of an invitation to CXR or 
sputum cytology found no evidence of benefit of either test (7, 10). The SRs 
also noted that the rate of harms associated with lung cancer screening 
with LDCT was high, although the predominant harm was being recalled for 
further evaluation and short-term follow-up, and most abnormal findings 
were resolved with additional imaging. By comparison, false positive biop-
sy rates were fairly low, and positive predictive values associated with bi-
opsy were high (10). While the SRs noted other harms (radiation exposure, 
incidental findings, anxiety associated with false positives, overdiagnosis), 
none were judged to alter the favorable balance of benefits to harms.  Per-
haps the harm that is the greatest concern is that screening for lung cancer 
with LDCT results in overdiagnosis, defined as the detection of lung cancers 
that never would have become apparent or life threatening if the patient 
had not undergone screening. Each SR concluded that the occurrence of 
overdiagnosis is possible, but that presently the magnitude was uncertain. 
Recently, NLST investigators estimated that LCDT screening in the NLST re-
sulted in 18% of screen-detected cancers being over-diagnosed (15); how-
ever, the magnitude of this estimate has been challenged on the basis of 
inadequate follow-up of the NLST cohort and several other factors (16,17). 
In the 12 published papers on lung cancer screening in asbestos-exposed 
workers included in this review, the description of asbestos exposure com-
monly was vague and divergent (such as “definite” or “in contact with as-
bestos”) (Table 2). Only one paper makes fiber calculations (18). Only a sin-
gle paper provided a clear lower limit for asbestos exposure as an inclusion 
criterion (19). Only four studies described set inclusion criteria based on 
smoking history, which varied from any smoking history to minimum pack-
year thresholds (20–23) and three studies set pack-year thresholds at ten 
or 20 years based on asbestos exposure/non-exposure (20–22).  Ten papers 
provided participants’ smoking data, i.e. pack-years or smoking category 
(non-smoker or never-smoker, ex-smoker, current smoker). The mean/
median age of study subjects was provided in 11 papers, with only five 
providing clear inclusion criteria based on the minimum age of study sub-
jects, which typically was age 40 or 50 years, while upper age limits were 
described in four papers ranging from age 70–80 years.  One paper provid-
ed no age data. Inclusion/exclusion criteria other than asbestos exposure, 
smoking, or age was provided in seven papers. Three papers required 
good physical condition or capability for surgery of the subjects, while five 
papers required no previous cancer or symptoms of cancer being present. 
The number of workers participating in the included baseline screenings 
varied from 169 to 5662. 
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Ten papers gave at least some technical detail on the CT procedure (Table 
3). Single slice technology was used in six studies with slice thickness of 5 
mm in two studies (19, 24) and 10 mm in four studies (20, 22, 23, 25). Mul-
tislice/multidetector technology (MSCT) was used in four studies (21, 26–
28) and in two studies there was no description of the imaging parameters 
(18, 29). The milliampers (mA) varied from 10 to 125. Only the study by Das 
and colleagues (26) calculated effective dose (average 1.1. mSv). This study 
had the lowest mA values compared to other papers when mA values were 
noted, suggesting that higher radiation doses may apply to the rest of the 
studies.
There was a great variation in the definition of positive findings in screen-
ing. The ELCAP protocol (8) was referred to in two papers (18, 28); 5 papers 
gave their own nodule millimeter criteria for a positive finding, ranging 
from 2 to 6 mm in non-calcified solid nodules, one defined positive lesions 
as those under 20 mm, and the remainder were non-specific. Eight papers 
reported the results of baseline (prevalence) screening, while there were at 
least elements of repeat (incidence) screening in four papers. 
None of the studies had a control group, but one compared the lung cancer 
incidence to that of the regional register of residents and found no signifi-
cant difference (18). In two studies CT was compared to the performance 
of chest radiographs with the same patients (19, 24). 
In the included asbestos screening studies, the proportion of subjects with 
suspicious lung lesions varied from 6.1% to 57% (Table 4). Other incidental 
findings varied from 1.9% to 69.2%, with the wide range attributable to 
variable criteria for noting incidental findings. The number of lung cancers 
detected varied from 0.2% to 4.8% in the baseline (prevalence) screenings.  
One study found as many screen-detected mesotheliomas as lung cancers 
(28), and in two studies only 1 out of 5 screen-detected lung cancers was 
operated (18, 22).
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Table 2. Patient characteristics in CT screening projects among asbestos-exposed workers
Author (Yr.) Number 
screened
Age, yrs. Asbestos exposure Smoking history* Other inclusion/exclusion criteria
Callol (2007)20 466 1st 
round;
406 2nd 
round
50‒73
mean 60.5
In contact with asbestos 
at work
> 20 P-Y
> 10 P-Y (+ asbestos)
Incl: good physical condition, absence of neoplastic antecedents
Excl: Not amenable to surgery, other cancer, pregnancy
Clin (2009)19 719 50‒75
mean 61.3
High continued exposure 
> 1 y
High discontinued expo-
sure ≥ 10 y
NR** Asymptomatic for cancer
No contraindication for surgery
Clin (2011)29 5662 mean 63.02 Low - High Not required
Smoking category given for 
subjects with and without 
lung nodules
Register based volunteers
Das (2007)26 187 45‒75
 mean 66.6
16-45 y;  = 30 
High risk power-plant 
workers
NS=01%
FS=10%
CS=89%
Not reported
Fasola (2007)24 1045 40‒75
mean 58
Definite, median 30 yrs. Not required
Median 18.5 P-Y
No prior cancer
No suspicion on lung cancer
No chest CT during previous 2 years
Greenberg (2012)2012 1182 > 50
 mean 63.0
307 (26%) with asbestos 
exposure
>20 P-Y;  = 42 High-risk urban cohort
No prior cancer or chemotherapy
Loewen (2007)27 169 37‒83 70 (39.3%) with asbestos 
exposure
 P-Y = 58 High risk cohorts from several sources:
asbestos-exposed
anamnestic aerodigestive cancer with no evidence of disease for > 2 y
COPD patients
2 of 4 risk factors present, one of which could be asbestos-related lung disease 
on chest radiograph
Lynch (1988)25 260 NR Latency from initial asbes-
tos exposure > 10 y 
NR CT performed due to a mismatch of b-readers interpretation on the presence of 
asbestosis or pleural disease
Mastrangelo (2008)18 1119 (58% 
of invited)
 mean 57.1 All asbestos-exposed
 = 17.7yrs.
 =123 fiber/ml x y
NS=35%
FS=47.2%
CS=17.8%
Retired asbestos workers from companies’ registers
Roberts (2009)28 516 32‒83
mean 60.0
Asbestos exposure > 20 y 
ago or pleural plaques 
NS=23.4%
FS=56.4%
CS=20.2%
Volunteers from occupational health clinics and from workers’ unions etc.
Good health, no prior cancer
Tiitola  (2002)22 602 38‒81
mean 63.0
Asbestosis
Pleural plaques and smok-
ing > 10 p-y
>10 P-Y, if no asbestosis 
diagnosis 
P-Y  = 24 yrs.
Volunteers recognized from previous (non-CT) screening programs, occupational 
wards and trade union registers
Vierikko (2007)23 633 had 
HRCT;
180 also 
spiral CT
45‒86
mean 64.0
Spiral CT:
< 70 y
Asbestosis
Pleural plaques
Current or ex- smoker 
required for spiral CT
NS=22.0%
FS=58.0%
CS=19.9%
P-Y  = 17.2 yrs.
Volunteers recognized from previous screening programs, occupational wards
Spiral CT exclusion: non-operable
* NS=Non-smoker; FS=Former smoker; CS=Current smoker; P-Y = pack-years (
years of smoking multiplied by average number of packs, or fraction thereof, per day); ** NR=Not reported
* NS=Non-s oker; FS=For er s oker; CS=Current s oker; P-Y = pack-years (years of smoking multiplied 
by average number of packs, or fraction thereof, per day); ** NR=Not reported
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Table 2. Patient characteristics in CT screening projects among asbestos-exposed workers
Author (Yr.) Number 
screened
Age, yrs. Asbestos exposure Smoking history* Other inclusion/exclusion criteria
Callol (2007)20 466 1st 
round;
406 2nd 
round
50‒73
mean 60.5
In contact with asbestos 
at work
> 20 P-Y
> 10 P-Y (+ asbestos)
Incl: good physical condition, absence of neoplastic antecedents
Excl: Not amenable to surgery, other cancer, pregnancy
Clin (2009)19 719 50‒75
mean 61.3
High continued exposure 
> 1 y
High discontinued expo-
sure ≥ 10 y
NR** Asymptomatic for cancer
No contraindication for surgery
Clin (2011)29 5662 mean 63.02 Low - High Not required
Smoking category given for 
subjects with and without 
lung nodules
Register based volunteers
Das (2007)26 187 45‒75
 mean 66.6
16-45 y;  = 30 
High risk power-plant 
workers
NS=01%
FS=10%
CS=89%
Not reported
Fasola (2007)24 1045 40‒75
mean 58
Definite, median 30 yrs. Not required
Median 18.5 P-Y
No prior cancer
No suspicion on lung cancer
No chest CT during previous 2 years
Greenberg (2012)2012 1182 > 50
 mean 63.0
307 (26%) with asbestos 
exposure
>20 P-Y;  = 42 High-risk urban cohort
No prior cancer or chemotherapy
Loewen (2007)27 169 37‒83 70 (39.3%) with asbestos 
exposure
 P-Y = 58 High risk cohorts from several sources:
asbestos-exposed
anamnestic aerodigestive cancer with no evidence of disease for > 2 y
COPD patients
2 of 4 risk factors present, one of which could be asbestos-related lung disease 
on chest radiograph
Lynch (1988)25 260 NR Latency from initial asbes-
tos exposure > 10 y 
NR CT performed due to a mismatch of b-readers interpretation on the presence of 
asbestosis or pleural disease
Mastrangelo (2008)18 1119 (58% 
of invited)
 mean 57.1 All asbestos-exposed
 = 17.7yrs.
 =123 fiber/ml x y
NS=35%
FS=47.2%
CS=17.8%
Retired asbestos workers from companies’ registers
Roberts (2009)28 516 32‒83
mean 60.0
Asbestos exposure > 20 y 
ago or pleural plaques 
NS=23.4%
FS=56.4%
CS=20.2%
Volunteers from occupational health clinics and from workers’ unions etc.
Good health, no prior cancer
Tiitola  (2002)22 602 38‒81
mean 63.0
Asbestosis
Pleural plaques and smok-
ing > 10 p-y
>10 P-Y, if no asbestosis 
diagnosis 
P-Y  = 24 yrs.
Volunteers recognized from previous (non-CT) screening programs, occupational 
wards and trade union registers
Vierikko (2007)23 633 had 
HRCT;
180 also 
spiral CT
45‒86
mean 64.0
Spiral CT:
< 70 y
Asbestosis
Pleural plaques
Current or ex- smoker 
required for spiral CT
NS=22.0%
FS=58.0%
CS=19.9%
P-Y  = 17.2 yrs.
Volunteers recognized from previous screening programs, occupational wards
Spiral CT exclusion: non-operable
* NS=Non-smoker; FS=Former smoker; CS=Current smoker; P-Y = pack-years (
years of smoking multiplied by average number of packs, or fraction thereof, per day); ** NR=Not reported
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Table 3: Intervention and control characteristics in CT screening projects among 
asbestos-exposed workers
Author, 
year
CT methodology 
(slice thickness, 
mA etc.)
Definition of positive 
finding*
Screening type: 
Baseline/repeat 
interval/duration
Control group
Callol 
(2007)20
10 mm, 50 mA No lower limit two rounds/two-
year interval
No
Clin 
(2009)19 5 mm, 50 mA 1-6 nodules > 2 mm 
diameter
1‒3 rounds
CT compared to chest 
X-ray among the same 
patients
Clin 
(2011)29
NR Lesion > 5 mm or
“requiring surveillance 
“ or “suspicious”
Baseline No
Das 
(2007)26
MSCT, 10‒20 mA Nodule > 6 mm Baseline analyzed
(annual screening 
on-going)
No
Fasola 
(2007)24
5 mm, 40 mA NCNs, or CNs  >20 mm 
with malignant pattern
Baseline CT compared to chest 
X-ray among the same 
patients
Greenberg 
(2012)2012
MSCT, 40‒80 mA, 
various scanners
Nodule ≥ 4 mm Baseline No
Loewen 
(2007)27
MSCT, mA? “Clinically significant 
parenchymal abnor-
mality”
Baseline No
Lynch 
(1988)25
10 mm, mA? NR Baseline No
Mastrangelo 
(2008)18
Not reported ELCAP protocol Baseline Cancer incidence com-
pared to that 
in the population
Roberts 
(2009)28
MSCT, 50‒60 mA ELCAP criteria
SNs ≥ 5 mm
NSNs  ≥ 8 mm
>1 round in 
356/516 (on-go-
ing), annual
No
Tiitola  
(2002)22
10 mm, 125 mA NCNs > 5 mm Baseline No
Vierikko  
(2007)23
Spiral CT: 10 mm, 
36‒110 mA
NCNs, non-fatty nod-
ules
Baseline No
* NCNs=Noncalcified nodules; CNs=Calcified nodules; NSNs = Non-solid nodules; SNs=Solid nodules
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Table 3: Intervention and control characteristics in CT screening projects among 
asbestos-exposed workers
Author, 
year
CT methodology 
(slice thickness, 
mA etc.)
Definition of positive 
finding*
Screening type: 
Baseline/repeat 
interval/duration
Control group
Callol 
(2007)20
10 mm, 50 mA No lower limit two rounds/two-
year interval
No
Clin 
(2009)19 5 mm, 50 mA 1-6 nodules > 2 mm 
diameter
1‒3 rounds
CT compared to chest 
X-ray among the same 
patients
Clin 
(2011)29
NR Lesion > 5 mm or
“requiring surveillance 
“ or “suspicious”
Baseline No
Das 
(2007)26
MSCT, 10‒20 mA Nodule > 6 mm Baseline analyzed
(annual screening 
on-going)
No
Fasola 
(2007)24
5 mm, 40 mA NCNs, or CNs  >20 mm 
with malignant pattern
Baseline CT compared to chest 
X-ray among the same 
patients
Greenberg 
(2012)2012
MSCT, 40‒80 mA, 
various scanners
Nodule ≥ 4 mm Baseline No
Loewen 
(2007)27
MSCT, mA? “Clinically significant 
parenchymal abnor-
mality”
Baseline No
Lynch 
(1988)25
10 mm, mA? NR Baseline No
Mastrangelo 
(2008)18
Not reported ELCAP protocol Baseline Cancer incidence com-
pared to that 
in the population
Roberts 
(2009)28
MSCT, 50‒60 mA ELCAP criteria
SNs ≥ 5 mm
NSNs  ≥ 8 mm
>1 round in 
356/516 (on-go-
ing), annual
No
Tiitola  
(2002)22
10 mm, 125 mA NCNs > 5 mm Baseline No
Vierikko  
(2007)23
Spiral CT: 10 mm, 
36‒110 mA
NCNs, non-fatty nod-
ules
Baseline No
* NCNs=Noncalcified nodules; CNs=Calcified nodules; NSNs = Non-solid nodules; SNs=Solid nodules
Table 4: Outcome in CT screening projects among asbestos-exposed workers* 
Author,
year
Patients with 
suspicious lung 
lesions
Patients with 
other inciden-
tal findings
# False nega-
tives/ interval 
cancers
# Lung 
cancers
Complica-
tions, radia-
tion dose
Behavioral 
aspects, 
smoking, 
anxiety etc.
Other  
comments
Callol 
(2007)20
1st round =98 
(21%)
2nd round = + 9 
(2.2%)
9 (1.9%) NR 1st round = 
1/466 (0.2%);
2nd round =
4/406 (1%)
NR NR NR
Clin 
(2009)19
23% NR NR 2.16% NR NR NR
Clin 
(2011)29
933 (16.5%) NR NR 50/5662 (0.9%) NR NR NR
Das 
(2007)26
Total 163/187 
(87.7%)
6‒10 mm 
nodules 57/187 
(30.5%)
13/187 (7.0%) NR 9/187 (4.8%) Mean effec-
tive dose 1.1 
mSv
Thin slices as-
sociated with 
increased posi-
tive findings
Fasola 
(2007)24
44% Pleural abnor-
malities (44%)
1 thymic carci-
noid
NR 9/1045 (0.86%) NR NR NR
Greenberg 
(2012)2012
52% Emphysema 
35.6%
NR 30/1182 (2.5%) NR NR NR
Loewen 
(2007)27
93/169 (57%) NR 4/13 (31%) All modalities
13/169 (7%) 
With CT 9/169 
(5.3%)
NR NR NR
Lynch 
(1988)25
16/260 (6.2%) Fissural plaque 
6
Fibrotic bands 3
Rounded atelec-
tasis 8
NR 2/260 (0.77%) NR NR NR
Mastrangelo 
(2008)18
242/1119 (21%) Pleural plaques
32%
0% based on 
passive surveil-
lance of hos-
pital discharge 
registers
5/1119 (0.4%) NR Smoking 
cessation rec-
ommended
244 962 € 
cost/lung 
ca detected 
(only one was 
treatable)
Roberts 
(2009)28
All nodules 
371/516 (71.9%)
Screen positives 
91/516 (17.6%)
two pleural and 
two peritoneal 
mesotheliomas,
69.2% pleural 
plaques
four interval 
cancers found
4/516 (0.8%) 
prevalence 
lung ca, 2/356 
(0.6%) inci-
dence lung ca
Rate of 
invasive 
procedures 
1.1-1.9% of 
scans
NR NR
Tiitola  
(2002)22
111/602(18.5%), 
recognized by 
at least 2/3 
observers
one peritoneal 
mesothelioma
two additional 
lung cancers 
reported in 
cancer registry 
after three yrs: 
not retrospec-
tively visible in 
scans
5/602 (0.8%) NR NR 3 cancers 
potentially 
operable; only 
1 operated 
for various 
reasons
Vierikko 
(2007)23
86/633 (13.6%) Patients with 
incidental 
findings, 
277/633 
(46.2%),
46 requiring 
further 
examinations
NR 5/633 (0.8%) NR NR NR
* NR indicates no reported data in the paper; **NCNs=Noncalcified nodules; CNs=Calcified nodules; 
   NSNs = Non-solid nodules; SNs=Solid nodules
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Discussion
The SRs included in this review did not focus on asbestos-exposed indi-
viduals, but they offer high quality evidence on the methods, benefits and 
potential harms associated with LDCT screening for lung cancer in high-risk 
current and former smokers. The data provided by the NLST study per-
suaded a number of U.S. organizations to issue recommendations for LDCT 
lung cancer screening using the same, or nearly the same, criteria for the 
target population as were used as criteria for eligibility to participate in the 
NLST (30–34), while European countries are awaiting the results of their 
RCTs currently underway (35).
All three SRs resulted in the conclusion that LDCT screening in high-risk 
smokers and former smokers is associated with a reduction in mortality 
from lung cancer. However, all three SRs expressed concerns about the 
high initial rate of false positive findings, and stressed that many key as-
pects of LDCT screening for lung cancer remain uncertain. This latter is not 
unexpected soon after the demonstration of the efficacy of a screening 
test, since experience and evidence on the effectiveness of cancer screen-
ings accumulates over time after implementation and as protocols evolve. 
For example, data are needed on the cost effectiveness of screening that 
takes into account the frequency of screening and costs associated with 
various management strategies for adults with positive test results. Lung 
cancer screening will be a work in progress for the foreseeable future. 
We could find only 12 articles on LDCT lung cancer screening among asbes-
tos-exposed subjects that met the inclusion criteria. This number is surpris-
ingly low, because asbestos exposure is a well-known risk factor for lung 
cancer and many asbestos-exposed workers around the world have been 
and are regularly tested with CXR and high-resolution CT (HRCT) examina-
tions, despite lack of supporting evidence for their effectiveness. 
The number of lung lesions detected in these studies showed a wide range, 
which was most likely due to the different selection criteria of the subjects, 
the varying definitions of positive findings, observer factors and CT tech-
nology. The same also applies to secondary findings. Callol et al. (20) found 
suspicious lung lesions among 21% of the participants during their baseline 
screening, but only among 2.2% during their second screening round. This 
was likely due to the fact that they had previous images for comparison in 
the 2nd round. All studies of LDCT screening (in high-risk smokers and in 
asbestos-exposed workers) have shown a high rate of positive findings on 
baseline screening (of which the large majority are false positives), with a 
considerable decline in the recall rate in subsequent rounds. For example, 
in the review of Bach et al. (12), the average nodule detection rate per 
screening round was 20%. This rate varied from 3% to 30% in RCTs and 5% 
to 51% in the cohort studies. In NLST, the detection rate did not decrease 
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until the third round, but the persistence of an elevated rate of positive 
findings was largely due to the protocol, which defined a positive finding at 
screening automatically positive on the next examination (9). 
The published articles of asbestos-exposed persons have been case series 
with a limited number of subjects, no control groups and little follow-up 
data on mortality, providing only weak if any inferential evidence about the 
efficacy of lung cancer screening specifically targeted to adults with a his-
tory of asbestos exposure. A recent systematic review of LDCT screening of 
adults with occupational exposure to asbestos by Ollier, et al. (36) reached 
the same conclusions that are reached here, i.e., there is little evidence to 
measure the efficacy of lung cancer screening in asbestos-exposed adults, 
but the available evidence indicates that LDCT screening in this population 
detects asymptomatic lung cancer at a favorable stage similar to the per-
formance that has been observed in high risk former and current smokers. 
Therefore, at this time the assessment of how asbestos-exposed workers 
should be followed mainly must be based on risk assessment and the out-
come of the RCTs of LDCT screening for lung cancer in high-risk smokers. 
There are a limited number of tools for assessing absolute risk of lung can-
cer based on combined asbestos exposure and smoking history. With the 
exception of one study (26) in our review, there were no risk calculations 
to guide the identification of adults at high risk due to asbestos exposure 
or the combination of asbestos exposure and smoking. Das and colleagues 
(26) selected their subjects by using “an empiric lung cancer risk calcula-
tion” [age (years)/50] x 3 x asbestos exposure time (years) x smoking habits 
(non-smoker = 0.1, ex-smoker = 0.3, smoker = 1), although neither relative 
nor absolute risks were provided. At present, most lung cancer screening 
guidelines define risk-based eligibility for screening based on the same 
combination of age and smoking history that was used in the NLST (9), 
and several qualify adults for screening at a younger age and with fewer 
pack-years of smoking if one or more established risk factors (including 
asbestos exposure) are present (30, 31). Insofar as asbestos exposure, and 
the combination of asbestos exposure and smoking history, are associated 
with elevated risk for lung cancer, there is a need to identify the risk levels 
appropriate for screening among asbestos-exposed adults, and the degree 
to which the age/exposure indications that contribute to an absolute risk 
threshold in current and former smokers are appropriate for adults with a 
history of asbestos exposure.  In the meantime, there are a number of lung 
cancer risk assessment models (37), and several lung cancer risk calculators 
that include both smoking history and asbestos exposure, in addition to 
other relevant patient history factors (37).  
The Memorial Sloan Kettering lung cancer prediction model (MSK; also 
known as the Bach Model) was derived from subjects enrolled in the Caro-
tene and Retinol Efficacy Trial (CARET) (38). The CARET study had enrolled 
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18 172 subjects from two populations, one of which was a cohort of 4060 
men ages 45–69 years who were current or former smokers and had either 
radiographic evidence of asbestos exposure, or an employment history 
(minimum duration of 5 years) in an occupation at high risk for asbestos ex-
posure. A history of asbestos exposure was independently associated with 
a 24% increase in the risk of lung cancer (HR=1.24, 95% CI 1.04‒1.48; P=.02).  
The model is available on the internet as a decision tool that predicts the ab-
solute risk of lung cancer death over a six-year period in a 1000 adults who 
do and do not undergo screening with LDCT (39).
The Liverpool Lung Project (LLP, www.MyLungRisk.org) model was devel-
oped using data from the LLP case control study and is distinct from the 
MSK model in that it calculates lung cancer risk among current, former, and 
never smokers, while also including other important risk factors including 
asbestos exposure. Asbestos exposure was determined by collecting an 
occupational history using specialized tools, after which an expert judged 
the likelihood of asbestos exposure, frequency, and intensity of exposure. 
Since an underlying priority for the development of the model was to use 
only variables easily assessed by clinicians, asbestos exposure was positive 
if an individual was exposed for at least 1 year of their working life (40, 41). 
As was the case in the MSK model, exposure to asbestos was an indepen-
dent, statistically significant risk factor for lung cancer. After adjustment for 
occupational confounders, the overall risk of lung cancer based on asbestos 
exposure was 1.51 (95% CI: 1.02–2.04).  The LLP model highlights the degree 
to which smoking history confers a substantial increased risk for lung cancer 
when combined with family history, asbestos exposure, etc., but also reveals 
that combinations of risk factors in never smokers also can elevate the abso-
lute risk of lung cancer risk above the threshold presently used in guidelines 
for lung cancer screening. For example, Cassidy, et al. (40) observed that 
a male, never smoker, aged 67 with a personal history of cancer, a family 
history of lung cancer, and a history of exposure to asbestos had an absolute 
risk of lung cancer in the next five years of 3.16%.
The Institute of Cancer Policy (ICP) has an on-line lung cancer risk calculator 
that addresses some of the limitations described above by combining five 
risk calculators (38, 40, 42–44) into a single risk calculator that plots and 
displays the results of each (45). Since three of the models include asbestos 
exposure, it is possible for any given smoking history to observe how 
the addition of occupational asbestos exposure modifies the absolute risk 
estimate over time. 
Table 5 shows absolute risks of lung cancer using the ICP calculator for com-
binations of smoking history and occupational asbestos exposure, with es-
timates of five, six, and ten-year absolute risks of lung cancer in current and 
former smokers with and without asbestos exposure using the Tammemagi 
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(smoking history only), LLP, and MSK models. The Tammemagi model is 
included for comparison because it was the basis for estimating absolute 
risk for the NLST (44, 46). In these examples, we vary age, smoking status 
and history, and asbestos exposure for white males with a body mass index 
(BMI) of 25, no coronary obstructive pulmonary disease (COPD), emphyse-
ma, chronic bronchitis, and no personal history of cancer or family history 
of lung cancer. All current and former smokers began smoking at age 18, 
smoked 20 cigarettes per day, and all former smokers quit ten years prior 
to their current age. As would be expected, there is a substantial increase 
in risk as years of smoking increases, and in all instances risk is higher for 
current smokers compared with former smokers with and without prior 
occupational exposure to asbestos. Likewise, in all instances, current and 
former smokers with prior asbestos exposure have higher absolute five- 
and ten-year risks compared with adults without asbestos exposure. 
These models also reveal the degree to which adults ages 55 years and 
older with a smoking history less than 30 pack-years still exceed the ab-
solute risk threshold for the NLST (1.34% over 6 years) if asbestos expo-
sure and other risk factors (family history, emphysema, exposure to dust, 
pneumonia, COPD, etc.) are present. Further refinement of risk estimation 
algorithms, absolute risk thresholds for screening eligibility, and provider 
access to simple, easy to use risk calculators is a high priority as lung 
cancer screening programs are implemented.
34
Table 5: Absolute Risk of Lung Cancer* Among Current and Former by Asbestos Exposure  
Age Tammemagi 
(6 yr. risk)
LLP 
(5 yr. risk)
LLP-A 
(5 yr. risk)
MSK** 
(10 yr. risk)
MSK-A 
(10 yr. risk)
CS FS CS FS CS FS CS FS CS FS
55 1.5% 0.6% 0.7% 0.6% 1.1% 1.1% 2.4% 1.0% 5.0% 1.2%
60 2.6% 1.1% 3.2% 1.1% 5.8% 2.1% 6.6% 2.1% 8.0% 2.6%
65 4.5% 1.9% 4.6% 1.7% 8.4% 3.1% 9.3% 4.0% 11.4% 4.9%
70 7.5% 3.2% 6.0% 6.0% 10.7% 10.7% 12.3% 6.5% 14.8% 7.9%
75 12.3% 5.5% 9.0% 9.0% 15.8% 15.8% - 8.8% - 10.6%
* The hypothetical subjects are white males ages 55‒75, high school graduates with BMI = 25, no COPD, 
emphysema, chronic bronchitis, and no personal or family history of lung cancer. Each initiated smoking 
at age 18, and smoked 20 cigarettes per day. CS= current smoker; FS=former smoker (quit ten years 
from current age, i.e., 55 yrs. old CS has 37 pack-years, FS has 27 pack-years); A = Asbestos exposure; 
MSK = Memorial Sloan Kettering model; LLP = Liverpool Lung Project model;
**The MSK model requires smoking duration of 25‒55 years
Table 5: Absolute Risk of Lung Cancer* Among Current and Former Smokers by Asbestos 
Exposure
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Several important caveats about these risk calculators are worth noting. 
First, absolute risk estimations using these models are shown here simply 
to demonstrate the greater than additive effect of asbestos exposure to 
lung cancer risk in the context of the lung cancer risk levels used by cur-
rent lung cancer screening guidelines. None of these models presently 
is endorsed by any organization as a basis for decisions about screening, 
and as with all risk calculators, each achieves only modest discriminatory 
power. Second, while the models produce similar absolute risks for some 
age, pack-year combinations, at other levels the estimates are dissimilar, 
which likely is due to the different populations and underlying exposures 
from which the risk estimates are generated, as well as different approach-
es to model inputs. For example, model inputs for exposures differ in that 
some are categorical, some are continuous, and some have minimum and 
maximum thresholds, resulting in the paradoxical appearance of similar 
absolute lung cancer risks for adults with very different exposure histories. 
Finally, it is not clear how the interplay between cumulative exposures of 
asbestos exposure and tobacco exposure modify the age-incidence curve, 
resulting in uncertainty about the interplay between absolute risk and the 
age to begin screening. 
Recommendations
Current U.S. organization recommendations for lung cancer screening are 
presented in Table 6. Most of the recommendations have adapted the 
inclusion criteria of the NLST. At the moment there are no clear data for 
how these guidelines can be adapted to asbestos-exposed persons. 
While the NCCN and the American Association for Thoracic Surgery have 
endorsed screening between ages 50–74 for adults with a 20 pack-year his-
tory of smoking if they also have one additional risk factor for lung cancer 
(i.e., a family history, a history of occupational exposure to asbestos, etc.) 
this recommendation appears to be based on a general approximation of 
the greater than additive risk of multiple risk factors for lung cancer.  How-
ever, no risk calculator reveals risk levels approaching the NLST criteria for 
a 50-year-old man with a 20 pack-year history with either a family history 
or occupational exposure to asbestos. 
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Table 5: Absolute Risk of Lung Cancer* Among Current and Former by Asbestos Exposure  
Age Tammemagi 
(6 yr. risk)
LLP 
(5 yr. risk)
LLP-A 
(5 yr. risk)
MSK** 
(10 yr. risk)
MSK-A 
(10 yr. risk)
CS FS CS FS CS FS CS FS CS FS
55 1.5% 0.6% 0.7% 0.6% 1.1% 1.1% 2.4% 1.0% 5.0% 1.2%
60 2.6% 1.1% 3.2% 1.1% 5.8% 2.1% 6.6% 2.1% 8.0% 2.6%
65 4.5% 1.9% 4.6% 1.7% 8.4% 3.1% 9.3% 4.0% 11.4% 4.9%
70 7.5% 3.2% 6.0% 6.0% 10.7% 10.7% 12.3% 6.5% 14.8% 7.9%
75 12.3% 5.5% 9.0% 9.0% 15.8% 15.8% - 8.8% - 10.6%
* The hypothetical subjects are white males ages 55‒75, high school graduates with BMI = 25, no COPD, 
emphysema, chronic bronchitis, and no personal or family history of lung cancer. Each initiated smoking 
at age 18, and smoked 20 cigarettes per day. CS= current smoker; FS=former smoker (quit ten years 
from current age, i.e., 55 yrs. old CS has 37 pack-years, FS has 27 pack-years); A = Asbestos exposure; 
MSK = Memorial Sloan Kettering model; LLP = Liverpool Lung Project model;
**The MSK model requires smoking duration of 25‒55 years
Table 6: Lung Cancer Screening Recommendations from U.S. Organizations
Society* Year Age 
range
Minimum 
pack-
years 
(P-Y) **
Former 
Smokers- 
Years since 
cessation
Additional 
risk factors 
considered
Other Considerations***
ACS33 2013 55‒74 ≥30 ≤ 15 No Adults who are candidates for screening 
should engage in a process of shared decision 
making; Screening only should be done in 
an institution that supports multidisciplinary 
teams, and has experience with LDCT imag-
ing. Recommend against chest radiograph 
for screening. Strong emphasis on smoking 
cessation for current smokers.
USPSTF32 2014 55‒80 ≥30 ≤ 15 No Adults who are candidates for screening 
should engage in a process of shared decision 
making; Once former smokers have reached > 
15 years since smoking cessation, they should 
stop screening. 
ACCP34 2013 55‒74 ≥30 ≤ 15 No Screening only should be done in an institu-
tion that supports multidisciplinary teams, 
and has experience with LDCT imaging.
ASCO12 2013 55‒74 ≥30 ≤ 15 No Screening only should be done in an institu-
tion that supports multidisciplinary teams, 
and has experience with LDCT imaging.
ALA48 2012 55‒74 ≥30 ≤ 15 No No history of lung cancer; Screening only 
should be done in an institution that supports 
multidisciplinary teams, and has experience 
with LDCT imaging. Strong emphasis on smok-
ing cessation for current smokers; Recom-
mend against chest radiograph for screening; 
Screening centers should develop ethical 
practices for advertising and promotion;
NCCN30 2012 55‒74 ≥30 ≤ 15 Yes Adults with one or more risk factors in 
addition to smoking history (i.e., asbestos or 
other occupational hazards, radon exposure, 
family history, personal cancer history, COPD, 
pulmonary fibrosis may begin screening if 
they are age 50 and have a ≥ 20 P-Y history of 
smoking.
AATS31 2012 55‒74 ≥30 ≤ 15 Yes Adults with one or more risk factors in 
addition to smoking history (i.e., asbestos or 
other occupational hazards, radon exposure, 
family history, COPD with FEVI < 70%, cancer/
thoracic radiation, pulmonary fibrosis, and 
> 5% absolute risk of developing lung cancer 
within the next 5 years may begin screening 
if they are age 50 and have a ≥ 20 P-Y history 
of smoking
* ACS=American Cancer Society; USPSTF=United States Preventive Services Task Force; ACCP= American College 
of Chest Physicians; ASCO=American Society of Clinical Oncology; ALA=American Lung Association; NCCN=
National Comprehensive Cancer Network; AATS=American Association of Thoracic Surgeons.
** Pack-years is a unit for measuring smoking history, and is calculated by multiplying the number of packs of 
cigarettes smoked per day by years smoked, i.e. 1 pack-year = 1 pack per day for 1 year, or 2 pack years = 2 packs 
per day for 1 year.
*** All organizations recommend that candidates for screening should be in good health and not have any life-
limiting co-morbidity that would preclude curative treatment.
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However, according to the LLP model, a 60-year-old man with a ten-pack 
year history, asbestos exposure, and a family history of either early or 
late-onset lung cancer exceeds NLST absolute risk thresholds. Thus, there 
is an urgent need to further study asbestos-exposed adults to determine 
how to accurately estimate absolute risk of lung cancer based on actual or 
approximations of asbestos exposure alone or combined with smoking his-
tory and other risk factors, and to determine the benefits, adverse effects, 
and economic issues concerning their inclusion in LDCT screening for lung 
cancer. Ongoing studies, preferentially RCTs, with sufficient power may 
still provide an opportunity to identify study subjects with prior asbestos 
exposure, either in individual trials, or through data pooling projects. Well- 
designed cohort studies may also be useful, but in either case, it is critically 
important that there is adherence to a common methodology so that me-
ta-analysis is possible going forward.  
The optimal screening interval for lung cancer may not be dependent on 
the underlying risk factors, but more work on estimating risk-based sojourn 
times will need to be done before this statement can be made with greater 
confidence. Pastorino et al. (47) detected more cancer with annual vs. bi-
ennial screening, but did not observe a survival benefit with either interval 
compared to the control arm; in contrast, the NLST observed a mortality 
reduction associated with annual screening (9). Given the high costs associ-
ated with lung cancer screening, the question of whether wider screening 
intervals might be equally effective among all or some subgroups undergo-
ing screening will likely be a focus of future investigations. 
The responsibility for screening should be nationally or regionally organized 
so that preferably a single unit/institute would be in charge for the whole 
process. This includes the organization of screening, quality control, the 
collection and analysis of all data on benefits, complications and economic 
issues. The organizer should have sufficient expertise on epidemiology, 
pulmology, radiology and other relevant sciences. The participating units 
should be included in the most feasible manner nationally and educated in 
a sufficient manner. 
In conclusion, at this time there is limited evidence to guide risk estimation 
and LDCT screening in workers at high risk for lung cancer due to asbestos 
exposure with or without a history of smoking. However, based on the 
favorable outcome of the lung cancer LDCT screening studies, the dose–re-
sponse risk of lung cancer in asbestos-exposed workers, and the well-es-
tablished greater than additive contribution to risk in adults exposed to 
both asbestos and tobacco smoke, it is reasonable to recommend that 
adults with asbestos exposure be evaluated for eligibility for lung cancer 
screening. Those adults with prior exposure to asbestos who are in reason-
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ably good health and who are at or above the risk threshold set for partic-
ipation in the NLST, whether based on smoking history, the combination of 
asbestos exposure and smoking history, or asbestos exposure alone should 
be considered for screening for lung cancer. 
Much work remains to be done related to risk estimation for lung cancer 
screening eligibility, especially the interplay between age, smoking history, 
other exposures to tobacco smoke, and other risk factors such as occupa-
tional history or genetic predisposition. Going forward it is imperative that 
efforts are focused on answering these key questions about lung cancer 
risk, patient selection, and the benefits and harms of lung cancer screening 
in asbestos-exposed adults. 
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Introduction 
Based on the two International Expert Meetings in Helsinki: Asbestos, Asbes-
tosis and Cancer, 1997 and New Advances in Radiology and Screening of As-
bestos-Related Diseases, 2000 (1, 2), the Helsinki Criteria for the diagnosis and 
follow-up of asbestos-related diseases were developed.  Now, 13–16 years later 
due to new knowledge in the field, together with the fast development of new 
imaging techniques for early diagnosis of pulmonary effects related to asbestos 
exposure, it seems it is time to discuss the need for updating these criteria. This 
paper will focus on criteria for the follow-up of asbestos-exposed workers and 
the diagnosis of non-malignant asbestos diseases. It will address recommenda-
tions for the follow-up of asbestos-exposed workers, related to non-malignant 
outcomes, such as asbestosis and pleura plaque, and also discuss diagnostic 
criteria and classification systems based on new imaging techniques, such as 
HRCT.
  Follow-up of asbestos-exposed workers
What is the role of the imaging methods: plain radiograph, HRCT, 
spiral CT, others? 
The traditional method for medical screening of asbestos-exposed workers has 
been the conventional chest radiograph, with standardized interpretation using 
the ILO system for classification of radiographs for pneumoconiosis (3). 
The recommended follow-up routines for the radiological follow-up of asbestos- 
exposed workers differ between countries, as exemplified in Table 1, which is 
based on questionnaire information recently received from some of the partici-
pants of the Helsinki Criteria Conference in 2000, and the available literature.   
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Table 1.  Recommended radiological follow-up schema of asbestos-exposed workers in some countries.  
Country Method  Interval Comment Reference
Italy Chest x-ray 
or CT 
 Left to 
occupational 
physician’s 
decision*
The occupational physician 
responsible for health sur-
veillance should decide on 
further examinations.
Legislative Decree 81/08 and 
subsequent modifications 
and integrations; art. 259 
Guidelines – Health surveillance of 
workers exposed to carcinogen and/
or mutagenic substances at 
the workplace edited by Italian 
Society of Occupational Health and 
Industrial Hygiene (SIMLII), 2007,  
Latest update 2013
UK “Specific exam-
ination of the 
chest”
At least two 
years
Health records are kept for 
at least 40 years from the 
date of last entry.
Health and Safety, 2012 No. 632. 
The Control of Asbestos Regulations 
2012 
U.S. Chest X-ray One to five 
years depend-
ing on age and 
latency
Only required of current 
workers
OSHA (U.S. Federal government) 
[https://www.osha.gov/pls/oshaweb/
owadisp.
show_document?p_table=
standards&p_id=9995]
Canada,
Ontario
Occupational health is 
a provincial, not federal 
responsibility. 
No regulations specifying follow-up 
of exposed workers
Japan Chest X-ray Twice a year Subjects are present and 
past workers who handle 
asbestos as well as indi-
rectly exposed workers. 
Laws and ordinances under the 
framework of the Industrial Safety 
and Health Law
http://www.mhlw.go.jp/new-info/
kobetu/roudou/sekimen/iryo/
Finland Chest X-ray 1st before 
work, 2nd  after 
ten years, and 
thereafter 
every three 
years
Goverment Regulation 1485/2001; 
Nordman et al. 2006 (4)
Norway Chest X-ray Only the first 
x-ray is com-
pulsory  
There is no systematic 
national follow-up of pre-
vious asbestos-exposed 
workers for non-malignant 
asbestos diseases.
Employees allowed to remove 
asbestos at present are followed 
according to EU regulations.
Sweden Chest X-ray Biannually It is recommended that ex-
aminations continue after 
cessation of exposure, but 
this is not mandatory.
Swedish Work Environment Author-
ity: Provisions and general recom-
mendations: 2006:6, Occupational 
medical supervision.
Korea Chest X-ray Annually Retired workers included Guideline for Health Examination
(in Korean).
Germany Chest X-ray Every one to 
three years
Retired workers included, 
high risk workers** low 
dose CT yearly 
DGUV 2010 (5) and Kraus 2014 (6)
* Italy: Health examination of workers should be carried out: a) at beginning of employment, b) in periodical checkups 
(at least once every three years or according to occupational physician’s decision) and planned follow-ups on retirement. 
They should include at least the following measures: 1) keeping records of a worker’s medical and occupational history, 
2) a general clinical examination, with particular reference to the chest and 3) lung function tests.
** Definition of the high risk group in Germany: first exposure before 1985, at least ten years of exposure, more than 
30 pack years tobacco smoking, age at least 55 years of age, fit for thoracic surgery, no previous lung cancer.
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From this table, it seems that the chest X-ray still is the dominant method of 
radiological follow-up of asbestos-exposed workers. However, several coun-
tries have now introduced HRCT for the radiological follow-up of asbestos-ex-
posed workers, either as a supplementary method to the chest X-ray, or as a 
substitute for the traditional chest X-ray. The national recommendations in this 
field, however, seem to be primarily related to the early detection of asbes-
tos-related lung cancer, and not so much to non-malignant pulmonary effects. 
In addition, it seems that the current national follow-up regulations of asbestos 
workers are developed more for medico-legal and compensation purposes 
than based on pure, medical criteria.   
HRCT is used if possible in the diagnosis of asbestosis. The poor sensitivity and 
specificity of radiographs to detect lung fibrosis have become well known in 
the use of CT/HRCT (7, 8, 9) (Figure 1). The correlation between the ILO score 
and the HRCT fibrosis score was 0.41, giving the coefficient of determination 
(r2) of only 0.17, which indicates the proportion of variance in HRCT fibrosis 
explained by the ILO score. While lung tissue can be directly visualized with CT/
HRCT, radiographs have poorer contrast resolution, are disturbed by superpos-
ing soft tissues, and are more liable to be affected by patients’ positioning and 
varying degree of inspiration. 
Figure 1. Association between the ILO radiograph score and HRCT classifica-
tion of interstitial lung fibrosis according to the Finnish system (adapted from 
Huuskonen et al. 2001 (10)).
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Therefore, chest radiographs should be supplemented with HRCT imaging at 
least when 
•	  borderline lung fibrosis (ILO 0/1-1/0) is detected
•	 there is a discrepancy between lung function pointing to restriction 
and radiographs interpreted as normal
•	 widespread pleural changes severely hamper the radiographic visibility 
of lung parenchyma
HRCT imaging should be conducted in the prone position to guarantee the op-
timal aeration of dorsobasal lung parts, i.e. the area that is usually most affect-
ed by fibrotic changes. Radiation aspects should be taken into account and six 
or more slices (11) imaged.  Modern multislice/detector CT (MSCT/MDCT) pro-
vides an easy method for imaging the whole lungs with thin slices thus virtually 
combining the information from conventional spiral imaging and HRCT. This 
technology blurs the boundary between HRCT imaging of special lung signs e.g. 
for finding or follow-up of fibrosis and screening for lung cancer.
During the last two decades, several classification or coding systems for the 
evaluation of pneumoconiosis in CT have been presented by Japan, Germa-
ny, France and Finland (12). The Helsinki meeting in 2000 recommended that 
a common, international classification scheme for pulmonary and pleural 
abnormalities detected on CT scans of asbestos-exposed workers should be 
established for the early identification of occupational and environmental res-
piratory diseases, comparable to the 1980 ILO International Classification of 
Radiographs for pneumoconiosis (2). Such a common classification system was 
described by Kusaka et al. (12) and by Hering et al. (13). This classification has 
now been further developed (ICOERD) (14, 15). Some countries, such as France, 
have developed a nationally-based classification system. For international 
comparison, we recommend the use of the ICOERD classification. 
The role of other methods for follow up: spirometry, 
questionnaires, and others   
In accordance with previous recommendations, based on the HCU criteria, we 
still recommend the use of spirometry together with questionnaires on past or 
current exposure, and current symptoms as a reference check-up for all asbes-
tos-exposed workers. Reliable work histories provide the most practical and 
useful measure of occupational asbestos exposure. Using structured question-
naires and checklists, trained interviewers can identify workers who have 
a work history compatible with significant asbestos exposure. A cumulative 
fiber dose as expressed in fiber-years per cubic centimeter, is an important 
parameter of asbestos exposure. The questionnaire should provide detailed 
information on past (and current) asbestos exposure, and smoking habits, for 
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further classification into relevant risk groups for stratified follow-up, especial-
ly if the follow-up schema is stratified according to the quantity of exposure 
it is recommended to calculate or approximate worker’s exposure as fiber 
years. The most comprehensive method for calculation of fiber-years has been 
created by Deutsche Gesetzliche Unfallversicherung, DGUV in Germany (17). 
To quantify the risk of smoking for lung cancer, calculation of pack-years for 
current and ex-smokers is recommended, and also years since cessation for 
ex-smokers.
The spirometry should include flow-volume curves. Measurements of diffusion 
capacity for CO are not recommended for screening purposes. Mild functional 
changes may be seen even in case of a normal radiograph, but these are not 
specific to asbestos diseases. To make a diagnosis, radiographic changes are 
needed. For clinical and medico-legal purposes, however, regular follow-up 
with spirometry might be useful, based on national practice and legal require-
ments. This might take place every three to five years, depending on exposure 
level, time since cessation of exposure and age. It is more important to advise 
all asbestos-exposed workers to contact their doctor if they develop symptoms 
or signs of respiratory disease.    
Should the follow up schema be stratified according to  
the intensity and duration of exposure? 
We recommend that a general follow-up schema of asbestos-exposed workers 
should be stratified according to the intensity and duration of exposure. High 
priority should be given to workers with high cumulative asbestos exposure 
who are current or past smokers. The rationale behind the stratified follow-up, 
however, will mainly be related to future lung cancer risk, rather than non-ma-
lignant effects. The question of whether there should be a minimum exposure 
requirement (e.g. fiber-years) for a life-long surveillance of the worker or if the 
follow-up should end, e.g. 30 years after the last exposure, will mainly depend 
on estimations of the individual worker’s lung cancer risk.  
Asbestos-related deterioration of lung function may progress over a long time, 
at least 15 years after cessation of the exposure (16). Short term exposure to 
amosite was followed by radiographic parenchymal and pleural progression, 
which were still detectable ≥ 20 years after the end of exposure (18). The risk 
of progression of radiographic fibrotic processes was higher among smokers, 
workers employed during earlier years, those with a longer latency period, 
blue-collar workers directly involved in the production processes, and employ-
ees in the asbestos cement and/or textile industries (19). 
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It is therefore evident that both radiographic and functional pulmonary deteri-
oration may occur long after asbestos exposure. Follow-up is necessary, espe-
cially if it is relevant from the compensation point of view. Asbestos-exposed 
patients with pathological lung and pleural signs in HRCT (20) or lung function-
al deterioration (21) have increased mortality. We therefore recommend the 
follow-up of asbestos-exposed workers for at least 30 years after cessation of 
exposure.
Could biomarkers be of practical benefit for 
follow-up diagnostics? 
The question has been raised as to whether some biomarkers could be of prac-
tical benefit for the follow-up diagnostics of asbestos-related disease. It has 
been shown that asbestosis patients have increased alveolar NO output and 
high levels of LTB4 and 8-isoprostane in exhaled breath condensate reflecting 
the chronic pulmonary inflammation and tissue damage (22; 23). Borderline 
parenchymal changes on HRCT in asbestos-exposed subjects are also associ-
ated with increased markers of pulmonary inflammation (24). Such borderline 
parenchymal changes are likely a mild or early form of the same pathological 
process that leads to asbestosis. More studies are needed to assess if the 
markers of inflammation could be used to predict the risk of developing diffuse 
pulmonary fibrosis and asbestosis among subjects with borderline parenchy-
mal changes. For mesothelioma diagnosis, several new biomarkers, such as 
soluble mesothelin-related peptides/proteins, osteopontin etc. have been un-
der consideration. See Pathology and biomarkers, page 123. 
Immunization or vaccination of asbestosis patients
The last decades have seen reports related to a possible increased risk of 
pneumonia among workers exposed to gases and fumes. The question has 
now been raised as to whether asbestos-exposed workers also have an in-
creased incidence of or mortality from pneumonia, and could thus benefit 
from Pneumococci vaccination.   
A recent study reported an increased risk for pneumonia mortality (ICD-10 
codes J10-J18) among asbestos-exposed workers with lung fibrosis in Finland. 
The hazard ratio (HR) was 2.26 (95% CI:0.98‒5.19) among subjects with “some 
interstitial fibrosis”, and 3.30 (95%CI:1.22‒11.23) among subjects with “definite 
interstitial fibrosis” (25).  Based on these findings, the authors recommend that 
both current and former asbestos workers with lung fibrosis should be vacci-
nated against influenza and Pneumococcus. We are not aware of other studies 
that have examined this specific association among asbestos- 
exposed workers. 
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However, there are several reports on the relationship between welding expo-
sure and mortality from pneumonia, and the British Health Authorities have 
recently recommended that welders exposed to metal fumes are offered the 
pneumococcal vaccine, paid by the employer (26). We recommend influenza 
and pneumococcus vaccination to patients with documented asbestosis.  Fur-
ther studies on the relationship between asbestos exposure, asbestosis and 
pleura plaque on the one hand, and incidence and mortality from pneumococ-
ci pneumonia on the other, are required before any recommendation can be 
given for extending this recommendation to asbestos-exposed workers in gen-
eral. Cost benefit considerations must also be included in a further assessment 
of such recommendations.  
Diagnosis of non-malignant asbestos diseases      
(asbestosis and pleural plaques)
Should there be a definition of minimum criteria for diagnosis of   
asbestosis in HRCT?  
It is well known that ILO abnormalities occur in the general population without 
work-related asbestos exposure. According to a meta-analysis, the prevalence 
of small opacity profusion that is considered pathological (1/0 or greater) var-
ies widely, from 0.21% to 11.7%, showing an average population prevalence of 
5.3% (27). 
Figure 2. Relation between age and HRCT fibrosis among asbestos-exposed workers and 
age-matched hospital controls with unlikely or possible asbestos exposure.
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Small lung opacities and pleural abnormalities were considerably more preva-
lent in the older age groups and in men (28). There is less data on HRCT abnor-
malities occurring in the general population, supposedly because of the study 
problems from radiation exposure. The previously unpublished plot below is 
based on Finnish ‘ASBE’ screening material (29, 30).   
It is clear that HRCT lung fibrosis also exists among those with different as-
bestos exposure and shows a distinct, although limited increase with age. The 
occurrence of limited lung fibrosis among the general population makes the 
definition of a threshold value for asbestosis important. This depends on the fi-
brosis classification system used and the characteristics of the national general 
population. The Finnish threshold value is 2, using the classification system in 
Figure 2. This corresponds to the sum grade of irregular opacities of 2–3 on the 
ICOERD scale or finding of bilateral honeycombing. It is the authors’ opinion 
that the ICOERD scale is somewhat rough considering very limited opacities. 
Subclasses (e.g. 1/0, 1/1, 1/2  mimicking the ILO system) could be used. 
We therefore recommend that fibrosis sufficient for asbestosis according to 
the ICOERD system could represent the sum grade of ≥ 2–3 irregular opacities 
or bilateral honeycombing (sum grade ≥ 2). 
Should there be minimum criteria for plaques to be accepted as   
occupational disease? 
If yes, these criteria and the classification system to be used must 
be defined. 
Very small plaques may be common but difficult to separate from naturally 
thicker than average pleura, intercostal muscles, subpleural scars, adhesions 
etc. in CT/HRCT. They possess little if any functional or other deleterious 
effects. Diagnosing them may thus be frustrating and even harmful to the 
patient. From 2000 onwards, even the ILO system for reporting radiographs 
records only plaques of ≥ 3 mm in thickness. In Finland, a considerable number 
of the general population harbors radiographic plaques (Zitting 1995). 
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When asbestos-exposed workers with pleural plaques were compared to hos-
pital patients with no known asbestos exposure with CT (Tiitola et al. 2002b), 
the following differences emerged:
Plaque characteristics Controls Exposed workers
Greatest thickness < 10 mm > 5 mm
Calcification none
little
little
considerable
abundant
Plaque area in hemithorax* < 45 cm2 > 45 cm2
* Best cut-off value determined by ROC-analysis
However, even the smaller plaques can be caused by asbestos exposure, thus 
it is difficult to recommend any minimum criteria for diagnosis. According to 
ICOERD, all visible pleural thickening is recorded: differential diagnosis of 
etiology depends upon disease and occupational history.
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Introduction
In 1997, The Helsinki Criteria document was developed by a group of 19 par-
ticipants from eight countries. The group was charged to “discuss disorders in 
association with asbestos and…agree upon state of the art criteria...for diagno-
sis and attribution with respect to asbestos” (1). The 1997 Criteria provided a 
framework for determining attribution of asbestos-causation at the individual 
level for several conditions, including asbestosis, pleural disorders, mesothelio-
ma, and lung cancer.
From the standpoint of determining asbestos-causation at the individual level, 
lung cancer was perhaps the greatest challenge. As noted in the Criteria, lung 
cancer occurs at a relatively high incidence in the general, non-asbestos-ex-
posed population. Thus, it is not possible to determine with certainty whether 
an asbestos-exposed individual’s lung cancer developed because of asbestos 
exposure or from some other cause. Instead, attribution at the individual level 
requires a probabilistic approach, estimating the likelihood that asbestos has 
caused or contributed materially to disease development. 
The model underlying the Criteria’s approach to lung cancer estimated a lin-
ear increase in the relative risk (RR) for lung cancer with increasing cumulative 
asbestos exposure (2). The Criteria considered a level of exposure associated 
with a 50% or greater chance of asbestos-causation as a threshold for deter-
mining individual attribution based on the often used “more likely than not” 
civil standard of proof. The RR associated with this attributable fraction among 
the exposed (AF) is 2. However, lower levels of RR are also associated with 
some probability of causation. This can be calculated using the following for-
mula: AF = (RR-1)/RR (3). Proceedings of the Criteria workgroup note that in 
some situations, a RR of 1.1 has been accepted as indication of a material 
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contribution to causation (2). Based on the formula above, this RR would 
be associated with a 9% chance of asbestos causation. The Criteria also ad-
dressed latency, requiring a minimum of ten years from the first asbestos ex-
posure to attribute lung cancer to asbestos. Finally, although the Criteria ac-
knowledged the importance of cigarette smoking as a cause of lung cancer, it 
did not attempt to apportion the relative contributions of asbestos exposure 
and tobacco smoking.
The Criteria and its associated proceedings document identify a cumulative 
asbestos exposure history of 25 fiber/mL-years as raising the RR of lung cancer 
to 2 and suggest practical ways to document exposure at or above that level 
in an individual. One approach is to document occupational history. Examples 
of sufficient occupational history included “1 year of heavy exposure (e.g. 
manufacture of asbestos products, asbestos spraying, insulation work with as-
bestos materials, and demolition of old buildings) or five to ten years of mod-
erate exposure (e.g., construction, shipbuilding)…In some circumstances of 
extremely high asbestos exposure, a 2-fold risk of lung cancer can be achieved 
with exposure of less than 1 year.” The presence of asbestosis diagnosed 
radiologically (by plain chest film or computed tomography) or histologically 
also documents sufficient exposure. 
The Criteria also addresses use of asbestos bodies and fiber counts in lung tis-
sue and bronchoalveolar lavage (BAL) fluid as biomarkers of 25 fiber/mL-years 
of exposure. It recommends that fiber levels of “2 million amphibole fibers 
(>5 µm) per gram of dry lung tissue or 5 million amphibole fibers (> 1 µm) per 
gram of dry lung tissue” be used as thresholds and notes that “[t]his lung fiber 
concentration is approximately equal to 5,000 to 15 000 asbestos bodies per 
gram of dry tissue, or 5 to 15 asbestos bodies per milliliter” of BAL. It also rec-
ommends electron microscopic fiber analyses “[w]hen asbestos body concen-
trations are less than 10 000 asbestos bodies per gram of dry tissue.” It should 
be noted that recommendations for fiber analyses apply only to amphibole 
fibers, since chrysotile fibers are cleared more quickly from lung tissue. Thus, 
occupational history is “probably a better indicator of lung cancer risk from 
chrysotile than fiber burden analysis.”
The current review addresses selected conditions not addressed by the origi-
nal Helsinki Criteria document where new evidence of asbestos-causation has 
since emerged. It provides information that will help those faced with the task 
of attributing causation to asbestos at the individual level. Although the risk of 
developing these conditions may increase with asbestos exposure, they also 
occur in the general population and are associated with other risk factors. 
Thus, the challenge in determining asbestos-causation of these conditions at 
the individual level parallels that faced by the original Criteria document in ad-
dressing lung cancer. Although complete information is not always available, 
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the review provides information to assist those who must determine individual 
causation, such as strength of evidence for asbestos-causation, magnitude of 
effect, exposure-response relationships, and other risk factors. 
Methods
New entities to be evaluated were suggested by the Helsinki Criteria Update 
Group, and supplemented based on suggestions from the New Entities Work-
group. Entities addressed in the report include the following cancers: laryngeal, 
ovarian, stomach, and colorectal. In addition, the report addresses ventilatory 
impairment and chronic airway obstruction; and retroperitoneal fibrosis. An 
individual Workgroup member took the lead for each evaluated entity. Work-
group products were reviewed by the entire group and final conclusions were 
required to be based on group consensus. 
When available, evaluations of the asbestos-related entities made use of one 
or more high-quality, structured, authoritative reviews that were available in 
English as foundations. For example, evaluations of asbestos-related cancers 
made use of a recent authoritative review by the International Agency for Re-
search on Cancer (IARC) in March, 2009 (4). The IARC study concluded that “[a]
sbestos causes mesothelioma and cancer of the lung, larynx, and ovary. Also 
positive associations have been observed between exposure to all forms of as-
bestos and cancer of the pharynx, stomach, and colorectum. For cancer of the 
colorectum, the Working Group was evenly divided as to whether the evidence 
was strong enough to warrant classification as sufficient.” The current review 
assesses whether literature published since IARC report provides information 
that might have affected its conclusions.
If past structured English-language reviews were not available, or to iden-
tify references published after the structured reviews, potential references 
for consideration were identified using searches of PubMed. At a minimum, 
searches included the disease entity name and the word “asbestos.” Abstracts 
were used to identify potentially relevant articles for further review. Poten-
tially relevant articles were also identified from the reference lists of the fully 
reviewed articles and Workgroup members’ personal knowledge of the liter-
ature. The focus of the review was on human studies, although information 
from animal studies was also considered, as appropriate. Tables documenting 
references considered in foundational structured reviews and additional refer-
ences identified by the workgroup are provided in an online supplement.
Evaluated entities were classified for strength of evidence for asbestos- 
causation using categories paralleling those that the US National Toxicology 
Program (NTP) uses to classify potential carcinogens (5). “Entity known to be 
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caused by asbestos” was defined by sufficient evidence in humans to indicate 
a causal relationship between exposure to asbestos and development of the 
entity. In the case of asbestos-related cancers reviewed here, it is equivalent to 
the IARC Group 1 classification, “sufficient evidence of carcinogenicity in hu-
mans.” “Entity reasonably anticipated to be caused by asbestos” was defined 
by limited evidence in humans which indicates that causal interpretation is 
credible, but that alternative explanations, such as chance, bias, or confound-
ing factors, could not adequately be excluded. In the case of asbestos-related 
cancers reviewed here, it is equivalent to the IARC Group 2A classification 
“probably carcinogenic in humans.” An additional category, “not classifiable” 
could also be used. In deciding whether new information had been published 
that might have affected the IARC classifications, the weight of evidence in 
light of conventional Bradford Hill Criteria (e.g. strength, consistency, specifici-
ty, temporality, biological gradient, plausibility) was considered.
In general, only limited exposure-response information is available for the new 
asbestos-related entities, including cancers, evaluated here. To provide an ap-
proximation of the RR for asbestos-causation of a new cancer entity relative to 
the RR for lung cancer in an exposed cohort, cohort studies that evaluated RRs 
for the both a new cancer entity and lung cancer were identified and the quan-
titative relationships between these RRs were assessed. For cohort studies that 
included men and women, lung cancer RRs based on data for both genders 
were used in the analyses. For stomach and colorectal cancer, linear regression 
analyses relating SMR values for these entities and for lung cancer were ob-
tained from figures 2.1 and 2.2 respectively of the IARC review of asbestos (4). 
For laryngeal cancer and ovarian cancer, SIR and SMR values respectively for 
the new cancer entity were obtained from published cohort studies reporting 
at least 2 asbestos-exposed individuals with the entity and the values related 
to reported risks for lung cancer by linear regression. Based on these analyses, 
for each new entity, RR for the entity when lung cancer RR is 2; and RR for lung 
cancer when the new entity RR is 2 are reported. In general, SMR or SIR values 
from total cohorts are used in these analyses. However, in a few studies, two 
non-overlapping cohorts were reported in a single publication. In this situation, 
cohorts were evaluated separately. 
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Cancers for which IARC found sufficient evidence for   
asbestos-causation in humans
Laryngeal cancer
Laryngeal cancer (ICD-9 161; ICD-10 C32) accounts for approximately 1.2% of 
world cancer cases and 82,000 deaths a year (6). Most laryngeal cancers are 
squamous and most arise in the glottis (vocal cords). Supraglottic, and subglot-
tic laryngeal cancers are relatively rare. This disease is markedly more frequent 
in males than in females; (male: female ratio of 12:1 and 6:1 in developing and 
developed countries, respectively) and there is a large geographic variability in 
disease frequency. Survival from cancer of the larynx in developed countries 
is moderately good. The main risk factors for cancer of the larynx are tobacco 
and alcohol, each of which has a multiplicative effect (7-9).
The role of asbestos in causing laryngeal cancer remains controversial (10) with 
differing results between cohort and case-control studies. 
Cohort studies
IARC reviewed available cohort studies as part of its recent update (4); Ta-
ble 1 in online supplement). As noted by IARC these studies cover a range of 
industries, some of which evaluated risk of laryngeal cancer in workers with 
asbestosis, who thus were heavily exposed. Many of the studies observed only 
small numbers of laryngeal cancers giving wide confidence intervals around 
the risk estimates. Larger studies include Reid (2004) (11), (RR=1.82, 95%CI 
1.16, 2.85), Liddell (1997) (12) (SMR=1.11), Selikoff and Seidman (1991) (13) 
(RR=1.70), Raffn (1989) (14) (SIR=1.66, 95%CI 0.91,2.78), Finkelstein (2004) 
(15) (SMR=1.32, 95%CI 0.72, 2.21), Tola (1988) (16) (SIR-1.20, 95%CI 0.77, 1.79) 
and Puntoni (2001) (17) (RR=1.64, 95%CI 1.21, 2.32). 
Cohort studies not reviewed in the IARC report include a cohort in the Swedish 
construction industry of 307 799 male workers followed during 1971–2000. As-
bestos exposure was related to an increased laryngeal cancer incidence, with 
a RR of 1.9 (95% CI=1.2-3.1) for workers ever exposed to asbestos (adjustment 
for smoking) (18). This association was stronger for workers with a moderate 
exposure level (RR=2.3, 95% CI=1.4-3.8); however, there were only two laryn-
geal cancers in the high-exposure group.
Harding et al. (2009) (19) report an SMR of 1.48 (95%CI 1.09, 1.45) and a PMR 
of 1.01 (95%CI 0.76, 1.34) in an update of a large cohort of British asbestos-ex-
posed workers. In a Poisson regression analysis adjusted for age and sex, laryn-
geal cancer was associated with age exposed, length of exposure and smoking 
status.
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The pooled analysis had 4 cohorts that provided results with latency and 27 
without. Overall, the meta-SMR for laryngeal cancer from these four cohort 
studies, without taking into account latency and confounding factors (tobacco 
and alcohol), was 1.33 (95% CI=1.14‒1.55), with a very high degree of homoge-
neity (p=0.99). In addition, a proxy of dosage exposure (using deaths from me-
sothelioma) showed no dose-response in laryngeal cancer. A weak association 
between laryngeal cancer and asbestos was concluded.
Browne and Gee (2000) reviewed 22 cohort studies including observed and 
expected numbers of laryngeal cancer deaths (32). The summary of all cohorts 
showed a mean SMR for laryngeal cancer of 1.08 (O=114, E=105.8); among 
these 22 studies, 17 are common with the meta-analysis by Goodman et al. 
(1999) (36). In addition, 17 case-control studies were also reviewed (9 with 
adjustment for smoking and alcohol, 4 with adjustment for only smoking and 
4 without adjustment): of the 17 studies, 8 showed no increase in relative risk; 
of the remaining nine, the increase in seven was not significant and the signifi-
cance was only borderline in the two remaining (RR=1.8, 95% CI=1.0‒3.4 (Olsen 
et al., 1984) (37); RR=2.4, 95% CI=1.0‒5.9 (Blot et al., 1980) (37). The mean RR 
for seven of the nine case-control studies with adjustment for smoking and al-
cohol was 1.25. Two studies were not included in the meta-analysis: Elwood et 
al., 1984 (38) did not give figures and mentioned that no indication of any sub-
stantial relationship was found; Zagraniski et al. (1986) (39) used two methods, 
one based on self-reported exposure and the other one based on occupations 
but only the last one was retained.
The U.S. Institute of Medicine (IOM) carried out a review and meta-analysis of 
both cohort studies and case-control studies (40). For cohort studies the RR 
was 1.4 (95%CI 1.19, 1.64) for any versus no exposure. For ‘high’ versus no ex-
posure the lower bound summary (using the smallest high versus no exposure 
metric in studies with multiple exposure gradient metrics) RR was 2.02 (95%CI 
1.64, 2.47) and the upper bound (using the largest high versus no exposure 
metric) RR was 2.57 (95%CI 1.47, 4.49). A meta-analysis of case-control studies 
gave a summary RR of 1.43 (1.15, 1.78) before adjusting for tobacco and alco-
hol with an adjusted summary meta-RR of 1.18 (95% CI 1.01, 1.37).
The meta-analysis by Fortunato et al. (2012) included nine of the studies which 
were thought to be relevant to exposure experience in GB (23). Five studies 
were excluded (Ahrens et al. 1991 (41), asbestos exposure assessment based 
on self-report; Berrino et al. 2003 (42), combined larynx and hypopharynx can-
cer; De Stefani et al. 1998 (43), Elci et al. 2002 (44), Shangina et al. 2006 (45) 
were conducted in countries with different exposure patterns to those in GB).
The meta-analysis, combining 9 studies and using the inverse weighted vari-
ance method, found an RR of 1.37 (95% CI= 1.17‒1.60) associated with any 
exposure to asbestos (test for heterogeneity: p=0.94). Four of the case-control 
55
Case-control studies
There have also been a number of case-control studies. IARC reviewed 15 of 
these; all except one (22) showed a positive association. Fortunato et al. (2012) 
(23) carried out a review and meta-analysis of 14 case-control studies that con-
trolled for alcohol and tobacco to inform selection of a suitable risk estimate 
for use in a laryngeal cancer burden estimate for Great Britain (GB). Nine of the 
14 studies were thought to be relevant to exposure experience in GB and were 
included in a meta-analysis (see below and Table 2 in online supplement). 
The studies vary in size with the odds ratios (OR) ranging from just below 1 to 
1.8. Four studies also gave risk estimates without adjustment for tobacco and 
alcohol consumption. In Dietz et al. (2004) (24) and Muscat & Wynder (1992) 
(25), the association between asbestos exposure and laryngeal cancer was 
weakened by controlling for other covariates; in Brown et al. (1988) (26) and 
Olsen et al. (1984) (27), the estimates were the same with or without adjust-
ment for tobacco and alcohol consumption.
Four of the case-control studies (Gustavsson et al. 1998 (28), Imbernon et al. 
1995 (29), Marchand et al. 2000 (30), Wortley et al. 1992 (31)) presented re-
sults on the dose-response relationships with two (Gustavsson and Marchand) 
showing a trend for increasing risk as cumulative exposure increased, but the 
results were unclear in the other two studies.
Reviews and meta-analyses
There have been several reviews of laryngeal cancer and asbestos exposure 
with varying conclusions. Four reviews (Browne & Gee 2000 (32), Edelman 
1989 (33), Griffiths & Molony 2003 (34), Wight et al. 2003 (35)) have concluded 
that, overall, the evidence does not indicate that asbestos exposure increas-
es the risk of laryngeal cancer and that positive results are probably due to a 
missing or insufficient adjustment for alcohol and tobacco consumption. They 
found that associations were significant in case-control studies without ad-
justment for smoking and alcohol consumption, or borderline significant with 
these adjustments. Among cohort studies, no associations were found.
In contrast, other reviews have concluded that there is a positive association 
between laryngeal cancer and asbestos exposure. Goodman et al. (1999) (36) 
reviewed 69 asbestos-exposed occupational cohorts, 42 in Europe, 22 in North 
America and the remainder elsewhere. The earliest study was published in 
1967 and the most recent in 1997. The studies covered a variety of occupa-
tions, including: asbestos products manufacture (22%); cement workers (20%); 
shipyard workers (12%); asbestos miners and millers (10%); and textile workers 
(10%). 
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The pooled analysis had 4 cohorts that provided results with latency and 27 
without. Overall, the meta-SMR for laryngeal cancer from these four cohort 
studies, without taking into account latency and confounding factors (tobacco 
and alcohol), was 1.33 (95% CI=1.14‒1.55), with a very high degree of homoge-
neity (p=0.99). In addition, a proxy of dosage exposure (using deaths from me-
sothelioma) showed no dose-response in laryngeal cancer. A weak association 
between laryngeal cancer and asbestos was concluded.
Browne and Gee (2000) reviewed 22 cohort studies including observed and 
expected numbers of laryngeal cancer deaths (32). The summary of all cohorts 
showed a mean SMR for laryngeal cancer of 1.08 (O=114, E=105.8); among 
these 22 studies, 17 are common with the meta-analysis by Goodman et al. 
(1999) (36). In addition, 17 case-control studies were also reviewed (9 with 
adjustment for smoking and alcohol, 4 with adjustment for only smoking and 
4 without adjustment): of the 17 studies, 8 showed no increase in relative risk; 
of the remaining nine, the increase in seven was not significant and the signifi-
cance was only borderline in the two remaining (RR=1.8, 95% CI=1.0‒3.4 (Olsen 
et al., 1984) (27); RR=2.4, 95% CI=1.0‒5.9 (Blot et al., 1980) (37). The mean RR 
for seven of the nine case-control studies with adjustment for smoking and al-
cohol was 1.25. Two studies were not included in the meta-analysis: Elwood et 
al., 1984 (38) did not give figures and mentioned that no indication of any sub-
stantial relationship was found; Zagraniski et al. (1986) (39) used two methods, 
one based on self-reported exposure and the other one based on occupations 
but only the last one was retained.
The British Institute of Medicine (IOM) carried out a review and meta-analysis 
of both cohort studies and case-control studies (40). For cohort studies the RR 
was 1.4 (95%CI 1.19, 1.64) for any versus no exposure. For ‘high’ versus no ex-
posure the lower bound summary (using the smallest high versus no exposure 
metric in studies with multiple exposure gradient metrics) RR was 2.02 (95%CI 
1.64, 2.47) and the upper bound (using the largest high versus no exposure 
metric) RR was 2.57 (95%CI 1.47, 4.49). A meta-analysis of case-control studies 
gave a summary RR of 1.43 (1.15, 1.78) before adjusting for tobacco and alco-
hol with an adjusted summary meta-RR of 1.18 (95% CI 1.01, 1.37).
The meta-analysis by Fortunato et al. (2012) included nine of the studies which 
were thought to be relevant to exposure experience in GB (23). Five studies 
were excluded (Ahrens et al. 1991 (41), asbestos exposure assessment based 
on self-report; Berrino et al. 2003 (42), combined larynx and hypopharynx can-
cer; De Stefani et al. 1998 (43), Elci et al. 2002 (44), Shangina et al. 2006 (45) 
were conducted in countries with different exposure patterns to those in GB).
The meta-analysis, combining 9 studies and using the inverse weighted vari-
ance method, found an RR of 1.37 (95% CI= 1.17‒1.60) associated with any 
exposure to asbestos (test for heterogeneity: p=0.94). Four of the case-control 
57
studies presented results on dose-response relationships (28‒31). The me-
ta-SIR from the combined analysis of the highest category of exposure from 
these 4 studies was 1.48 (95% CI=1.10‒1.97; test for heterogeneity: p = 0.65); 
for the lowest level of exposure the meta-SIR was 1.16 (95% CI=1.02‒1.31; test 
for heterogeneity: p = 0.99). However, all four studies used different measures 
of exposure and cut-offs for categorization so the result must be viewed cir-
cumspectly.
Sensitivity analyses removing each study in turn did not substantially change 
the results; however, the association was weakened (meta-SIR of the 14 stud-
ies =1.28, 95% CI=1.13‒1.44) with smaller homogeneity (p=0.62) when the five 
case-control studies without dose-response results were removed. 
Overall conclusions
Overall, both cohort and case-control studies and also meta-analyses provide 
consistent evidence of an increased risk of laryngeal cancer associated with 
asbestos exposure. There is also some evidence that increasing exposure in-
creases this risk, although results are limited by small numbers of cases and 
thus are not consistent across studies.
From the standpoint of magnitude of risk, the excess risk associated with 
ever exposure to asbestos varies between the studies  but is of the order of 
40–50%. Dose-response analyses do not consistently show an increasing risk 
with increased exposure and also other measures such duration of exposure 
and time since first exposure.  However, the excess risk for the highest expo-
sure categories tends to be higher than that associated with ever exposure and 
varies beween 40% and over 100% i.e. double the risk at the highest exposure.
Thus, the weight of literature remains consistent with IARC’s recent evaluation 
and laryngeal cancer is classified as an entity known to be caused by asbestos 
(equivalent to IARC Group 1). Based on laryngeal and lung cancer SIRs report-
ed from published cohort studies, we estimate the RR for laryngeal cancer in 
an exposed cohort to be somewhat less than the RR for lung cancer. Under 
conditions of asbestos exposure associated with a RR for lung cancer of 2, 
the estimated RR for laryngeal cancer is 1.58, with an estimated AF for asbes-
tos-causation of about 37%. When the RR for laryngeal cancer is 2, the esti-
mated RR for lung cancer is 2.78.
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Ovarian cancer
About 1.4% of women will be diagnosed with ovarian cancer during their life 
(46). Ovarian cancer is a heterogeneous disease, with several histopathological 
subtypes including serous, clear cell, endometriosis, and mucinous subtypes 
(47). Risk factors differ somewhat between subtypes (48). However, in general, 
risk factors include hereditary factors (family history of ovarian cancer, person-
al history of breast cancer, mutations in the genes BRCA1 or BRCA2, Lynch syn-
drome), advanced age, nulligravity, infertility, early age at menarche, late age 
at natural menopause, estrogen, androgens, perineal talc exposure, endome-
triosis, pelvic inflammatory disease, obesity, and residence at extremes in lati-
tude. Protective factors include multiparity, breastfeeding, oral contraceptives, 
progestin, hysterectomy, and tubal ligation. Impact of fertility drugs, exercise, 
and cigarette smoking remain to be fully established (49).
In 2009, the Monograph program of IARC conducted a review of fibers includ-
ing asbestos (50). The monograph committee reached the conclusion for the 
first time that there was sufficient evidence for a causal association between 
exposure to asbestos and the risk of ovarian cancer.
Fourteen studies were included in the IARC review (4) (see table 3 in online 
supplement for design and findings of various studies, including those con-
sidered by IARC). In its review, the Working Group included ten occupational 
cohorts, three studies with community exposure, and two case-control stud-
ies. They concluded that causality was clearly established based on the strong 
associations observed in five cohort studies of workers with high occupational 
exposures (51‒55), and was additionally support by weaker but positive find-
ings of an excess among women exposed from non-occupational sources 
(56‒58), and in two case-control studies (59, 60). They also considered the is-
sue of misclassification of mesothelioma and ovarian cancer. This is an import-
ant issue, since it has long been recognized that there may be severe misclassi-
fication in the diagnosis of ovarian cancer and mesothelioma. 
Histopathologic confirmation can be used to distinguish between these tu-
mors (61), however many of the studies relied on death certificates, which 
are known to be highly insensitive and non-specific for the diagnosis of meso-
thelioma. The Working Group noted that in three studies a careful pathologic 
review was conducted, and in all of them there were an insufficient number of 
misclassified cases to explain the observed positive associations. Finally, the 
Working Group suggested that the findings of an excess of ovarian cancer in 
women exposed to asbestos was biologically plausible based on the findings of 
accumulation of asbestos fibers in the ovaries of exposed women (62, 63).   
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Only two new epidemiologic investigations have been published since the 
time of the IARC review, both of which provide some additional support for 
the hypothesis that asbestos exposure is causally associated with ovarian can-
cer. The first was a cohort study of women who were exposed to crocidolite 
during childhood in Wittenoon, Australia (64). An approximately two to four 
fold increase in ovarian cancer incidence was observed depending on wheth-
er person-time was ended at the time when subjects were lost to follow-up 
(SIR=3.55, 95% CI=1.30,7.72) or not (SIR= 2.50,95%CI=0.92‒5.46). The latter 
analysis is negatively biased since it results in an overestimation of the expect-
ed number of cases. The second study reported an excess of ovarian cancer 
mortality based on one case (SMR=7.69, 95%CI=1.36, 43.58) in a cohort of Chi-
nese textile workers (65). Although the small number of cases in both of these 
studies precludes any strong conclusions, they are consistent with the excess 
of ovarian cancer observed in other cohorts previously reviewed by IARC.  
Risk of ovarian cancer mortality relative to lung cancer mortality in the cohort 
studies considered by IARC, supplemented with additional available studies, 
is shown in Figure 2 (ovarian and lung cancer SMRs were obtained from 17 
non-overlapping cohorts reported in 15 publications). One of the studies re-
ported SMRs in two ways (57). “SMR1” assumed that subjects who were lost 
to follow up were alive at the end of the study. “SMR2” censored subjects lost 
to follow up at the date last known to be alive. Because the first approach gen-
erated larger estimates of person-years at risk, it resulted in smaller “SMR1” 
values for cancers (lung & trachea = 1.74; ovarian = 1.26). The second approach 
generated smaller estimates of person-years at risk and larger “SMR2” values 
for cancers (lung & trachea = 2.15; ovarian = 1.52). Based on linear regression 
analysis of all studies, and using the “SMR1” values from that individual study, 
when the lung cancer SMR is 2, the ovarian cancer SMR is 2.18 (R2 = 0.36). 
When the ovarian cancer SMR is 2, the lung cancer SMR is 1.72. Essentially sim-
ilar results, shown in Figure 2, were obtained when the linear regression anal-
ysis was performed using “SMR2” values from that study (when lung cancer 
SMR = 2, ovarian cancer SMR = 2.18; when ovarian cancer SMR = 2, lung cancer 
SMR = 1.71; R2 = 0.35). 
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Figure 2. Ovarian and lung cancer correlation in asbestos cohorts.
Despite the conclusions by IARC and the support from recent studies, the hy-
pothesis that asbestos is cause of ovarian cancer remains controversial (66). 
Two other systematic reviews and meta-analyses have been published since 
the IARC review. These studies reached somewhat different conclusions largely 
due to differences in their criteria for study inclusion (66, 67).  In a meta-anal-
ysis by Camargo et al., the analysis was restricted to only include studies with 
clear, and unequivocal evidence of occupational exposure to asbestos (67). 
The meta-analysis by Reid et al. (66) included studies that involved non-occu-
pational exposure (56, 58) and two other case-control studies that Camargo et 
al. decided had inadequate documentation of asbestos exposure (59, 68).  
In addition, the analysis by Camargo et al. was able to include the findings from 
two cohort studies of U.S. asbestos textile workers (69, 70). The authors of 
these studies provided observed and expected deaths for ovarian cancer 
to Camargo et al., which had not been previously published and available to 
Reid et al.
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Camargo et al. reported a pooled relative risk (RR) estimate of 1.77 (95% 
CI=1.37‒2.28). There was borderline evidence of heterogeneity (p=0.06) in this 
analysis. This heterogeneity was attributable to higher estimates of risk in stud-
ies of workers with asbestosis, cohorts with RR of greater than 2 for lung can-
cer, and studies conducted in Europe. A sub-analysis of findings for high expo-
sure groups in each study yielded even stronger results with a nearly threefold 
increase in risk (RR= 2.78, 95%CI=1.36‒5.66). The authors reported that they 
did not observe any difference in the findings between the studies that did 
and did not include histopathologic confirmation. Based on their findings the 
authors concluded that their analysis supported the IARC conclusion that expo-
sure to asbestos in associated with an increased risk of ovarian cancer.
The meta-analysis by Reid et al. (65) reported a pooled estimate of the RR 
(RR=1.75, 95%CI=1.45-2.10) that was remarkably similar to the pooled estimate 
in the study by Camargo et al. (RR=1.77, 95% CI=1.37‒2.28) (67). However, they 
also observed that the findings were severely attenuated when they restricted 
the analysis to studies that included pathologic confirmation of the ovarian 
cancers (RR=1.29, 95%CI=0.97‒1.73). Based on their findings Reid et al. con-
cluded that although there was evidence of an increased rate of ovarian cancer 
among asbestos-exposed women that “result may have occurred because of 
disease misclassification”.
Overall conclusions
Overall, there are relatively strong and consistent findings of an increased risk 
for ovarian cancer among women in cohorts with relatively high asbestos ex-
posures. Although there is insufficient data from these studies to perform an 
exposure-response analysis, our conclusion is also supported by the increase in 
risk observed among workers in the highest exposure groups in the meta-anal-
ysis by Camargo et al. Misclassification of ovarian cancer and mesothelioma is 
a serious concern, which may have either negatively or positively biased some 
of these studies. However, the fact that a significant excess of ovarian cancer 
has also been demonstrated in several studies with pathologic confirmation 
suggests that the association cannot be entirely explained by misclassification 
of disease.
 
Thus, the weight of literature remains consistent with IARC’s recent evaluation 
and ovarian cancer is classified as an entity known to be caused by asbestos 
(equivalent to IARC Group 1). Based on ovarian and lung cancer SMRs reported 
from published cohort studies, under conditions of asbestos exposure associ-
ated with a RR for lung cancer of 2, the estimated RR for ovarian cancer is 2.18, 
with an estimated AF for asbestos-causation of about 54.1%. When the RR for 
ovarian cancer is 2, the estimated RR for lung cancer is 1.71.
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Cancers for which IARC found positive associations with  
asbestos exposure in humans
Colorectal cancer
Background
Colorectal cancer is the third most common cancer in men and the second in 
women worldwide. Incidence rates vary 10-fold worldwide, with higher rates 
in developed countries (6). Earlier case-control studies indicated a protective 
effect of dietary factors like intake of vitamins and fibres, but this has not been 
confirmed in later cohort studies. Alcohol consumption is positively associat-
ed with colorectal cancer risk while the effect of tobacco smoking is less clear 
(70). Physical activity, both occupational and during leisure-time has consis-
tently been associated with a reduced risk of colorectal cancer. High versus 
low activity was associated with a 50% reduced risk (72). Asbestos exposure is 
more common in manual occupations and physical activity may act as a nega-
tive confounder in cohort studies using the general population for reference, 
and thus attenuate the risk associated with asbestos exposure. Studies based 
on internal comparisons do not suffer from this potential bias. 
In March 2009, IARC evaluated the evidence for an association between asbes-
tos exposure and colorectal cancer (4). The present evaluation is based on the 
IARC review and relevant studies published since March 2009. Literature was 
searched in Medline in August 2013 with search terms “asbestos and cancer” 
(limit: humans) as well as “asbestos and colorectal cancer”.
The IARC evaluation in 2009
The IARC evaluation included 31 cohort studies (see table 4 in online supple-
ment). Of the 21 cohort studies that were considered more influential, 15 
showed positive evidence for an association and six showed no evidence. Stud-
ies investigating dose-response and/or latency are of special interest.   
An elevated mortality from cancer of the colorectum was found in a cohort of 
820 male factory workers in USA, exposed to amosite asbestos. SMR was 2.77 
(95% CI 1.16‒2.80). The ratio of observed to expected deaths increased with 
increasing interval since initial exposure to asbestos (73).
McDonald et al. (1980) reported an SMR for cancer of the colorectum of 0.78 
in a study of 10 939 male and 440 female asbestos miners and millers in Que-
bec with a predominant exposure to chrysotile asbestos (74). There was a clear 
trend for SMRs to be higher with heavier exposure. The relative risks for cancer 
of the colorectum increased in this cohort from 1.00 in workers with a cumula-
tive exposure less than 30 mpcf–y, to 0.93 in workers with 30–300 mpcf–y, 
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to 1.96 in workers with 300–1000 mpcf–y, and in the group with heaviest ex-
posure, > 1000 mpcf–y, to 5.26.
Albin et al. (1990) reported an overall SMR for cancer of the colorectum of 1.5 
(95%CI: 0.7–3.0) in a cohort of 1465 Swedish asbestos-cement workers (75). 
A positive association between cumulative asbestos exposure and cancer of 
the colorectum was noted. The SMR was 1.3 (95%CI: 0.5–2.9) for a cumulative 
exposure of < 15 fibre–years/mL; for those with cumulative exposure of 15–39 
fibre–years/ mL, the SMR was 1.1(95%CI: 0.3–3.9); and for those workers in 
highest exposure category with > 40 fibre–years/mL, the SMR for cancer of the 
colorectum was 3.4 (95%CI: 1.2–9.5). The trend towards increasing mortality 
from cancer of the colorectum with increasing cumulative exposure to asbes-
tos was statistically significant, p = 0.04. A similar trend was seen for colorec-
tum cancer morbidity. 
An excess mortality from colon cancer was observed in a heavily exposed 
cohort of over 5 000 asbestos insulation board workers in London (52).  
The overall SMR for colon cancer in this cohort was 1.83 (95%CI: 1.20–2.66). 
There was evidence for a positive dose–response relationship, in that excess 
mortality from colon cancer was confined to men who had worked as laggers 
or had been severely exposed for more than two years. This positive trend 
was statistically significant, p = 0.017. 
A report on the incidence of cancer of the colorectum from the Beta- 
Carotene and Retinol Efficacy Trial (CARET) found a relative risk of 1.36 (95%CI: 
0.96–1.93) among 3897 heavy smoker participants occupationally exposed to 
asbestos as compared to smoker participants not exposed to asbestos (76). 
The relative risk for cancer of the colorectum was 1.54 (95%CI: 0.99–2.40) 
among participants with asbestos-induced pleural plaques, interpreted as a 
marker for heavy asbestos exposure. Risk for cancer of the colorectum in-
creased with worsening pulmonary asbestosis, p for trend = 0.03. 
There are a number of other cohort studies supporting an association between 
asbestos exposure and colorectal cancer (56, 77‒84). No evidence of an associ-
ation was found in six cohort studies (69, 70, 85‒88).
The IARC evaluation considered the evidence for a causal association from 
case-control studies less strong than from cohort studiers. However, positive 
findings were reported in five studies (89‒93). No association was found in two 
studies (94, 95).
There are two studies, both from Sweden, investigating location-specific risk. 
Both studies (using different study bases) showed that asbestos exposure 
seems to affect the risk of cancer of colon ascendens (the right part of colon), 
but not other parts of colon (78, 90).
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The IARC evaluation considered five meta-analyses, two of them more recent. 
IOM (2006) conducted a meta-analysis of 31 cohort studies examining the 
association between asbestos exposure and cancer of the colorectum (40). In 
studies comparing “any” versus no exposure, the summary relative risk was 
1.15 (95%CI: 1.01–1.31). For studies comparing “high” versus no exposure, 
the lower-bound summary relative risk was 1.24 (95%CI: 0.91–1.69), and the 
upper-bound summary relative risk, 1.38 (95%CI: 1.14–1.67). The IOM also 
conducted a meta-analysis of the published case-control studies. Overall, 13 
studies comparing “any” versus no exposure gave a summary relative risk of 
1.16 (95%CI: 0.90–1.49). IOM also noted a biological plausibility for a causal as-
sociation between asbestos exposure and colorectal cancer since the presence 
of asbestos bodies and asbestos fibers have been demonstrated in the colon of 
asbestos workers. The IOM (2006) considered the overall epidemiological evi-
dence for a causal association as suggestive but not sufficient (40).
Gamble et al. performed a meta-analysis based on 40 studies focused on 
dose-response associations (96). They noted no association between cumula-
tive dose of asbestos and colorectal cancer risk, and they observed no trend in 
cancer of the colorectum mortality with increasing percentage of deaths due 
to mesothelioma. However, there was a significantly elevated standardized 
mortality ratio of 1.60 (95%CI: 1.29–2.00) for cancer of the colorectum when 
the standardized mortality ratio for lung cancer exceeded 3.00, taken as evi-
dence of high exposure to asbestos. There was no elevation of colorectal can-
cer risk in studies with a lung cancer SMR < 3. The authors developed a scatter-
plot of SMR for colorectal cancer versus SMR for lung cancer, in a similar way 
as in the IARC evaluation (see below), with a similar finding: colorectal cancer 
SMRs tended to be higher in studies showing a high SMR for lung cancer. There 
was no association between asbestos exposure and rectal cancer.  
The IARC working group concluded that the cohort studies gave stronger ev-
idence for an association between asbestos exposure and colorectal cancer 
than did the case-control studies (4). The working group developed a scatter-
plot of SMRs for lung cancer versus colorectal cancer from 29 cohort studies. 
A positive association was seen, R2= 0.59 (no p-value was given), supporting a 
causal relationship for colorectal cancer (Figure 3).  SMRs for colorectal cancer 
tended to be lower than SMRs for lung cancer, indicating that the effect of 
asbestos, in terms of relative risk, is weaker for colorectal cancer than for lung 
cancer. Based on the linear regression reported by IARC, when the lung cancer 
SMR is 2, the colorectal cancer SMR is 1.1. When colorectal cancer SMR is 2, 
the lung cancer SMR is 5.2.
The IARC Working Group was evenly divided in assessing the evidence from 
human epidemiology studies for an association between asbestos exposure 
and colorectal cancer as “sufficient” or “limited”.
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Figure 3. Colorectal and lung cancer correlation in asbestos cohorts (IARC 2012). 
 
Studies published after the IARC evaluation
Harding et al. (2009) reported the mortality in a cohort of 98 117 British asbes-
tos-exposed workers followed from 1971 to 2006 (19). There were 297 deaths 
from cancer of the colon, SMR 128 (95% CI 114‒144), and 183 deaths from rec-
tal cancer SMR 151 (130‒174).
Strand et al. (2010) investigated the cancer incidence from 1953 to 2007 in a 
cohort of 28 300 officers and enlisted servicemen in the Royal Norwegian navy 
(21). An excess of mesothelioma was found among engine room crew only – 
supposedly more exposed to asbestos than non-engine room crew. The SIR 
for colorectal cancer in cohort members in vessel service > 2 years was 1.15 
(0.95‒1.39), but no association was seen with engine room work, and the study 
does not support an association with asbestos exposure. 
Pesch et al. (2010) reported the mortality up to 2007 among 576 German 
workers exposed to asbestos (96). The SMR for colorectal cancer (7 cases) was 
0.77 (0.31 –1.59).
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Clin et al. (2011) reported the cancer incidence 1978–2004 in a cohort of 2024 
workers from an asbestos reprocessing plant in Calvados (France) (98). There 
were 25 cases of colorectal cancer, the SIR among workers with the highest 
average exposure level (9‒107 fibers/ml) showed a SIR for colorectal cancer of 
7.20 (0.91‒56.7). P for trend with average exposure level was 0.02. The associa-
tion with cumulative exposure was weaker.  
Menegozzo et al. (2011) reported the mortality 1965–2005 in a cohort of 1,247 
male asbestos cement workers in Naples, Italy (20). There were 14 deaths from 
cancer of the colon and rectum, SMR 129.9 (71.0‒218.0). Dose-response data 
were not reported for colorectal cancer. 
Pavone et al. (2012) studied the mortality in cohort of 1849 railway rolling 
stock and repair workers in Bologna, followed for mortality 1960–2008 (99). 
There were 12 cases of colon cancer, SMR 0.81 (95%CI 0.46‒1.42). An increased 
mortality was found both for mesothelioma and lung cancer.
Three small cohort studies, from Japan (100), China (65) and Italy (101) includ-
ed only few cases of colorectal cancer, no statistically significant excess was 
reported. 
Mortality and cancer incidence in association with environmental exposure to 
blue asbestos during childhood, the Wittenoom residents’ cohort, was report-
ed by Reid et al. (2013) (64). The cohort included 2460 adults that have lived 
in an asbestos mining town before age 15. Two methods of deriving expected 
numbers were used which gave different results. Assumption that all lost to 
follow-up (20% of the cohort) were alive and disease-free at end of follow-up, 
which underestimates risk, gave a smoking-adjusted SIR for colorectal cancer 
of 1.21 (0.55‒2.29). Censoring of person-years for calculation of expected 
numbers (but not cases) at latest date known to be alive, which results in 
greater estimates of risk, gave an SIR of 2.15 (0.98‒4.08). 
Overall conclusions
The IARC working group considered the evidence quite strong but not defini-
tive for a causal relationship between asbestos exposure and colorectal cancer. 
Half of the working group considered the evidence from human epidemiology 
to be sufficient, half considered it limited. Of studies published after the IARC 
evaluation, a very large cohort of British asbestos workers supported a caus-
al relationship, and a study of French asbestos reprocessing plant workers 
showed a significantly increasing SIR with average exposure (but not cumu-
lative exposure) to asbestos. A study of Norwegian navy officers and service 
men, using indirect exposure indicators, a cohort of Italian railway workers, 
and a smaller study of German asbestos workers gave no support for an associ-
ation between asbestos exposure and colorectal cancer. 
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Thus, a relatively large number of cohort and case-control studies show an 
excess of colorectal cancer in association with asbestos exposure, but the 
findings are not entirely consistent. A few studies showed a significant positive 
association with cumulative exposure to asbestos, and one study showed a sig-
nificant association with average exposure. A meta-analysis taking SMR of lung 
cancer as an indirect indicator of asbestos exposure showed a fairly consistent 
pattern with increasing SMR for colorectal cancer when the SMR for lung can-
cer increased. SMR for colorectal cancer increased with severity of asbestosis 
in one study. Taken together, these dose-response data are supportive of a 
causal relationship between asbestos exposure and colorectal cancer. The 
plausibility of the theory that asbestos causes colorectal cancer has support in 
mechanistic data showing the presence of asbestos and asbestos bodies in the 
colon of exposed persons. 
Most of the reported studies are cohort studies comparing the risk of colorec-
tal cancer among workers in manual occupations with the general population, 
with a potential for negative confounding due to the protective effect of physi-
cal activity at work on the risk of colon cancer. This may have tended to under-
estimate the observed relative risk rather than overestimating it. Considering 
the large number of positive studies, the demonstrated dose-response, and 
potential for negative confounding, it seems likely that asbestos exposure is 
causally related to colorectal cancer. However, the reports published since the 
IARC evaluation are not definitive. Recognizing that the available evidence is 
relatively strong, colorectal cancer is classified as reasonably anticipated to be 
caused by asbestos (equivalent to IARC Group 2A).
Few studies have presented risk estimates separately for colon and rectal can-
cer. For those which have done this, asbestos seems to affect the risk of cancer 
of the colon, especially cancer of the right part of colon.
The magnitude of the reported relative risk varies between studies and is in 
the range of 1.3 to 5. Assessed study-by-study, SMRs for colorectal cancer 
tended to be lower than SMRs for lung cancer, indicating that the effect of 
asbestos, in terms of relative risk, is considerably weaker for colorectal can-
cer than for lung cancer. Based on IARC’s analysis shown in Figure 3, under 
conditions of asbestos exposure associated with a RR for lung cancer of 2, 
the estimated RR for colorectal cancer is 1.1, with an estimated AF for asbes-
tos-causation of about 9%. When the RR for colorectal cancer is 2, the estimat-
ed RR for lung cancer is 5.2.
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Stomach cancer
Stomach cancer is one of the most frequently occurring cancers and causes of 
cancer death globally (6). Age-standardised incidence rates vary considerably 
among countries with high levels prevailing in Japan and Eastern Asia, China, 
Eastern Europe and tropical South America and much lower rates in Eastern 
and Northern Africa, North America and Southern Asia (102). On average, de-
veloped countries have a better 5-year survival rate (overall 28%) than devel-
oping countries (18%) (102). The strongest factor known to be associated with 
stomach cancer is chronic infection with Helicobacter pylori, a gram-negative 
bacterium (103). The prevalence of H. pylori infection in humans is higher in 
developing countries (approximately 75%) and lower (around 60%) in devel-
oped countries although it has been suggested that only 5% of infected hosts 
will develop this cancer (102). A high dietary intake of irritant substances, such 
as salts and nitrates, are known to cause chronic in flammation and gastritis 
(104). 
Cohort studies
Cohort studies reviewed in the recent update by IARC (4) together with more 
recent papers identified in a systematic review and meta-analysis by Fortunato 
& Rushton (found in (105)) are summarized in table 5 of the online supplement. 
Studies have been carried out mainly in Europe and North America, but also 
include cohorts from China, Russia and Australia and range from very small 
to over 55 000 workers. Several cohorts included women although they were 
usually a small proportion of the total. Four cohorts involved only women (51, 
53, 106) and 3 reported results for the total cohort (86, 107, 108). Asbestos 
exposure occurred in a range of industries with the most common occupations 
being insulators, generic asbestos workers, textile asbestos workers, cement 
asbestos workers, and miners.  
The largest overall cohort RRs for stomach cancer mortality were among the 
earliest studies of insulation workers (82) with a RR of 3.52 (95%CI 2.19, 5.67), 
and among two sets of workers in Chinese asbestos factories Pang 1997 (109), 
Zhu & Wang 1993 (108): RRs were 4.40 (95%CI 1.64, 11.84) and 2.40 (95%CI 
1.65, 3.48), respectively for stomach cancer mortality. Two studies carried out 
in Canada (Liddell et al 1997 (12)) and UK (Harding et al. 2009 (19)), involving 
183 and 322 deaths from stomach cancer, show significantly increased RR es-
timates with narrow confidence intervals: RR=1.24 (95%CI 1.07, 1.44) and RR= 
1.66 (95% CI 1.49, 1.86) respectively. Fewer stomach cancer incidence studies 
have been carried out.  The largest overall cohort RR for incidence was among 
Danish asbestos cement workers (Raffn et al. 1989 (14)) with a RR of 1.43 (95% 
CI:1.03‒1.93). All the other incidence studies reported RRs close to one.
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Estimates of cumulative (e.g. fibre-years) or duration of exposure among as-
bestos-exposed workers were reported in at least 11 studies but patterns were 
unclear in most studies. For example, no clear patterns of increase in mortality 
of stomach cancer by duration of exposure were found in Harding et al (19), by 
degree of exposure in Berry et al (52), or by cumulative exposure in Liddell et 
al (12); the RR for the highest cumulative exposure category (>1000 mcpf/year) 
in Liddell et al was 3.21. In contrast, Selikoff et al 1979 (82) found evidence of 
a dose–response relationship with duration of asbestos exposure to asbestos 
with the SMR for cancer of the stomach increasing from 0.00 in workers ex-
posed for < 20 years, to 4.00 (95%CI: 1.47–8.71) in those exposed for 20−35 
years, and to 3.42 (95%CI 1.82–5.85) in those exposed for >35 years. 
Risk of stomach cancer mortality relative to lung cancer mortality in 30 ex-
posed cohorts was reported by IARC, which found a linear relationship be-
tween SMRs for stomach cancer and lung cancer, with an R2 value of 0.6623 
(Figure 4) (4). SMRs for stomach cancer were generally lower than those for 
lung cancer. Based on the linear regression equation reported by IARC, under 
conditions of asbestos exposure associated with a lung cancer SMR of 2, the 
stomach cancer SMR is 1.2. When the stomach cancer SMR is 2, the lung can-
cer SMR is 3.96. 
Figure 4. Stomach and lung cancer correlation in asbestos cohorts (IARC 2012).
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There have been several studies carried out more recently. No results were 
reported for stomach cancer in the recent update of mortality and cancer in-
cidence in association with environmental exposure to blue asbestos during 
childhood in the Australian Wittenoon residents’ cohort (64). No elevated risk 
of stomach cancer was seen in the study of Norwegian navy personnel (21). A 
study of German workers exposed to asbestos found a SMR of 1.15 (0.37, 2.68) 
for stomach cancer mortality (97). A study of Italian asbestos textile workers 
reported an SMR of 1.20 (0.67, 1.98) (101).
Case-control studies 
IARC reviewed five case control studies exploring the relationship between 
asbestos exposure and stomach cancer and concluded that they gave inconsis-
tent results. A study from Poland (Krstev et al., 2005) found an OR for cancer 
of the stomach of 1.5 (95%CI 0.9, 2.4) for workers ever exposed to asbestos, 
and of 1.2 (95%CI: 0.6–2.3) for workers with tenor more years of exposure to 
asbestos (109). The largest case–control study (Cocco et al., 1994) reported 
OR of 0.7 (95%CI: 0.5–1.1) for workers ever exposed to asbestos, and of 1.4 
(95%CI: 0.6−3.0) for those with 21+ years of exposure to asbestos (111). 
The most strongly positive case–control study linking asbestos to cancer of the 
stomach is the case–control study nested within the Western Australia mining 
cohort (Reid et al.,2004) (11). They found an OR of 1.38 (95%CI 0.99, 1.92) for 
cumulative exposure to crocidolite per fiber/mL-year. Smoking status was asso-
ciated with cancer of the stomach, but not significantly.
Reviews and meta-analyses
IARC reviews three reviews and meta-analyses. An early one by Frumkin & Ber-
lin (1988) stratified studies by SMR for lung cancer and percentage of deaths 
from mesothelioma and found an SMR of 0.91 (95%CI 0.71,1.16) for cohorts 
where the lung cancer SMR was <2.00 and an SMR of 1.34 (95%CI 1.07,1.67)for 
the lung cancer SMR > 2.00 (112). Gamble (2008) evaluated the weight of evi-
dence for an association between asbestos and stomach cancer and concluded 
overall that the epidemiological evidence was weak (96). 
A meta-analysis of 42 cohort studies by the IOM noted that the ‘majority of 
cohort relative risk estimates for cancer of the stomach exceed the null value 
(1.0), indicating excesses, although estimates varied considerably in strength’ 
(39). A meta-RR of 1.17 (95%CI 1.07, 1.28) was found for any versus no expo-
sure. For high versus no exposure, the lower meta-RR was 1.31 (95%CI 0.97, 
1.76), and the higher bound meta-RR was 1.33 (95%CI 0.98, 1.79). A meta-
analysis of the five case–control studies gave a combined RR of 1.11 
(95%CI 0.76, 1.64). 
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The summary OR increased when only extreme exposure was considered 
(OR, 1.42 95%CI 0.92, 2.20).
In addition to the above, Goodman et al. (1999) reviewed 69 asbestos-exposed 
occupational cohorts, 42 in Europe, 22 in North America and the remainder 
elsewhere (36). The earliest study was published in 1967 and the most recent 
in 1997. The studies covered a variety of occupations, including: asbestos 
products manufacture (22%); cement workers (20%); shipyard workers (12%); 
asbestos miners and millers (10%); and textile workers (10%). The pooled 
analysis had 9 cohorts that provided results for stomach cancer with a latency 
period of ten years and 33 without. Overall, the meta-SMR for stomach cancer, 
without taking into account latency, was 1.06 (95%CI 0.99, 13), with no signif-
icant evidence of heterogeneity (p=0.13). However, there was no excess risk 
when the analysis was based on only 4 studies taking into account latency (me-
ta-SMR=0.92, 95%CI 0.11, 1.10). 
An updated meta-analysis of cohort stomach cancer and asbestos studies that 
included exploration of heterogeneity and publication bias by Fortunato & 
Rushton (included in reference (105)) found an overall meta-SMR for stomach 
cancer mortality in the total cohort of 1.16 (95% CI 1.04, 1.30), with heteroge-
neous results across studies (p<0.001). 
In a sensitivity analysis, results from Selikoff (1979) (82), Ohlson (1984) (113) 
and Zhu (1993)(108) had the most influence on the overall result. Statistically 
significant excesses were observed for men in studies from North America 
(meta-SMR=1.32, 95% CI 1.06, 1.64), but not in Europe (meta-SMR=1.04, 95%CI 
0.90, 1.20) or “Other” (meta-SMR = 1.49, 95% CI: 0.58, 3.83). The pooled anal-
ysis within occupational strata demonstrated the highest meta-SMR for stom-
ach cancer among generic asbestos workers (meta-SMR=1.51, 95% CI: 1.16, 
1.97), followed by insulators (meta-SMR= 1.27, 95% CI: 0.88, 1.82). When stud-
ies were divided into tertiles according to percentage of deaths due to meso-
thelioma, there was a dose-response relationship of increasing stomach cancer 
meta-SMRs with increasing percentage of mesothelioma deaths: < 0.69% (SMR 
= 1.00, 95% CI: 0.85, 1.19); >0.69% < 2.7% (SMR = 1.18, 95% CI: 1.01, 1.38); > 
2.7% (SMR = 1.25, 95% CI: 1.02, 1.53). 
There is also a meta-analysis (Sun et al 2008) (114) published in Chinese with 
an abstract in English, which included Chinese literature as well that reports 
a meta-SMR of 1.20 (P<0.01) among workers exposed to chrysotile alone or 
mixed asbestos. The stomach cancer SMR was significantly increased in the as-
bestos cement workers, the screening mine workers and the insulators, (1.27, 
1.21 and 2.13 respectively, P < 0.05).
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Overall conclusions
Overall, the cohort studies and the various meta-analyses of cohort studies 
generally provide consistent evidence of an increased risk of stomach cancer 
associated with asbestos exposure. Risk estimates tend to be higher in cohorts 
where heavy exposure to asbestos occurs and with long follow-up periods. 
There is also evidence that increasing exposure increases this risk. There are 
few case-control studies and these give less consistent results. There is limited 
information to draw conclusions about the different asbestos fibre types.
From the standpoint of magnitude of risk, the excess risk associated with ever 
exposure to asbestos varies between the studies but is of the order of 15‒20%. 
Positive dose–response relationships have been observed between cumulative 
asbestos exposure and stomach cancer mortality in several cohort studies e.g. 
Selikoff & Hammond (1979) (82), Liddell et al., (1997) (12), Pang et al., (1997) 
(109). 
IARC’s recent evaluation continues to be relevant and stomach cancer is clas-
sified as an entity that is reasonably anticipated to be caused by asbestos 
(equivalent to IARC Group 2A). Based on IARC’s analysis shown in Figure 4, 
under conditions of asbestos exposure associated with a RR for lung cancer of 
2, the estimated RR for stomach cancer is 1.2, with an estimated AF for asbes-
tos-causation of about 17%. When the RR for stomach cancer is 2, the estimat-
ed RR for lung cancer is 3.96.
Non-malignant entities
Ventilatory impairment and chronic airway obstruction
Over the years, the relationship between asbestos exposure, asbestos-in-
duced parenchymal and pleural disease and chronic lung function impairment 
has received much attention. In 2004, the American Thoracic Society (ATS) 
noted that asbestos exposure was traditionally considered a cause of restric-
tive impairment, but its role as a cause of obstructive impairment was more 
controversial (115). However, ATS also noted that asbestos exposure had long 
been associated with physiological obstruction and described the involvement 
of small airways by asbestosis as a potential explanation. Several years later, 
a Delphi study was conducted by the American College of Chest Physicians 
(116). The Delphi panel could not reach consensus in answering the question of 
whether asbestos exposure, in the absence of interstitial fibrosis, could cause 
chronic obstructive pulmonary disease (COPD). Nor could it reach consensus 
on the question of whether a decline in small airway flow rates in a smoker can 
be attributed to asbestos.
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Many factors are associated with chronic airway obstruction, of which COPD is 
the most important cause. In the U.S.A., approximately 75% of COPD cases are 
attributed to cigarette smoking and another 15% to occupational exposures. 
COPD is also associated with genetic factors like alpha-1 anti-trypsin deficiency, 
asthma, respiratory infections and exposure to air pollutants (117). Occupa-
tional exposure to a variety of organic and inorganic dusts, vapors, gases, and 
fumes have been associated with risk for COPD (118). In developing countries, 
exposure to smoke generated by burning biomass as fuel is a very important 
risk factor for COPD and, in fact, might be the most important global risk factor 
for COPD (119).
Longitudinal studies
Cohort studies with longitudinal assessment of spirometry results avoid some 
limitations of cross-sectional studies. For example, they allow comparison of 
individuals’ findings to their own previous results, avoiding the problem en-
countered in cross-sectional studies that workers often have better pulmonary 
function than might be expected from the clinical prediction equations derived 
from general populations that are used to interpret results (120).  A review of 
the literature identified 20 peer-reviewed longitudinal studies (see table 6 in 
online supplement). One of those reviewed (121) was a follow-up to an earlier 
study (122). 
In general, cohorts had substantial asbestos exposures and substantial preva-
lence of interstital and/or pleural findings (see table 6 in online supplement).
Although their findings vary, several general themes can be drawn from these 
longitudinal studies. In general, lung function decrements associated with 
asbestos exposure are restrictive, with forced expiratory volume in 1 second 
(FEV1) and forced vital capacity (FVC) falling together and FEV1/FVC percent 
relatively spared but falling a small amount in some studies (121‒131). Radio-
graphic changes that have been associated in many studies with worse pul-
monary function at initial evaluation and in some with more rapid subsequent 
decline are interstitial involvement characterized by irregular small opacities, 
and diffuse pleural thickening (DPT) (123, 127, 129, 132‒135). Findings of stud-
ies evaluating associations between the presence of localized pleural thicken-
ing (LPT) or pleural plaques and pulmonary function have been less consistent, 
perhaps due to lesser magnitude of effect (126, 131, 136). There is a suggestion 
that progression with greater extent of pleural involvement may be associated 
with greater effect on lung function (131). Smoking contributes to the decline 
in lung function, in many studies with greater effect on FEV1 than FVC (123, 
124, 127, 132, 134, 135, 137). In most studies, greater than additive effects  
of asbestos and tobacco smoke exposure have not been reported. However,  
a few have suggested possible interactions (126, 132). 
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Cumulative asbestos exposure history contributes to rate of FEV1 and FVC 
decline, but in general the magnitude of effect of exposure alone is less than 
the magnitude of effect of interstitial disease, DPT, or smoking (123, 133, 135, 
138). In a study with mean duration of exposure of about tenyears, decline in 
FVC and FEV1 accelerated after about 15 years since first exposure (122). In a 
few studies where there had been a long latency of several decades between 
asbestos exposure and baseline evaluation, the main impact of asbestos expo-
sure on lung function appeared to have occurred by the time of the baseline 
evaluation (123, 132).
Relationship between radiographic changes and ventilatory 
impairment 
 
The relationship between radiographic changes and lung function impairment 
in asbestos-exposed people was recently been examined in a structured lit-
erature review and meta-analysis (139). The review identified studies that re-
ported lung function, radiographic findings by computed tomography or plain 
film, and proportion of smokers among participants. Radiographic changes 
were categorized as normal imaging, pleural fibrosis (including both pleural 
plaques [PP] and DPT), or asbestosis (interstitial disease). Information needed 
to be available about quality of spirometry and the reference equations used 
to evaluate lung function results. A total of 27 cross-sectional, one case-con-
trol, and two longitudinal studies met criteria for inclusion. The final number of 
participants in the meta-analysis was 9921. The mean duration of occupational 
exposure to asbestos, reported in 22 studies, ranged from 8.4 to 32.7 years. 
The latency time, reported in 9 studies, ranged from 24.5 to 43.3 years.
The overall findings were that, among exposed workers, lung function was best 
in those with normal imaging, worsened in the presence of pleural fibrosis and 
further worsened in the presence of asbestosis.  The quantitative findings of 
the meta-analysis were as follows: FVC (mean % predicted): normal imaging 
– 95.7%, pleural fibrosis – 89.0%, asbestosis – 86.5%.  FEV1: normal imaging – 
93.6%, pleural fibrosis – 89.2%, asbestosis – 85.7%. A smaller group of studies 
reported FEV1/FVC (as % predicted) in a way that was usable in the meta-anal-
ysis, and there was not the same gradient by radiological finding in this param-
eter (mean FEV1/FVC [% predicted]): normal imaging – 96.4%, pleural fibrosis 
– 95.4%, asbestosis – 95.5%. In general, the impact of radiological findings on 
lung function was less when chest computed tomography (CT) was used in 
studies to identify changes than when plain imaging was used, perhaps reflect-
ing the greater sensitivity of CT. Studies with larger proportions of non-smok-
ers tended to report less impairment in FEV1 in all three radiographic cate-
gories. In their discussion, the authors noted that the study could not answer 
whether the observed statistically significant lung function impairments at 
the population level were also of clinical relevance at the individual level and 
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also noted that small decreases in group mean did not preclude clinically im-
portant disease in individuals. The authors called for further research, especial-
ly on the role of smoking, other occupational exposures (such as other mineral 
dusts, welding fumes) and possible synergistic effects on the development of 
functional impairment, especially chronic airway obstruction, in asbestos-ex-
posed workers.
It has been suggested that asbestos exposure and cigarette smoking might 
interact in producing reduced FEV1/FVC ratio (140). A recent cross-sectional 
study not included in the meta-analysis addressed whether asbestos exposure 
alone in the absence of smoking causes obstructive lung disease (141). It evalu-
ated 277 Chinese chrysotile asbestos textile workers (mean exposure duration 
16.7 years, 22% nonsmokers) and 177 non-asbestos-exposed controls who 
worked in the electronics industry in the same geographical area. Obstructive 
impairment was 2.5 times more prevalent in asbestos-exposed workers than 
controls (34% vs. 15%). In multivariate analyses limited to nonsmokers, there 
were significant associations between asbestos exposure and low percent pre-
dicted FEV1, FVC and carbon monoxide diffusing capacity (DLCO) after account-
ing for age. The non-smoking asbestos workers had about 3% lower FEV1/FVC 
ratios compared to non -smoker control workers of similar age and height, but 
this difference did not achieve statistical significance. The authors concluded 
that asbestos exposure, especially when radiographic evidence of interstitial 
fibrosis from asbestosis is present, leads to significant decreases in FVC, FEV1 
and DLCO. 
However, asbestos exposure alone was not associated with a significant reduc-
tion in the FEV1/FVC ratio.  In their discussion, the authors suggested that the 
failure to demonstrate a significant decrease in FEV1/FVC ratio in nonsmoking 
asbestos-exposed individuals was the result of insufficient sample size. They 
also noted that FEV1/FVC ratio generally reflects large airways function, but 
that the earliest asbestos lung lesions are peri-bronchiolar and not captured by 
standard lung function testing. They called for further research to assess the 
progression and clinical significance of asbestos-induced airway dysfunction. 
Another recent investigation evaluated associations between radiographic 
findings and spirometry in 6475 participants in a community-based screeening 
program in Libby, MT, where there had been widespread amphibole asbestos 
exposure (142). Participants were evaluated by plain chest radiography and 
spirometry. A total of 50 participants had parenchymal abnormalities, 58 DPT, 
and 708 LPT. Parenchymal abnormalities were signficantly associated with 
restriction and mixed abnormal spirometry, but not isolated obstruction. DPT 
and LPT were both significantly associated with restrictive spirometric ab-
normalities, with the magnitude of effect greater for DPT. Among those with 
LPT, severity of restriction correlated with the severity of LPT. Several other 
large cross-sectional studies have also demonstrated a significant association 
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between LPT and reduction in FVC or restrictive impairment, a lesser effect 
on lung function of LPT than DPT, and an association between degree of lung 
function impairment and extent of LPT (143-145).
Several studies have sought to correlate pulmonary function impairment with 
anatomic changes identifiable by thin-section CT (146-149). One of these stud-
ies reported an effort to apportion pulmonary function deficit between asbes-
tos-induced and smoking-related disease using thin-section CT (147). 
In this retrospective study of asbestos-exposed individuals who had undergone 
chest CT, an initial multivariate analysis was used to relate CT features with 
reduction in total lung capacity (TLC) and DLCO. Important significant individ-
ual predictors included extent of pulmonary fibrosis and circumference of dif-
fuse pleural thickening (asbestos-induced effects) and emphysema (felt to be 
a smoking-associated effect). Combined CT variables could account for 58% of 
the variability in TLC and 57% of the variability in DLCO. When these predictive 
equations were applied to a validation group, they were able to explain 52% 
of the variance in TLC, 40% of the variance in DLCO, and 46% of the variance 
in FVC. Another study of 590 asbestos-exposed workers in construction trades 
found that FVC and TLC were negatively correlated with fibrosis score, paren-
chymal bands, and extent of pleural thickening. They were positively associat-
ed with widened retrosternal space. FEV1⁄FVC was negatively correlated with 
emphysema and widened retrosternal space and positively correlated with 
parenchymal bands and subpleural nodules. Thickened bronchial walls did not 
separate between restriction and obstruction (148).
Overall conclusion
Available studies indicate that the pattern of spirometric impairment associ-
ated with asbestos exposure is primarily restrictive, with reduced FEV1 and 
FVC and relatively preserved FEV1/FVC ratio. Studies have also suggested that 
a component of airways obstruction can also be present, in particular small 
airways obstruction, although in the absence of other hazardous co-exposures 
such as tobacco smoke, obstructive changes are generally of lesser prominence 
and are more difficult to demonstrate. Statistically significant spirometric 
impairment can be demonstrated in populations with sufficient exposure to 
cause pleural thickening or asbestosis, even among those without radiographic 
changes. However, the prevalence of clinically significant spirometric impair-
ment in such individuals is unclear. The magnitude of impairment is consider-
ably greater in the presence of DPT and/or asbestosis. Also, some studies have 
also identified LPT as a risk factor for spirometric impairment. Magnitude of 
impairment increases with age and with smoking. 
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Thus, restrictive ventilatory impairment in those with sufficient asbestos ex-
posure to potentially cause parenchymal or pleural disease, whether radio-
graphically present or not, is known to be caused by asbestos. Large airway 
obstruction associated with decreased FEV1/FVC ratio has been associated 
with asbestos exposure in some studies, but the findings have not been as con-
sistent as for restriction. Thus, large airway obstruction is categorized as rea-
sonably anticipated to be caused by asbestos. Smoking interacts with asbestos 
exposure in producing this pattern of impairment.
Findings of asbestos-induced pleuroparenchymal disease and of emphysema 
have been reported to explain only about half the variance in TLC, FVC, and 
DLCO in those exposed to asbestos with or without tobacco smoking. There-
fore, more remains to be learned about the determinants of lung function 
impairment in asbestos-exposed individuals, particularly in those without 
radiographic evidence of asbestos-induced parenchymal or pleural disease. In 
addition, more needs to be learned about how to attribute impairment in lung 
function to various potential causes when more than one potential cause is 
present.
Retroperitoneal fibrosis
Retroperitoneal fibrosis (RPF) or Ormond’s disease was first described in 1948 
and is a rare disease featuring the proliferation of fibrous tissue in the retro-
peritoneum compartment of the body containing the kidneys, urinary tract, 
aorta, and various other structures (150).  Symptoms result from entrapment 
of the ureters, the great vessels and their branches, and the surrounding 
nerves and include lower back, flank and/or abdomen pain, weight loss, fever, 
malaise, anorexia, non-specific gastrointestinal complaints, and less frequently, 
urinary symptoms (151).  
The pathognomonic feature of RPF is a thick retroperitoneal fibrotic mass cov-
ering the abdominal aorta and compressing the ureters (150).  About 10‒15% 
of patients with RPF will also have fibrosis outside of the abdomen (152).  His-
tologically, RPF appears as a nonspecific inflammatory process that evolves 
over time from collagen bundles, with capillary proliferation, and abundant 
inflammatory cells, predominantly lymphocytes, plasma cells and fibroblasts, 
to dense matted avascular and acelluar connective tissue (151).  The inflam-
matory nature idiopathic RPF is supported by common findings of elevated 
erythrocyte sedimentation rate, positive antinuclear antibodies, and response 
to anti-inflammatory medications (150).  Malignancy associated RPF is virtually 
indistinguishable from RPF from other causes and may only be determined by 
demonstration of small islands of tumor cells within the fibrotic tissue and im-
munohistological studies (151).  
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The incidence of RPF was estimated to be one per one million person-years 
(age standardized) in Finland. Case identification was based on diagnostic 
codes 5934A (other ureteric obstruction including idiopathic RPF) in ICD 9 (In-
ternational Classification of Diseases, 9th revision) for 1990–1995 and D20•0 
(retroperitoneal benign neoplasm) in ICD 10 for 1996–2001 (150). Prevalence 
of RPF was estimated to be 1.38/100,000 for the study area in Finland (150). 
There is a similar prevalence of 1.3 per 100,000 people in the Netherlands 
(153). 
A frequency of 1 case per 25,000 hospital admissions was reported in the USA 
(152). Males are affected 2-3 times more often than females and patients are 
usually diagnosed in the 4th -7th decades of life (152). About 2/3 of the cases of 
RPF are idiopathic with the remaining cases secondary to a variety of causes 
including malignant disease (mostly metastatic disease from lung, breast, pros-
tate or digestive tract, and malignant lymphoma or sarcoma), radiation ther-
apy, abdominal surgery, pancreatitis, haematomas, infections, and as a side 
effect of several drugs, especially methysergide and other ergot derivates  (150, 
151).  Additionally, RPF has also been associated with IG4-related abnormali-
ties, with elevated serum IgG4 concentrations and infiltration of IgG4-positive 
plasma cells in affected tissues (154). 
Cases and studies of asbestos and RPF
Evidence of an association between asbestos exposure and RPF is limited to 
case reports, two case-series, and one case-control study as described below. 
Case Reports
Asbestos exposure as a possible causative factor for RPF was first reported in 
1991 in a patient with significant asbestos exposure and rapidly progressive 
pleural and retroperitoneal fibrosis (155).  Subsequently, there have been ten 
additional case reports describing individuals with RPF, a history of asbestos 
exposure, asbestos-related radiologic findings, and no other known risk fac-
tors for RPF (156‒159). In one of these cases, an autopsy was performed and 
asbestos fibers were demonstrated to have reached the retroperioneal space 
(159).  All cases were males, age at diagnosis ranged from 48‒67, with a history 
of occupational or workplace-related asbestos exposures (see table 7 in online 
supplement).    
Case Series
Sauni et al. (158) retrospectively identified 13 idiopathic RPF cases diagnosed 
between 1987 and 1995 at one hospital in southern Finland.  Cases were fol-
lowed up questionnaires and interviews. Of the 13 cases, 7 male patients had a 
history of occupational asbestos exposure and five had radiographic evidence 
of asbestos-related abnormalities (included in table in online supplement).   
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Overall, male patients with RPF, in comparison to the Finnish male population, 
appeared to more commonly have asbestos exposure and asbestos-related 
radiographic findings (158).  Similarly, van Bommel et. al. (153) prospectively 
evaluated 53 consecutive patients with idiopathic RPF at a tertiary care center 
in the Netherlands from April 1998‒January 2008.  The authors found high 
frequency of occupational asbestos exposure (20%) and asbestos-related pleu-
ral changes (17%) among males with RPF (153). An autopsy series of individ-
uals who underwent medical-legal autopsy for suspicion of asbestos-related 
disease documented an accumulation of asbestos fibers in retroperitoneal 
para-aortic lymph nodes taken at the level of the renal arteries and in mesen-
teric lymph nodes of all of individuals with lung fiber concentrations exceeding 
1 million fibers/gram of dry tissue. Asbestos fibers were also demonstrated 
in the para-aortic and mesenteric lymph nodes of a substantial proportion of 
those with lesser lung fiber burdens (160).
Case Control Study
Uibu et al. (150) performed a case-control study to assess asbestos exposure 
as a risk factor for RPF in three hospital districts in Finland from 1990‒2001.  
The study included 43 patients with RPF and 179 controls (matched on year 
of birth, sex, hospital district/catchment area) that were all alive during the 
study period.  Information concerning risk factors for RPF and occupational 
exposures were gathered through questionnaires and interviews.  Cumulative 
asbestos exposure (fiber-years) were classified by an industrial hygienist, expo-
sure grading was masked, and interviewers were blinded to participant status. 
Cases of RPF were strongly associated with asbestos exposure. The odds ratio 
(OR) adjusted for potential risk factors for RPF was 5•54 (1•64–18•65) for less 
than ten fiber-years of asbestos exposure and increased to 8•84 (2•03–38•50) 
for tenor more fiber-years.  A follow-up study of 38 cases and 18 controls with 
HRCT found that 73% of asbestos-exposed RPF cases also had asbestos-related 
pleural pathology, however, interstitial fibrosis was not elevated among those 
with RPF (161).  
Overall conclusions
Evidence for causation of RPF by asbestos is suggested by a limited body of 
literature including case reports, two case series and one case control study. 
Thus, the epidemiological evidence alone is insufficient to permit a firm con-
clusion about causation of RPF by asbestos. However, a case report and an 
autopsy series documenting accumulation of asbestos fibers in the retroper-
itoneal space supports the biological plausibility of asbestos-causation and it 
is reasonable to conclude that RPF can be caused by asbestos. All RPF patients 
should be evaluated for a history of asbestos exposure along with other risk 
factors.
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There is limited information about intensity of exposures required to cause RPF, 
relative potencies of different asbestos fiber types, etc. However, available evi-
dence suggests that those with sufficient exposure to develop asbestos-related 
pleural pathology are at increased risk. 
Summary
Laryngeal cancer as an asbestos-related disease
IARC recently concluded that there is sufficient evidence for asbestos-causation 
of laryngeal cancer in humans (4). Overall, both cohort and case-control studies 
provide consistent evidence of an increased risk of laryngeal cancer associated 
with asbestos exposure. There is also evidence that increasing exposure increas-
es this risk. Thus, laryngeal cancer is known to be caused by asbestos (equivalent 
to IARC Group 1).
Based on laryngeal and lung cancer SIRs reported from published cohort stud-
ies, we estimate the RR for laryngeal cancer in an exposed cohort to be some-
what less than the RR for lung cancer. Under conditions of asbestos exposure 
associated with a RR for lung cancer of 2, the estimated RR for laryngeal cancer 
is 1.58, with an estimated AF for asbestos-causation in the exposed population 
of about 37%. When the RR for laryngeal cancer is 2, the estimated RR for lung 
cancer is 2.78.
Research opportunities include elucidating the asbestos exposure characteris-
tics associated with increased risk for laryngeal cancer; and documenting mech-
anisms for asbestos-induction of laryngeal cancer, including evaluation of inter-
actions between asbestos and other known risk factors.
Ovarian cancer as an asbestos-related disease
IARC recently concluded that there is sufficient evidence for asbestos-causation 
of ovarian cancer in humans (4). Overall, there are relatively strong and consis-
tent findings of an increased risk for ovarian cancer among women in cohorts 
with relatively high asbestos exposures. Some evidence exists to support in-
creased risk at higher exposures, but it is limited. There is insufficient informa-
tion available detailing the histopathological subtypes of ovarian cancer assocat-
ed with asbestos-exposure. Still, it may now be concluded that ovarian cancer is 
known to be caused by asbestos (equivalent to IARC Group 1).
Based on ovarian and lung cancer SMRs reported from published cohort studies, 
we estimate that under conditions of asbestos exposure associated with a RR for 
lung cancer of 2, the RR for ovarian cancer is 2.18, with an estimated AF in the 
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exposed population for asbestos-causation of about 54.1%. When the RR for 
ovarian cancer is 2, the estimated RR for lung cancer is 1.71.
Research opportunities include elucidating the asbestos exposure charac-
teristics associated with increased risk for ovarian cancer; and documenting 
mechanisms for asbestos-induction of ovarian cancer, including evaluation of 
interactions between asbestos and other known risk factors. In this regard, it 
will be important to document the histological subtypes of ovarian cancer that 
are associated with asbestos exposure.
Colorectal cancer as an asbestos-related disease
IARC recently concluded that there is limited evidence in human epidemiology 
studies for an association between exposure to asbestos and cancer of the col-
orectum (4). However, the IARC working group was evenly divided as to wheth-
er the evidence was strong enough to view it as sufficient or limited. Consider-
ing the large number of positive studies, the demonstrated dose-response, and 
potential for negative confounding, it seems likely that asbestos exposure is 
causally related to colorectal cancer. However, the reports published since the 
IARC evaluation are not consistent. Recognizing that the available evidence is 
relatively strong, colorectal cancer is classified as reasonably anticipated to be 
caused by asbestos (equivalent to IARC Group 2A).
Based on IARC’s analysis of colorectal and lung cancer SMRs, under conditions 
of asbestos exposure associated with a RR for lung cancer of 2, the estimated  
RR for colorectal cancer is 1.1, with an estimated AF for asbestos-causation in 
the exposed population of about 9%. When the RR for colorectal cancer is 2,  
the estimated RR for lung cancer is 5.2.
Research opportunities include elucidating the asbestos exposure character-
istics associated with increased risk for colorectal cancer; and documenting 
mechanisms for asbestos-induction of colorectal cancer, including evaluation 
of interactions between asbestos and other known risk factors. In this regard, 
it will be important to document risks and mechanisms separately for colon 
and rectal cancer and to follow up on indications that the right part of colon is 
at higher risk. Also, since the RR and AF for colorectal cancer in an asbestos-ex-
posed population are lower than for lung cancer, it will be important to iden-
tify strategies to improve attribution of causation to asbestos in individuals, 
particularly when other risk factors are present.
Stomach cancer as an asbestos-related disease
IARC recently concluded that there is limited evidence in human epidemiol-
ogy studies for an association between exposure to asbestos and cancer of 
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the stomach (4). Overall, most cohort studies and the various meta-analyses 
of cohort studies provide consistent evidence of an increased risk of stomach 
cancer associated with asbestos exposure. Risk estimates tend to be higher 
in cohorts where heavy exposure to asbestos occurs and with long follow-up 
periods. There is also evidence that increasing exposure increases this risk. 
There are few case-control studies and these give less consistent results. Stom-
ach cancer may be viewed as reasonably anticipated to be caused by asbestos 
(equivalent to IARC Group 2A).
Based on IARC’s analysis of stomach and lung cancer SMRs, under conditions 
of asbestos exposure associated with a RR for lung cancer of 2, the estimated 
RR for stomach cancer is 1.2, with an estimated AF for asbestos-causation in 
the exposed population of about 17%. When the RR for stomach cancer is 2, 
the estimated RR for lung cancer is 3.96.
Research opportunities include elucidating the asbestos exposure character-
istics associated with increased risk for stomach cancer; and documenting 
mechanisms for asbestos-induction of stomach cancer, including evaluation of 
interactions between asbestos and other known risk factors. Also, since the RR 
and AF for stomach cancer in an asbestos-exposed population are lower than 
for lung cancer, it will be important to identify strategies to improve attribution 
of causation to asbestos in individuals, particularly when other risk factors are 
present.
Ventilatory impairment and chronic airway obstruction  
related to asbestos
Spirometric impairment, whether obstructive or restrictive, can have many 
causes. In evaluating for causation by asbestos, it is important to assess for 
other potential causes. Restrictive impairment has been demonstrated by 
many studies to occur in those with asbestos exposure at levels known to 
cause parenchymal or pleural disease. It has often been associated with reduc-
tion in DLCO. Although, on average, the magnitude of impairment is greater in 
the presence of pleural or parenchymal disease, restriction can also be demon-
strated at the population level in those with unremarkable chest radiographs. 
Thus, restrictive abnormalities are known to be caused by asbestos. At the 
individual level, restrictive or mixed obstructive/restrictive patterns of ventila-
tory impairment can be attributed to asbestos if asbestos-related pleural and/
or intersitial radiographic changes are present, particularly if alternative causes 
are not identified. Additional studies are needed to develop specific criteria for 
individual attribution of clinically significant restrictive or mixed obstructive/
restrictive impairment in the absence of radiographic changes.
Large airway obstruction associated with decreased FEV1/FVC ratio has been 
associated with asbestos exposure in some studies, but the findings have not 
been as consistent as for restriction, with many studies failing to show an asso-
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ciation with asbestos exposure. Thus, this type of airway obstruction is catego-
rized as reasonably anticipated to be caused by asbestos. Many studies suggest 
that smoking interacts with asbestos exposure in producing this pattern of 
impairment. Additional studies are needed to develop specific criteria for indi-
vidual attribution of clinically significant large airway obstruction to asbestos 
exposure.
Research opportunities include elucidating the determinants of lung func-
tion impairment in asbestos-exposed individuals, particularly those without 
radiographic evidence of parenchymal or pleural disease. Even in those with 
asbestos-induced pleuroparenchymal disease, CT findings have been reported 
to explain only about half the variance in TLC, FVC, and DLCO. Although studies 
have shown statistically significant spirometric impairment in the absence of 
radiographic changes at the population level, more needs to be known about 
the frequency with which such individuals develop clinically significant chang-
es in lung function. Also, more needs to be learned about how to to attribute 
impairment in lung function to various potential causes when more than one 
potential cause is present.
Retroperitoneal fibrosis (RPF) as an asbestos-related disease
RPF is a rare condition that most often affects men in the 4th–7th decades of 
life. Evidence for causation by asbestos is based on a limited body of literature, 
including case reports, case series, and a case-control study. Thus, the epi-
demiological evidence alone is insufficient to permit a firm conclusion about 
causation of RPF by asbestos. However, biological plausibility is supported by 
a case report and an autopsy series documenting accumulation of asbestos 
fibers in the retroperitoneal tissues of exposed individuals.  Considering this 
information in total, it is reasonable to view RPF as being caused by asbestos. 
However, this is based on a very limited number of studies and the status of 
RPF might possibly change with new studies.
Available evidence suggests that those with sufficient exposure to develop as-
bestos-related pleural pathology are at increased risk, so presence of pleural 
findings indicates that sufficient exposure has occurred for attribution to as-
bestos. RPF occurring in an individual with evidence of asbestos exposure but 
without asbestos-related radiologic findings can be viewed as caused by asbes-
tos if other risk factors are not identified. All RPF patients should be evaluated 
for a history of asbestos exposure along with other risk factors. 
Research opportunities include elucidation of asbestos exposure characteristics 
associated with increased risk for RPF, such as intensity of exposures, relative 
potencies of different asbestos fiber types, etc. In addition, it will be important 
to elucidate the mechanisms underlying asbestos-causation of RPF.
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Table 2: Laryngeal cancer and exposure to asbestos, case-control studies with adjustment for 
tobacco and alcohol consumption
Reference Exposure Country Type of 
Study*
Study size 
period
Exposure Assessment Adjustment for smoking and alcohol consumption 
(and other potential cofounders)
1 2 3 Comments
Ever versus never exposed Dose-response relationships
1. Brown et al. 
(1988)
12 industries 
8 occupational 
categories 
Job titles 
12 chemicals 
(asbestos)
US Ho 183 M Ca 
250 M Co 
1975-1980
Jobs held at least 6 months, after 
1939 
Industrial hygienist classified job 
titles for exposure to specific ex-
posures
Exposed: 88 Ca, 99 Co 
RR=1.46 (0.98-2.18) 
CRR=1.46
Not studied HQ Y Y  
2. Imbernon et al. 
(1995)
Cohort of workers 
in the electricity 
and gas industry
France In 116 M Ca 
457 M Co 
1978-1989
All jobs in the company EDF 
JEM 
Industrial hygienist
Exposed: 38 Ca, 107 Co 
Adj for SES 
 
OR=1.5 (0.9-2.4)
Asbestos exposure, cumulative 
(all subjects) (fibers/cm3) 
Quartile1: RR=1.1 (0.5-2.8)
(8 Ca, 30 Co)
Quartile 2: RR=1.3 (0.5-3.3)
(7 Ca, 23 Co)
Quartile 3: RR=2.1 (0.9-4.3)
(14 Ca, 31 Co) 
Quartile 4: RR=1.6 (0.7-3.7)
(9 Ca, 23 Co)
- Y Y Case-control study nested within 
the cohort of 170,000 workers. 
They did not have information 
about smoking and alcohol 
consumption. They used socio-
economic status (smoking habits 
vary considerably in relation to 
SES)
3. Muscat et al. 
(1995)
Exposures 
(asbestos) 
Occupations
US Ho 194 M Ca 
184 M Co 
1985-1990
1. 6 jobs held at least 1yr 
occupation and linkage system 
applied to determine exposure 
probability and intensity 
2. Self-reported exposure (at least 
8hrs per week)
1. Occupation 
Exposed: 63 Ca, 48 Co 
RR=1.2 (0.7-2.0) 
CRR=1.3 
 
2. Self-reported exposure to 
asbestos 
Exposed: 15 Ca, 13 Co 
RR=0.8 (0.3-1.9) 
CRR=1.1
Not studied HQ Y Y Use RR from the analysis using 
occupations and not this one 
with the self-reported exposure: 
3 Ca of 15 Ca did not work in 
occupations classified as asbes-
tos related
4. Olsen et al. 
(1984)
Exposures (asbes-
tos)
Denmark Ho 326 Ca (276 
M, 50 W) 
1134 Ca (1134 
M, 163 W) 
1980-1982
Questions about their exposure 
to specific chemicals and physical 
agents
only men 
Exposed: 17 Ca, 34 Co 
OR=1.8 (1.0-3.4) 
COR=1.8
Not studied LQ Y Y  
5. Wortley et al. 
(1992)
Exposures (asbes-
tos) 
Occupations
US Po 235 Ca 
547 Co 
1983-1987
Job history 
Industrial hygienist performed JEM 
exposure assignments
NS but results not shown 
 
Meta-SIR=1.22 (0.86-1.72)
Highest exposure code for sub-
ject (code 0: never exposed, 
1-3=L-M-H) 
Low: OR=1.2 (0.6-7.1)
(3 Ca, 6 Co) 
Medium: OR=1.3 (0.8-2.0) 
(57 Ca, 94 Co) 
High: OR=1.1 (0.6-1.9)
(30 Ca, 54 Co)
- Y Y No overall RR for subjects ever 
exposed to asbestos. However, 
no significant dose-response 
relationship. Combined analysis 
of the RRs for the 3 levels: 
meta-SIR=1.22 (0.86-1.72), test 
for heterogeneity: p=0.91 
in agreement with authors’ com-
ment: suggestion of increased 
risk associated with asbestos
6. Zagraniski et al. 
(1986)
Industries 
Occupations 
(asbestos workers)
US Ho 92 M Ca 
181 M Co 
1975-1980
1. Job history (all jobs) 
2. Self-reported exposure 
(at least 20hrs per week for 
6 months or more)
1. Asbestos workers 
Exposed: 11 Ca, 18 Co 
OR=1.1 (0.4-2.9) 
 
2. Self reported exposure to 
asbestos: 
Exposed: 10 Ca, 24 Co 
OR=0.8 (0.4-1.7)
Not studied HQ Y Y Use the RR from the analysis 
using occupations
7. Dietz et al. 
(2004)
Cement dust 
related occupa-
tional groups
Germany Po 257 Ca (236 
M, 21 F) 
769 Co (702 
M, 67 F) 
1998-2000
1. Jobs held at least 6 months 
2. Quantification using job-specific 
supplementary questionnaires 
validated for asbestos
Only men 
Exposed: 59 Ca, 104 Co 
2. NS but results not shown 
 
High exposed group 
(>1000hrs) 
OR=1.3 (0.8-2.1) 
COR=2.1
Not studied HQ N Y  
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for heterogeneity: p=0.91 
in agreement with authors’ com-
ment: suggestion of increased 
risk associated with asbestos
6. Zagraniski et al. 
(1986)
Industries 
Occupations 
(asbestos workers)
US Ho 92 M Ca 
181 M Co 
1975-1980
1. Job history (all jobs) 
2. Self-reported exposure 
(at least 20hrs per week for 
6 months or more)
1. Asbestos workers 
Exposed: 11 Ca, 18 Co 
OR=1.1 (0.4-2.9) 
 
2. Self reported exposure to 
asbestos: 
Exposed: 10 Ca, 24 Co 
OR=0.8 (0.4-1.7)
Not studied HQ Y Y Use the RR from the analysis 
using occupations
7. Dietz et al. 
(2004)
Cement dust 
related occupa-
tional groups
Germany Po 257 Ca (236 
M, 21 F) 
769 Co (702 
M, 67 F) 
1998-2000
1. Jobs held at least 6 months 
2. Quantification using job-specific 
supplementary questionnaires 
validated for asbestos
Only men 
Exposed: 59 Ca, 104 Co 
2. NS but results not shown 
 
High exposed group 
(>1000hrs) 
OR=1.3 (0.8-2.1) 
COR=2.1
Not studied HQ N Y  
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Reference Exposure Country Type of 
Study*
Study size 
period
Exposure Assessment Adjustment for smoking and alcohol consumption 
(and other potential cofounders)
1 2 3 Comments
Ever versus never exposed Dose-response relationships
8. Gustavsson et 
al. (1998)
17 specific 
substances
Sweden Po 157 M Ca 
641 M Co 
1988-1990
Jobs held at least 1yr 
Occupational hygienist assigned 
exposure intensity 
Probability to 17 specific 
occupational exposures
1. > median of cumulative 
dose among exposed Co 
Exposed: 34 Ca 
RR high=1.69 (1.05-2.74) 
 
2. <  median of cumulative 
dose among exposed Co 
Exposed: 28 Ca 
RR low=1.21 (0.73-2.02)
Cumulative exposure distri-
bution among exposed Co 
(exposure intensity*prob of 
exposure *duration of expo-
sure) 
Quartile1: RR=1.16 (1.02-1.32)
(13 Ca, 43 Co) 
Quartile 2: RR=1.35 (1.04-1.74)
(15 Ca, 45 Co) 
Quartile 3: RR=1.56 (1.06, 2.30)
(16 Ca, 44 Co) 
Quartile 4: RR=1.82 (1.08-3.04)
(18 Ca, 45 Co)
- N Y No overall RR for subjects ever 
exposed to asbestos, only RR 
for subjects ever exposed to 
high/low level of asbestos 
Use the RR for high exposure 
to asbestos
9. Marchand et al. 
(2000)
Asbestos 
Man-made 
vitreous fibers
France Ho 296 M Ca 
295 M Co 
1989-1991
1. Job history (all jobs) 
2. Job-exposure matrix (JEM): 
prob of exposure, concentration, 
frequency
Exposed: 216 Ca, 185 Co 
OR=1.24 (0.83-1.90)
Cumulative exposure distribu-
tion (exposure intensity*prob 
of exposure*duration of 
exposure) 
Low: OR=1.10 (0.66-1.82)
(67 Ca, 67 Co) 
Intermediate:
OR=1.20 (0.73-1.99)
(72 Ca, 67 Co) 
High: OR=1.47 (0.87-2.46)
(77 Ca, 51 Co)
HQ N Y  
10. Ahrens et al. 
(1991)
21 industries 
31 occupations 
Job titles 
19 substances 
(asbestos)
Germa-
ny
Ho 85 M Ca 
100 M Co 
1984-1986
Jobs held at least 6 months 
Self-reported exposure
Self-reported exposure to 
asbestos 
Ca and Co exposed: 36 
(19.5%) 
OR=1.1 (0.5-2.4) 
COR=1.2
Not studied LQ Y N Not included in the meta-anal-
ysis because only self-reported 
exposure
11. Berrino et al. 
(2003)
Job titles France 
Italy 
Spain 
Switzer-
land
Po 315 Ca (215 
larynx) 
819 Co
1979-1982
All jobs held for at least 1 year after 1944 
JEM 
Industrial hygienists, occupational 
physicians (probability of exposures 
to specific agents)
Exposed: 215 Ca, 380 Co 
OR=1.6 (1.0–2.5)
Not studied - N N Not included in the meta-anal-
ysis because combined analysis 
with 100 Ca of hypopharyngeal 
cancer (ICD-10 C13)
12. De Stefani et 
al. (1998)
 Uruguay Ho 112 M Ca 
352 M Co 
1993-1995
1. Jobs held at least 1yr 
2. Specific questions concerning use 
of several substances
Exposed: 23 Ca, 70 Co 
OR=1.8 (0.9-3.2)
Not studied LQ N N This study was conducted in 
Uruguay. Exposure might be 
not portable in GB
13. Elci et al. 
(2002)
 Turkey Ho 940 M Ca 
1519 M Co 
1979-1980
Job history 
Industrial hygienist performed 
JEM exposure assignments
Exposed: 150 Ca 
OR=1.0 (0.8-1.3)
Not studied HQ N N This study was conducted in 
Turkey. Exposure might be not 
portable in GB
14. Shangina et al. 
(2006)
43 agents Roma-
nia, 
Poland, 
Russia, 
Slovakia
Ho 316 M Ca 
728 M Co 
(cancers) 
1999-2002
Jobs held at least 1yr 
- 13 specific jobs, 73 agents 
- intensity, frequency, confidence 
IH estimation
Exposed: 26 Ca, 65 Co 
OR=0.86 (0.51-1.45)
Not studied - N N This study was conducted in 
East Europe. Results were 
mainly observed for Poland.  
Exposure might be not porta-
ble in GB
Ca: case, Co: control
* Ho:  hospital-based study, In: industry-based study, Po: population-based study
1 Exposure assessment method from the book ”Asbestos: Selected Cancers”, 2006. HQ: high quality, 
LQ: low quality
2 studies included in the review by Browne & Gee (2000): Y: yes, N: no
3 studies included in the meta-analysis: Y: yes, N: no
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Reference Exposure Country Type of 
Study*
Study size 
period
Exposure Assessment Adjustment for smoking and alcohol consumption 
(and other potential cofounders)
1 2 3 Comments
Ever versus never exposed Dose-response relationships
8. Gustavsson et 
al. (1998)
17 specific 
substances
Sweden Po 157 M Ca 
641 M Co 
1988-1990
Jobs held at least 1yr 
Occupational hygienist assigned 
exposure intensity 
Probability to 17 specific 
occupational exposures
1. > median of cumulative 
dose among exposed Co 
Exposed: 34 Ca 
RR high=1.69 (1.05-2.74) 
 
2. <  median of cumulative 
dose among exposed Co 
Exposed: 28 Ca 
RR low=1.21 (0.73-2.02)
Cumulative exposure distri-
bution among exposed Co 
(exposure intensity*prob of 
exposure *duration of expo-
sure) 
Quartile1: RR=1.16 (1.02-1.32)
(13 Ca, 43 Co) 
Quartile 2: RR=1.35 (1.04-1.74)
(15 Ca, 45 Co) 
Quartile 3: RR=1.56 (1.06, 2.30)
(16 Ca, 44 Co) 
Quartile 4: RR=1.82 (1.08-3.04)
(18 Ca, 45 Co)
- N Y No overall RR for subjects ever 
exposed to asbestos, only RR 
for subjects ever exposed to 
high/low level of asbestos 
Use the RR for high exposure 
to asbestos
9. Marchand et al. 
(2000)
Asbestos 
Man-made 
vitreous fibers
France Ho 296 M Ca 
295 M Co 
1989-1991
1. Job history (all jobs) 
2. Job-exposure matrix (JEM): 
prob of exposure, concentration, 
frequency
Exposed: 216 Ca, 185 Co 
OR=1.24 (0.83-1.90)
Cumulative exposure distribu-
tion (exposure intensity*prob 
of exposure*duration of 
exposure) 
Low: OR=1.10 (0.66-1.82)
(67 Ca, 67 Co) 
Intermediate:
OR=1.20 (0.73-1.99)
(72 Ca, 67 Co) 
High: OR=1.47 (0.87-2.46)
(77 Ca, 51 Co)
HQ N Y  
10. Ahrens et al. 
(1991)
21 industries 
31 occupations 
Job titles 
19 substances 
(asbestos)
Germa-
ny
Ho 85 M Ca 
100 M Co 
1984-1986
Jobs held at least 6 months 
Self-reported exposure
Self-reported exposure to 
asbestos 
Ca and Co exposed: 36 
(19.5%) 
OR=1.1 (0.5-2.4) 
COR=1.2
Not studied LQ Y N Not included in the meta-anal-
ysis because only self-reported 
exposure
11. Berrino et al. 
(2003)
Job titles France 
Italy 
Spain 
Switzer-
land
Po 315 Ca (215 
larynx) 
819 Co
1979-1982
All jobs held for at least 1 year after 1944 
JEM 
Industrial hygienists, occupational 
physicians (probability of exposures 
to specific agents)
Exposed: 215 Ca, 380 Co 
OR=1.6 (1.0–2.5)
Not studied - N N Not included in the meta-anal-
ysis because combined analysis 
with 100 Ca of hypopharyngeal 
cancer (ICD-10 C13)
12. De Stefani et 
al. (1998)
 Uruguay Ho 112 M Ca 
352 M Co 
1993-1995
1. Jobs held at least 1yr 
2. Specific questions concerning use 
of several substances
Exposed: 23 Ca, 70 Co 
OR=1.8 (0.9-3.2)
Not studied LQ N N This study was conducted in 
Uruguay. Exposure might be 
not portable in GB
13. Elci et al. 
(2002)
 Turkey Ho 940 M Ca 
1519 M Co 
1979-1980
Job history 
Industrial hygienist performed 
JEM exposure assignments
Exposed: 150 Ca 
OR=1.0 (0.8-1.3)
Not studied HQ N N This study was conducted in 
Turkey. Exposure might be not 
portable in GB
14. Shangina et al. 
(2006)
43 agents Roma-
nia, 
Poland, 
Russia, 
Slovakia
Ho 316 M Ca 
728 M Co 
(cancers) 
1999-2002
Jobs held at least 1yr 
- 13 specific jobs, 73 agents 
- intensity, frequency, confidence 
IH estimation
Exposed: 26 Ca, 65 Co 
OR=0.86 (0.51-1.45)
Not studied - N N This study was conducted in 
East Europe. Results were 
mainly observed for Poland.  
Exposure might be not porta-
ble in GB
Ca: case, Co: control
* Ho:  hospital-based study, In: industry-based study, Po: population-based study
1 Exposure assessment method from the book ”Asbestos: Selected Cancers”, 2006. HQ: high quality, 
LQ: low quality
2 studies included in the review by Browne & Gee (2000): Y: yes, N: no
3 studies included in the meta-analysis: Y: yes, N: no
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Table 3. Ovarian cancer and exposure to asbestos, study characteristics and findings
Authors, year Country Outcome 
studied
Industry
Type
Asbestos
Type
Size
Size Period of
employ-
ment
Folow-up Peson-
years
Total 
deaths
Total 
can-
cers
Lung cancer
SMR 
Obs/Exp
SMR or SIR (95% CI)
Ovarian can-
cer results
Comparison
Acheson et al, 
1982
Leyland and 
Preston , UK
Mortality (SMR) Gas mask 
assemblers
Mixed 
(mainly crocidolite)
757 1927-1939 1951-
1980
18,781 219 66 2.41+++ 12/4.4 2.75
(1.42-4.81)
Local area 
mortality 
rates
Blackburn, UK Mortality (SMR) Gas mask 
assemblers
Chrysotile 570 1927-1945 1951-
1980
14,324 177 44 1.45+++ 5/3.4 1.48
(0.48-3.44)
Local area 
mortality 
rates
Wignall & Fox, 
1982
UK Mortality (SMR) Gas mask 
assemblers
Crocidolite (from 
Western Australia)
535 1939-1944 1951-
1977
- 133 64 2.73 6/2.8 2.13
Gardner et al, 
1986
UK Mortality (SMR) Cement Chrysotile 657f
1510m
1941-1954 1941-
1984
- 102f
384m
26f
95m
1.42f
0.97mf
3/2.7 1.11
(0.23-3.25)
National  
death rates
Newhouse et al, 
1989
UK Mortality (SMR) Production of 
friction materials
Chrysotile 4,346f
9104m
1941-1979 1941-
1986
- 522f
2055m
148
530m
0.66f
1.05mf
+++
11/10.1 1.08
(0.61-1.79)
Rosler et al, 
1994
Germany Mortality (PMR) Mixed 
(mainly textile)
Mixed 
(mainly chrysotile)
616 - 1977-
1988
6,236 64 32 3.39 2/1.8 1.09
(0.13-3.95)
National  
death rates
Tarchi et al, 
1994
Italy Mortality (SMR) Mining Chrysotile 120f
367m
- 1965-
1989
- 28f
72m
8f
33m
4.14f
1.46mf
+
2/0.42 4.76
(0.58-17.2)
Death rates 
in Tuscany 
region
Germani et al, 
1999
Italy Mortality (SMR) Textile 
(compensated 
for asbestosis) 
Mixed 
(mainly chrysotile)
276 - 1980-
1997
3,761 123 40 6.82 4/0.76 5.26
(1.43-13.47)
National  
death rates
Mortality (SMR) Cement 
(compensated 
for asbestosis)
Mixed 278 - 1980-
1997
3,932 129 54 2.39 5/0.93 5.4 
(1.75-12.61)
National  
death rates
Berry et al, 2000 UK Mortality (SMR) Textiles and 
prefabricated 
cement pipes
Mixed 700f
4400m
1936-1942
1933-1964 
(worked at 
least 30d)
Up to 
1980
17,146f - 129f
408m
7.46f
3.01mf
9/3.56 2.53
(1.16-4.8)
England and 
Wales death 
rates
Szeszenia-Dab-
rowska et al 
2002
Poland Mortality (SMR) Mixed (asbestosis 
- mainly asbes-
tos processing 
plants)
Mixed 490f
907m
1970-1997
(dx period)
Up to 
Dec. 31, 
1999
- 121f
300m
34 6.21f
2.06mf
1/1.27 0.79
(0.02-4.39)
National  
death rates
Mamo et al, 
2004
Italy Mortality Textile Chrysotile 645 1951-1978 1981-
1995
7,450 84 36 5.23 1/0.78 1.28
(0.02-7.12)
Regional 
mortality 
rates
Wilczynska et al, 
2005
Poland Mortality (SMR) Asbestos product 
plan workers; 
various products
Not specified; likely 
mixed
1382f
2805m
1945-1980 Up to 
1999
42,168f
76,574m 
some not 
exposed
414f
1353m
124f
272m
2.09f
1.34mf
8/4.5 1.76
(0.76-3.47)
National  
death rates
McDonald et al, 
2006
UK Mortality
(SMR)
Gas mask 
assemblers
Crocidolite 1,073; 722 traced 1940-1944 1963-
2003
- 632 228 2.5 if all 
were f; 
2.0 if ad-
justed for 
7% m*
10/5.6 1.8
(0.9-3.3)
England and 
Wales death 
rates
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Table 3. Ovarian cancer and exposure to asbestos, study characteristics and findings
Authors, year Country Outcome 
studied
Industry
Type
Asbestos
Type
Size
Size Period of
employ-
ment
Folow-up Peson-
years
Total 
deaths
Total 
can-
cers
Lung cancer
SMR 
Obs/Exp
SMR or SIR (95% CI)
Ovarian can-
cer results
Comparison
Acheson et al, 
1982
Leyland and 
Preston , UK
Mortality (SMR) Gas mask 
assemblers
Mixed 
(mainly crocidolite)
757 1927-1939 1951-
1980
18,781 219 66 2.41+++ 12/4.4 2.75
(1.42-4.81)
Local area 
mortality 
rates
Blackburn, UK Mortality (SMR) Gas mask 
assemblers
Chrysotile 570 1927-1945 1951-
1980
14,324 177 44 1.45+++ 5/3.4 1.48
(0.48-3.44)
Local area 
mortality 
rates
Wignall & Fox, 
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UK Mortality (SMR) Gas mask 
assemblers
Crocidolite (from 
Western Australia)
535 1939-1944 1951-
1977
- 133 64 2.73 6/2.8 2.13
Gardner et al, 
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UK Mortality (SMR) Cement Chrysotile 657f
1510m
1941-1954 1941-
1984
- 102f
384m
26f
95m
1.42f
0.97mf
3/2.7 1.11
(0.23-3.25)
National  
death rates
Newhouse et al, 
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UK Mortality (SMR) Production of 
friction materials
Chrysotile 4,346f
9104m
1941-1979 1941-
1986
- 522f
2055m
148
530m
0.66f
1.05mf
+++
11/10.1 1.08
(0.61-1.79)
Rosler et al, 
1994
Germany Mortality (PMR) Mixed 
(mainly textile)
Mixed 
(mainly chrysotile)
616 - 1977-
1988
6,236 64 32 3.39 2/1.8 1.09
(0.13-3.95)
National  
death rates
Tarchi et al, 
1994
Italy Mortality (SMR) Mining Chrysotile 120f
367m
- 1965-
1989
- 28f
72m
8f
33m
4.14f
1.46mf
+
2/0.42 4.76
(0.58-17.2)
Death rates 
in Tuscany 
region
Germani et al, 
1999
Italy Mortality (SMR) Textile 
(compensated 
for asbestosis) 
Mixed 
(mainly chrysotile)
276 - 1980-
1997
3,761 123 40 6.82 4/0.76 5.26
(1.43-13.47)
National  
death rates
Mortality (SMR) Cement 
(compensated 
for asbestosis)
Mixed 278 - 1980-
1997
3,932 129 54 2.39 5/0.93 5.4 
(1.75-12.61)
National  
death rates
Berry et al, 2000 UK Mortality (SMR) Textiles and 
prefabricated 
cement pipes
Mixed 700f
4400m
1936-1942
1933-1964 
(worked at 
least 30d)
Up to 
1980
17,146f - 129f
408m
7.46f
3.01mf
9/3.56 2.53
(1.16-4.8)
England and 
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rates
Szeszenia-Dab-
rowska et al 
2002
Poland Mortality (SMR) Mixed (asbestosis 
- mainly asbes-
tos processing 
plants)
Mixed 490f
907m
1970-1997
(dx period)
Up to 
Dec. 31, 
1999
- 121f
300m
34 6.21f
2.06mf
1/1.27 0.79
(0.02-4.39)
National  
death rates
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2004
Italy Mortality Textile Chrysotile 645 1951-1978 1981-
1995
7,450 84 36 5.23 1/0.78 1.28
(0.02-7.12)
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mortality 
rates
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2005
Poland Mortality (SMR) Asbestos product 
plan workers; 
various products
Not specified; likely 
mixed
1382f
2805m
1945-1980 Up to 
1999
42,168f
76,574m 
some not 
exposed
414f
1353m
124f
272m
2.09f
1.34mf
8/4.5 1.76
(0.76-3.47)
National  
death rates
McDonald et al, 
2006
UK Mortality
(SMR)
Gas mask 
assemblers
Crocidolite 1,073; 722 traced 1940-1944 1963-
2003
- 632 228 2.5 if all 
were f; 
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7% m*
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England and 
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rates
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Authors, year Country Outcome 
studied
Industry
Type
Asbestos
Type
Size
Size Period of
employ-
ment
Folow-
up
Peson-
years
Total 
deaths
Total 
can-
cers
Lung cancer
SMR 
Obs/Exp
SMR or SIR (95% CI)
Ovarian can-
cer results
Comparison
Hein et al, 2007 US Mortality (SMR) Textile Chrysotile 1265f
1807m
1940-1965 1979-
2001
49,922f 709f
1252m
169f
294m
2.22f
1.95mf
+
6/9.68 0.62
(0.23-1.35)
National  
death rates
Magnani et al, 
2007
Italy Mortality Cement Mixed 777 1950-1986 1965-
2003
22,367 371 169 2.21f
2.42mf
9/4 2.27
(1.04-4.32)
Regional 
mortality 
rates
Pira et al, 2007 Italy Mortality (SMR) Textiles Mixed 1,077f
889m
1946-1984 up to Dec. 
31, 2004
36,886f
25,139m
254f
476m
130f
195m
6.47f
3.10mf
8/2.8 2.83
(1.22-5.57)
National  
death rates
Reid et al, 2008 Australia (Wit-
ttenoom)
Mortality (SMR) Women exposed 
environmentally 
and domestically
Crocidolite 2552 1943-1992 1950-
2004
- 419 149 2.15
++++
9/5.92 1.52 (0.69-
2.88)
Death rates 
for Western 
Australian 
women
Loomis et al, 
2009
US Mortality (SMR) Textile Chrysotile 1,795f
3975m
1950-1973 up to Dec. 
31, 2003
59,949f 608f
1975m
160f
482m
1.73f
1.96mf
+
9/7.34 1.23
(0.56-
2.33)++
National  
death rates
Reid et al, 2009 Australia Incidence
(SIR)
Mining and 
milling
Crocidolite 416 1943-1966 1960-
2006
- - - - 1/1.54 0.65
(0.02-3.64)
Abbreviations: SMR, standardized mortality ratio; SIR, standardized incidence ratio; Obs/Exp, observed/expected 
deaths or cases; CI, confidence interval.
+ Trachea, bronchus and lung.
++ 3 plants only – data provided by authors.
+++ Lung and pleura.
++++Lung and trachea; SMR data shown for this study are based on subjects being censored 
at time last known to be alive (see text).
* Respiratory cancer other than mesothelioma
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Authors, year Country Outcome 
studied
Industry
Type
Asbestos
Type
Size
Size Period of
employ-
ment
Folow-
up
Peson-
years
Total 
deaths
Total 
can-
cers
Lung cancer
SMR 
Obs/Exp
SMR or SIR (95% CI)
Ovarian can-
cer results
Comparison
Hein et al, 2007 US Mortality (SMR) Textile Chrysotile 1265f
1807m
1940-1965 1979-
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49,922f 709f
1252m
169f
294m
2.22f
1.95mf
+
6/9.68 0.62
(0.23-1.35)
National  
death rates
Magnani et al, 
2007
Italy Mortality Cement Mixed 777 1950-1986 1965-
2003
22,367 371 169 2.21f
2.42mf
9/4 2.27
(1.04-4.32)
Regional 
mortality 
rates
Pira et al, 2007 Italy Mortality (SMR) Textiles Mixed 1,077f
889m
1946-1984 up to Dec. 
31, 2004
36,886f
25,139m
254f
476m
130f
195m
6.47f
3.10mf
8/2.8 2.83
(1.22-5.57)
National  
death rates
Reid et al, 2008 Australia (Wit-
ttenoom)
Mortality (SMR) Women exposed 
environmentally 
and domestically
Crocidolite 2552 1943-1992 1950-
2004
- 419 149 2.15
++++
9/5.92 1.52 (0.69-
2.88)
Death rates 
for Western 
Australian 
women
Loomis et al, 
2009
US Mortality (SMR) Textile Chrysotile 1,795f
3975m
1950-1973 up to Dec. 
31, 2003
59,949f 608f
1975m
160f
482m
1.73f
1.96mf
+
9/7.34 1.23
(0.56-
2.33)++
National  
death rates
Reid et al, 2009 Australia Incidence
(SIR)
Mining and 
milling
Crocidolite 416 1943-1966 1960-
2006
- - - - 1/1.54 0.65
(0.02-3.64)
Abbreviations: SMR, standardized mortality ratio; SIR, standardized incidence ratio; Obs/Exp, observed/expected 
deaths or cases; CI, confidence interval.
+ Trachea, bronchus and lung.
++ 3 plants only – data provided by authors.
+++ Lung and pleura.
++++Lung and trachea; SMR data shown for this study are based on subjects being censored 
at time last known to be alive (see text).
* Respiratory cancer other than mesothelioma
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Table 4. Colorectal cancer and exposure to asbestos, cohort studies evaluated by IARC.                  
 From Table 2.7 in IARC Vol 100C.
Citation Label CanType LICD UICD ExpGrad ExpCat Total 
Cohort
Obs Cases Exp Cases RR LCL UCL Cover %
Germani99 (women with asbestosis) colon 153 153 1 any 631 8 2,38 1,03 4,70 95
(women with asbestosis) rectum 154 154 1 any 631 1 0,62 0,02 3,45 95
Karjalainen99 (men with asbestosis, incidence) colon 153 153 1 any 1287 3 0,90 0,20 2,50 95
(men with benign pleural disease) colon 153 153 1 any 4708 8 1,10 0,50 2,10 95
(women with asbestosis) colon 153 153 1 any 89 2 4,60 0,60 16,50 95
(women with benign pleural disease) colon 153 153 1 any 179 1 3,40 0,10 19,10 95
(men with asbestosis) rectum 154 154 1 any 1287 4 1,30 0,30 3,20 95
(men with benign pleural disease) rectum 154 154 1 any 4708 8 1,20 0,50 2,40 95
SzesDab02 (men with asbestosis) colon 153 153 1 any 902 1 0,51 95
(men with asbestosis) rectum 154 154 1 any 902 2 0,77 95
(women with asbestosis) colon 153 153 1 any 489 2 1,99 0,24 7,19 95
(women with asbestosis) rectum 154 154 1 any 489 1 0,86 95
Aliyu05 (men, incidence) colorectal 153 154 1 any 3897 85 2,00 1,60 2,50 95
(men, incidence) colorectal 153 154 34 pleural abnormality (positive) 1847 51 1,40 0,88 2,23 95
(men, incidence) colorectal 153 154 35 radiographic profusion (3/2 to 3/+) 24 1 1,38 0,18 10,60 95
(men, incidence) colorectal 153 154 36 yrs in high risk trade (>40) 156 3 0,49 0,12 2,00 95
(men, incidence) colorectal 153 154 37 From 1st expo  (longest = 42+ yrs) 707 29 1,20 0,48 3,04 95
Armstrong88 (men) ”intestines including 
rectum” ?
152 154 1 any 6505 14 0,70 0,41 1,18 95
Reid04 (men) colon/rectum 153 154,1 1 any 5685 49 37 1,31 0,99 1,74 95
(men, incidence) colon/rectum C18.0 C20.9 1 any 5685 88 84 1,05 0,85 1,29 95
MacDonald93 (men) ”colon/rectum” 152 154 1 any 10918 73 88,9 0,82
Meurman94 (men, incidence) ”colorectum” ? 153 154 1 any 736 3 0,55 0,11 1,60 95
 (men, incidence) ”colorectum” ? 153 154 26 heavy 736 1 0,28 0,01 1,56 95
 (men, incidence) ”colorectum” ? 153 154 20 heavy & >5yr 212 1 0,76 0,02 4,25 95
Piolatto90  (men) ”intestinal” ? 152 154 1 any 1058 6 6,6 0,90 p>0.05
 (men) ”intestinal” ? 152 154 5 duration >20 yrs 1058 3 2,3 1,30 p>0.05
Selikoff79  (male insulators starting 1943-1962) ”colon-rectum” ? 153 154 1 any 632 23 8,3 2,77
 (male insulators starting 1943-1962) ”colon-rectum” ? 153 154 33 From 1st expo   >35yrs 632 16 6,2 2,58
 (male members insulation unions 1967) ”colon-rectum” ? 153 154 1 any 17800 121 1,37 p<0.01
Acheson84  (men) colon 153 153 1 any 4820 6 4,4 1,37 p>0.05
 (men) rectum 154 154 1 any 4820 4 3,2 1,24 p>0.05
Levin98  (white men) large intestine 153 153 1 any 753 6 2,9 2,07 0,76 4,51
 (white men) rectum 154 154 1 any 753 0 0,7
Pira05  (men + women) colorectal 152-154 159 1 any 1966 16 1,45 0,83 2,35 95
 (men + women) colorectal 152-154 159 7 duration >10 yrs 1966 5 1,67 p>0.05
Peto85  (men) ”colon/rectum” ? 153 154 1 any 3211 20 26,7 0,75
 (men) ”colon/rectum” ? 153 154 27 duration >10 yrs, >20 yrs since 1st 3211 5 4,86 1,03
 (women) ”colon/rectum” ? 153 154 1 any 283 4 2,02 1,98
Raffn96  (men, incidence) colon ? 153 153 1 any 7887 51 45,49 1,12 0,83 1,47 95
 (men, incidence) colon ? 153 153 28 1st employed 1928-1950, >15 yrs 
since 1st expo
7887 23 14,05 1,64 1,04 2,46 95
 (men, incidence) rectum ? 154 154 1 any 7887 51 38,22 1,33 0,99 1,75 95
 (men, incidence) rectum ? 154 154 28 1st employed 1928-1950, >15 yrs 
since 1st expo
7887 16 12,48 1,28 0,73 2,08 95
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Table 4. Colorectal cancer and exposure to asbestos, cohort studies evaluated by IARC.                  
 From Table 2.7 in IARC Vol 100C.
Citation Label CanType LICD UICD ExpGrad ExpCat Total 
Cohort
Obs Cases Exp Cases RR LCL UCL Cover %
Germani99 (women with asbestosis) colon 153 153 1 any 631 8 2,38 1,03 4,70 95
(women with asbestosis) rectum 154 154 1 any 631 1 0,62 0,02 3,45 95
Karjalainen99 (men with asbestosis, incidence) colon 153 153 1 any 1287 3 0,90 0,20 2,50 95
(men with benign pleural disease) colon 153 153 1 any 4708 8 1,10 0,50 2,10 95
(women with asbestosis) colon 153 153 1 any 89 2 4,60 0,60 16,50 95
(women with benign pleural disease) colon 153 153 1 any 179 1 3,40 0,10 19,10 95
(men with asbestosis) rectum 154 154 1 any 1287 4 1,30 0,30 3,20 95
(men with benign pleural disease) rectum 154 154 1 any 4708 8 1,20 0,50 2,40 95
SzesDab02 (men with asbestosis) colon 153 153 1 any 902 1 0,51 95
(men with asbestosis) rectum 154 154 1 any 902 2 0,77 95
(women with asbestosis) colon 153 153 1 any 489 2 1,99 0,24 7,19 95
(women with asbestosis) rectum 154 154 1 any 489 1 0,86 95
Aliyu05 (men, incidence) colorectal 153 154 1 any 3897 85 2,00 1,60 2,50 95
(men, incidence) colorectal 153 154 34 pleural abnormality (positive) 1847 51 1,40 0,88 2,23 95
(men, incidence) colorectal 153 154 35 radiographic profusion (3/2 to 3/+) 24 1 1,38 0,18 10,60 95
(men, incidence) colorectal 153 154 36 yrs in high risk trade (>40) 156 3 0,49 0,12 2,00 95
(men, incidence) colorectal 153 154 37 From 1st expo  (longest = 42+ yrs) 707 29 1,20 0,48 3,04 95
Armstrong88 (men) ”intestines including 
rectum” ?
152 154 1 any 6505 14 0,70 0,41 1,18 95
Reid04 (men) colon/rectum 153 154,1 1 any 5685 49 37 1,31 0,99 1,74 95
(men, incidence) colon/rectum C18.0 C20.9 1 any 5685 88 84 1,05 0,85 1,29 95
MacDonald93 (men) ”colon/rectum” 152 154 1 any 10918 73 88,9 0,82
Meurman94 (men, incidence) ”colorectum” ? 153 154 1 any 736 3 0,55 0,11 1,60 95
 (men, incidence) ”colorectum” ? 153 154 26 heavy 736 1 0,28 0,01 1,56 95
 (men, incidence) ”colorectum” ? 153 154 20 heavy & >5yr 212 1 0,76 0,02 4,25 95
Piolatto90  (men) ”intestinal” ? 152 154 1 any 1058 6 6,6 0,90 p>0.05
 (men) ”intestinal” ? 152 154 5 duration >20 yrs 1058 3 2,3 1,30 p>0.05
Selikoff79  (male insulators starting 1943-1962) ”colon-rectum” ? 153 154 1 any 632 23 8,3 2,77
 (male insulators starting 1943-1962) ”colon-rectum” ? 153 154 33 From 1st expo   >35yrs 632 16 6,2 2,58
 (male members insulation unions 1967) ”colon-rectum” ? 153 154 1 any 17800 121 1,37 p<0.01
Acheson84  (men) colon 153 153 1 any 4820 6 4,4 1,37 p>0.05
 (men) rectum 154 154 1 any 4820 4 3,2 1,24 p>0.05
Levin98  (white men) large intestine 153 153 1 any 753 6 2,9 2,07 0,76 4,51
 (white men) rectum 154 154 1 any 753 0 0,7
Pira05  (men + women) colorectal 152-154 159 1 any 1966 16 1,45 0,83 2,35 95
 (men + women) colorectal 152-154 159 7 duration >10 yrs 1966 5 1,67 p>0.05
Peto85  (men) ”colon/rectum” ? 153 154 1 any 3211 20 26,7 0,75
 (men) ”colon/rectum” ? 153 154 27 duration >10 yrs, >20 yrs since 1st 3211 5 4,86 1,03
 (women) ”colon/rectum” ? 153 154 1 any 283 4 2,02 1,98
Raffn96  (men, incidence) colon ? 153 153 1 any 7887 51 45,49 1,12 0,83 1,47 95
 (men, incidence) colon ? 153 153 28 1st employed 1928-1950, >15 yrs 
since 1st expo
7887 23 14,05 1,64 1,04 2,46 95
 (men, incidence) rectum ? 154 154 1 any 7887 51 38,22 1,33 0,99 1,75 95
 (men, incidence) rectum ? 154 154 28 1st employed 1928-1950, >15 yrs 
since 1st expo
7887 16 12,48 1,28 0,73 2,08 95
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Botta91  (men) colon & rectum ? 153 154 1 any 2608 11 16,9 0,65 0,32 1,16 95
 (women) colon & rectum ? 153 154 1 any 759 7 3,9 1,80 0,73 3,70 95
Smailyte04  (men, incidence) colon, rectum 153 154 1 any 1285 17 1,60 1,00 2,60 95
 (men, incidence) colon, rectum 153 154 7 duration >10 yrs 1285 8 2,40 1,20 4,40 95
 (men, incidence) colon, rectum 153 154 21 from 1st expo (>24 yrs) 1285 7 1,60
 (women, incidence) colon, rectum 153 154 1 any 602 3 0,80 0,10 1,80 95
Albin90  (men) colon, rectum 153 154 1 any (all >20 yr latency) 1465 26 1,50 0,70 3,00 95
 (men) colon, rectum 153 154 29 cum expo (>40 fiber-yrs/ml)  & >20 
yr latency
1118 3,40 1,20 9,50 95
Jakobsson94  (men, incidence) right colon 153,0 153,1 1 any 981 12 5,04 2,38 1,23 4,16 95
 (men, incidence) left colon 153,2 153,3 1 any 981 1 4,72 0,22 0,00 1,18 95
 (men, incidence) rectum 154 154 1 any 981 13 7,87 1,65 0,88 2,83 95
Gardner86  (men + women) colon 153 153 1 any 2090 6 9,2 0,65
 (men + women) rectum 154 154 1 any 2090 5 6,2 0,81
Hughes87  (men) colon, rectum 153 154 1 any (all latency >20 yrs) 5492 21 23,3 0,98
 (men) colon, rectum 153 154 5 duration >15 yrs 5492 4 3,3 1,21
Woitowitz86  (men + women, exposure done after1972) colon + rectum 153 154 1 any 3070 5 0,79 p>0.05
 (men + women, exposure done before1972) colon + rectum 153 154 1 any 665 3 2,15 p>0.05
Berry00  (male factory workers) colon 153 153 1 any 3000 17 9,16 1,86
 (male factory workers) colon 153 153 30 severe & >2yrs 3000 8 1,97 4,06
 (male insulators) colon 153 153 1 any 1400 7 1,62 4,32
 (female factory workers) colon 153 153 1 any 700 3 3,29 0,88
 (female factory workers) colon 153 153 30 severe & >2yrs 700 1 1 1,00
 (male factory workers) rectum 154 154 1 any 3000 5 6,02 0,83
 (male factory workers) rectum 154 154 30 severe & >2yrs 3000 0 1,53
 (male insulators) rectum 154 154 1 any 1400 1 1,18 0,85
 (female factory workers) rectum 154 154 1 any 700 4 1,89 2,12
 (female factory workers) rectum 154 154 30 severe & >2yrs 700 0 0,47
Hodgson86  (men) colon ? 153 153 1 any 31500 6 16,7 0,36 p<0.01
 (men) colon ? 153 153 5 duration >20 yrs 31500 3 8,6 0,35
 (men) rectum ? 154 154 1 any 31500 10 12,9 0,78
 (men) rectum ? 154 154 5 duration >20 yrs 31500 7 6,8 1,03
Seidman86  (male producers of shipyard insulation) colon & rectum ? 153 154 1 any 820 22 11,9 1,85 p<0.05
Enterline87  (men) colon 153 153 1 any 1074 14 14,24 0,93 p>0.05
 (men) rectum 154 154 1 any 1074 9 5,66 1,59 p>0.05
Finkelstein04  (men) colorectal ? 153 154 1 any (with 20 yrs latency) 24500 96 1,16 0,94 1,42 95
Tola88  (men, incidence) colorectal 153 154 1 any 7775 35 44,1 0,79 0,55 1,10 95
 (men, incidence) colorectal 153 154 15 shipyard pipefitters 608 1 3,5 0,29 0,01 1,59 95
Battista99  (men) ”intestine & rectum” ? 152 154 1 any 734 6 6,45 0,93 0,41 1,84 90
Puntoni01  (men) colon & rectum 153 154 1 any 3984 59 58,9 1,00 0,76 1,29 95
Sanden87  (men, incidence) rectum 154 154 1 any (with 20 yrs latency) 3787 3 6,6 0,83
 (men, incidence) rectum 154 154 31 heavy (with 20 yrs latency) 3787 2 3,1 0,65
 (men, incidence) colon 153 153 1 any 3787 0
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Botta91  (men) colon & rectum ? 153 154 1 any 2608 11 16,9 0,65 0,32 1,16 95
 (women) colon & rectum ? 153 154 1 any 759 7 3,9 1,80 0,73 3,70 95
Smailyte04  (men, incidence) colon, rectum 153 154 1 any 1285 17 1,60 1,00 2,60 95
 (men, incidence) colon, rectum 153 154 7 duration >10 yrs 1285 8 2,40 1,20 4,40 95
 (men, incidence) colon, rectum 153 154 21 from 1st expo (>24 yrs) 1285 7 1,60
 (women, incidence) colon, rectum 153 154 1 any 602 3 0,80 0,10 1,80 95
Albin90  (men) colon, rectum 153 154 1 any (all >20 yr latency) 1465 26 1,50 0,70 3,00 95
 (men) colon, rectum 153 154 29 cum expo (>40 fiber-yrs/ml)  & >20 
yr latency
1118 3,40 1,20 9,50 95
Jakobsson94  (men, incidence) right colon 153,0 153,1 1 any 981 12 5,04 2,38 1,23 4,16 95
 (men, incidence) left colon 153,2 153,3 1 any 981 1 4,72 0,22 0,00 1,18 95
 (men, incidence) rectum 154 154 1 any 981 13 7,87 1,65 0,88 2,83 95
Gardner86  (men + women) colon 153 153 1 any 2090 6 9,2 0,65
 (men + women) rectum 154 154 1 any 2090 5 6,2 0,81
Hughes87  (men) colon, rectum 153 154 1 any (all latency >20 yrs) 5492 21 23,3 0,98
 (men) colon, rectum 153 154 5 duration >15 yrs 5492 4 3,3 1,21
Woitowitz86  (men + women, exposure done after1972) colon + rectum 153 154 1 any 3070 5 0,79 p>0.05
 (men + women, exposure done before1972) colon + rectum 153 154 1 any 665 3 2,15 p>0.05
Berry00  (male factory workers) colon 153 153 1 any 3000 17 9,16 1,86
 (male factory workers) colon 153 153 30 severe & >2yrs 3000 8 1,97 4,06
 (male insulators) colon 153 153 1 any 1400 7 1,62 4,32
 (female factory workers) colon 153 153 1 any 700 3 3,29 0,88
 (female factory workers) colon 153 153 30 severe & >2yrs 700 1 1 1,00
 (male factory workers) rectum 154 154 1 any 3000 5 6,02 0,83
 (male factory workers) rectum 154 154 30 severe & >2yrs 3000 0 1,53
 (male insulators) rectum 154 154 1 any 1400 1 1,18 0,85
 (female factory workers) rectum 154 154 1 any 700 4 1,89 2,12
 (female factory workers) rectum 154 154 30 severe & >2yrs 700 0 0,47
Hodgson86  (men) colon ? 153 153 1 any 31500 6 16,7 0,36 p<0.01
 (men) colon ? 153 153 5 duration >20 yrs 31500 3 8,6 0,35
 (men) rectum ? 154 154 1 any 31500 10 12,9 0,78
 (men) rectum ? 154 154 5 duration >20 yrs 31500 7 6,8 1,03
Seidman86  (male producers of shipyard insulation) colon & rectum ? 153 154 1 any 820 22 11,9 1,85 p<0.05
Enterline87  (men) colon 153 153 1 any 1074 14 14,24 0,93 p>0.05
 (men) rectum 154 154 1 any 1074 9 5,66 1,59 p>0.05
Finkelstein04  (men) colorectal ? 153 154 1 any (with 20 yrs latency) 24500 96 1,16 0,94 1,42 95
Tola88  (men, incidence) colorectal 153 154 1 any 7775 35 44,1 0,79 0,55 1,10 95
 (men, incidence) colorectal 153 154 15 shipyard pipefitters 608 1 3,5 0,29 0,01 1,59 95
Battista99  (men) ”intestine & rectum” ? 152 154 1 any 734 6 6,45 0,93 0,41 1,84 90
Puntoni01  (men) colon & rectum 153 154 1 any 3984 59 58,9 1,00 0,76 1,29 95
Sanden87  (men, incidence) rectum 154 154 1 any (with 20 yrs latency) 3787 3 6,6 0,83
 (men, incidence) rectum 154 154 31 heavy (with 20 yrs latency) 3787 2 3,1 0,65
 (men, incidence) colon 153 153 1 any 3787 0
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Table 5 : Cohort studies of asbestos exposure and stomach cancer (adapted and updated
from Table 2.6 IARC Monograph 100C)
Citation Label LICD UICD Expo-
sure 
Gradi-
ent
Exposure 
Category
Total 
Cohort
Obs Cases Exp Cases RR LCL UCL Cover %
Acheson et al. 1982 (women: manufacture of gas masks) 151 151 1 any 1327 9 7.50 1.20    
Acheson et al. 1984 (men: manufacture of inhalation board) 151 151 1 any 4820 7 7.50 0.94   p>0.05
Armstrong et al 1988 (men: crocidolite miners & millers) 151 151 1 any 6505 17  1.16 0.72 1.87 95
Amandus and Wheeler1987 (men: vermiculite miners and millers) 151 151 1 any 575 2 1.60 1.24 0.15 4.49  
Battista et al 1999 (men: railway carriage construction & repair) 151 151 1 any 734 13 9.95 1.31 0.77 2.08 90
Berry et al 2000 (women: asbestos factory workers) 151 151 1 any 700 5 3.51 1.42    
151 151 30 severe & >2yrs 700 3 0.88 3.41    
Berry et al 2000 (male factory : asbestos factory workers) 151 151 1 any 3000 21 16.97 1.24    
151 151 30 severe & >2yrs 3000 5 3.85 1.30    
Berry et al 2000 (male insulators) 151 151 1 any 1400 2 2.61 0.77    
Botta et al 1991 (men: asbestos cement factory) 151 151 1 any 2608 17 20.90 0.81 0.47 1.30 95
Botta et al 1991 (women: asbestos cement factory) 151 151 1 any 759 4 2.90 1.36 0.37 3.48 95
Cheng & Kong 1992 (Men and women: chrysotile asbestos
 products workers) 151 151 1 any 1172 7 1.29 0.93 1.80
DeKerk et al 1989 (men: crocidolite miners & millers) 151 151 14 duration (>5 yrs) 360 0  0.00 0.00 6.40 95
151 151 32 ave. concentration 
(>50 f/ml)
360 1  0.40 0.00 4.20 95
Finkelstein & Verma 2004 (men: pipe trades workers) 151 151 1 any (with 20 yrs 
latency)
24500 21  0.67 0.41 1.02 95
Frost et al 2008 (Men and women: asbestos removal workers) 151 151 1 any 52387 49 1.34 1.00 1.79
Gardner et al 1986 (men + women: asbestos cement factory) 151 151 1 any 2090 15 13.7 1.09    
Germani et al 1999 (women compensated for asbestosis) 151 151 1 any 631 2  0.45 0.05 1.61 95
Harding et al 2009 (Men and women: asbestos survey) 151 1511 1 any 9811 322 1.66 1.49 1.85
Hughes et al 1987 (men: asbestos cement factory) 151 151 1 any, all latency >20 yrs 5492 22 19.50 1.13    
151 151 5 duration >15 yrs 5492 1 2.70 0.37    
Karjalainen et al 1999 (men with asbestosis, incidence) 151 151 1 any 1287 4  0.70 0.20 1.90 95
Karjalainen et al 1999 (men with benign pleural disease) 151 151 1 any 4708 11  1.30 0.60 2.30 95
Karjalainen et al 1999 (women with asbestosis) 151 151 1 any 89 1  2.20 0.10 12.10 95
Karjalainen et al 1999 (women with benign pleural disease) 151 151 1 any 179 0 0.20  0.00 17.40 95
Kogan et al 1993 (men + women: friction products manufacture) 151 151 1 any 2834 14 24.00 0.58    
Krstev et al 2007 (Men and women: shopyard workers) 151 151 1 any 4702 23 0.86 0.56 1.32
Levin et al 1998 (white men: asbestos pipe insulation manufature) 151 151 1 any 753 0 1.1     
Liddell et al 1997 (men: asbestos miners and millers) 151 151 1 any 8900 183  1.24    
151 151 19 cum expo (mpcf.y) >300 7700 40 23.90 1.67    
Loomis et al 2009 (Men and women: asbestos textile workers) 151 151 1 any 5770 8 0.51 0.24 1.09
Meurman et al 1994 (men, incidence: asbestos miners) 151 151 1 any 736 13  1.42 0.76 2.43 95
151 151 26 heavy 736 7  1.24 0.50 2.56 95
151 151 20 heavy & >5yr 212 2  0.99 0.12 3.56 95
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Acheson et al. 1982 (women: manufacture of gas masks) 151 151 1 any 1327 9 7.50 1.20    
Acheson et al. 1984 (men: manufacture of inhalation board) 151 151 1 any 4820 7 7.50 0.94   p>0.05
Armstrong et al 1988 (men: crocidolite miners & millers) 151 151 1 any 6505 17  1.16 0.72 1.87 95
Amandus and Wheeler1987 (men: vermiculite miners and millers) 151 151 1 any 575 2 1.60 1.24 0.15 4.49  
Battista et al 1999 (men: railway carriage construction & repair) 151 151 1 any 734 13 9.95 1.31 0.77 2.08 90
Berry et al 2000 (women: asbestos factory workers) 151 151 1 any 700 5 3.51 1.42    
151 151 30 severe & >2yrs 700 3 0.88 3.41    
Berry et al 2000 (male factory : asbestos factory workers) 151 151 1 any 3000 21 16.97 1.24    
151 151 30 severe & >2yrs 3000 5 3.85 1.30    
Berry et al 2000 (male insulators) 151 151 1 any 1400 2 2.61 0.77    
Botta et al 1991 (men: asbestos cement factory) 151 151 1 any 2608 17 20.90 0.81 0.47 1.30 95
Botta et al 1991 (women: asbestos cement factory) 151 151 1 any 759 4 2.90 1.36 0.37 3.48 95
Cheng & Kong 1992 (Men and women: chrysotile asbestos
 products workers) 151 151 1 any 1172 7 1.29 0.93 1.80
DeKerk et al 1989 (men: crocidolite miners & millers) 151 151 14 duration (>5 yrs) 360 0  0.00 0.00 6.40 95
151 151 32 ave. concentration 
(>50 f/ml)
360 1  0.40 0.00 4.20 95
Finkelstein & Verma 2004 (men: pipe trades workers) 151 151 1 any (with 20 yrs 
latency)
24500 21  0.67 0.41 1.02 95
Frost et al 2008 (Men and women: asbestos removal workers) 151 151 1 any 52387 49 1.34 1.00 1.79
Gardner et al 1986 (men + women: asbestos cement factory) 151 151 1 any 2090 15 13.7 1.09    
Germani et al 1999 (women compensated for asbestosis) 151 151 1 any 631 2  0.45 0.05 1.61 95
Harding et al 2009 (Men and women: asbestos survey) 151 1511 1 any 9811 322 1.66 1.49 1.85
Hughes et al 1987 (men: asbestos cement factory) 151 151 1 any, all latency >20 yrs 5492 22 19.50 1.13    
151 151 5 duration >15 yrs 5492 1 2.70 0.37    
Karjalainen et al 1999 (men with asbestosis, incidence) 151 151 1 any 1287 4  0.70 0.20 1.90 95
Karjalainen et al 1999 (men with benign pleural disease) 151 151 1 any 4708 11  1.30 0.60 2.30 95
Karjalainen et al 1999 (women with asbestosis) 151 151 1 any 89 1  2.20 0.10 12.10 95
Karjalainen et al 1999 (women with benign pleural disease) 151 151 1 any 179 0 0.20  0.00 17.40 95
Kogan et al 1993 (men + women: friction products manufacture) 151 151 1 any 2834 14 24.00 0.58    
Krstev et al 2007 (Men and women: shopyard workers) 151 151 1 any 4702 23 0.86 0.56 1.32
Levin et al 1998 (white men: asbestos pipe insulation manufature) 151 151 1 any 753 0 1.1     
Liddell et al 1997 (men: asbestos miners and millers) 151 151 1 any 8900 183  1.24    
151 151 19 cum expo (mpcf.y) >300 7700 40 23.90 1.67    
Loomis et al 2009 (Men and women: asbestos textile workers) 151 151 1 any 5770 8 0.51 0.24 1.09
Meurman et al 1994 (men, incidence: asbestos miners) 151 151 1 any 736 13  1.42 0.76 2.43 95
151 151 26 heavy 736 7  1.24 0.50 2.56 95
151 151 20 heavy & >5yr 212 2  0.99 0.12 3.56 95
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Neuberger & Kundi 1990 (men: asbestos cement factory) 151 151 1 any 2816 54 1.29 0.93 1.80
Olshon et al 1984 (Men: railroad shop workers) 151 151 3442 41 0.57 0.42 0.79
Pang et al 1997 (men) 151 151 1 any 160 5 0.64 7.87    
Pang et al 1997 (women) 151 151 1 any 370 0 0.50 0.00    
Pesch et al 2010 (Men: asbestos screening survey) 151 151 1 any 576 5 1.15 0.46 2.85
Peto et al 1985 (men: asbestos textile workers) 151 151 1 any 3211 29 29.99 1.00    
151 151 27 duration >10 yrs, 
>20 yrs since 1st 3211 9 5.00 1.80    
Peto et al 1985 (women: asbestos textile workers) 151 151 1 any 283 2 1.08 1.85    
Pira et al 2005 (men + women: asbestos texiles) 151 151 1 any 1966 15  1.20 0.67 1.98 95
151 151 7 duration >10 yrs 1966 2  0.57   p>0.05
Puntoni et al 2001 (men: shipyard workers) 151 151 1 any 3984 67 58.60 1.14 0.86 1.45 95
Raffn et al 1989 (men, incidence: asbestos cement factory) 151 151 1 any 7996 43 30.09 1.43 1.03 1.93 95
151 151 14 duration >5 yrs 1884 15 11.83 1.27 0.70 2.07 95
151 151 14 first employed 
1928-1940 269 8 4.73 1.69 0.73 3.33 95
Reid et al 2004 (men: crocidolite miners) 151 151 1 any 5685 21 15.00 1.39 0.91 2.14 95
Reid et al 2004 (men, incidence: crodidolite miners) C16.0 C16.9 1 any 5685 27 22.00 1.31 0.82 1.75 95
Sanden & Jarvholm 1987 (men, incidence: shipyard workers) 151 151 1 any 3787 3 3.40 0.88 0.18 2.60  
151 151 1 any 
(with 20 yrs latency) 3787 3 2.80 1.07    
151 151 31 heavy 
(with 20 yrs latency) 3787 1 1.30 0.77    
Seidman et al 1986 (men:  producers of shipyard insulation) 151 151 1 any 820 11 5.78 1.90   p<0.05
Selikoff et al 1979 (male insulators starting 1943-1962) 151 151 1 any 632 19 5.40 3.52    
151 151 33 From 1st expo   
>35yrs 632 13 3.80 3.42    
Selikoff & Seidman 1991 (male members insulation unions 1967) 151 151 1 any 17800 38 29.36 1.29   p>0.05
Smailyte et al 2004 (men, incidence: asbestos cement factory) 151 151 1 any 1285 14  0.90 0.50 1.50 95
151 151 7 duration 
>10 yrs 1285 3  0.60 0.20 1.90 95
151 151 21 from 1st expo 
(>25 yrs) 1285 4  0.60    
Smailyte et al 2004 (women, incidence: asbestos cement factory) 151 151 1 any 602 4  1.20 0.40 3.20 95
Szeszenia-Dabrowska et al 2000 (men: asbestos cement factory) 151 151 1 any 2525 16 1.07 0.63 1.81
Szeszenia-Dabrowska et al 2002 (men compensated 
for asbestosis)
151 151 1
any 902 5  0.70 0.23 1.63 95
Tola et al 1988 (men, incidence: shipyard workers) 151 151 15 shipyard pipefitters 608 2 6.10 0.33 0.04 1.18 95
Zhu & Wang 1993 (men + women: asbestos factory) 151 151 1 any 5893 28  2.50   p<0.01
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Neuberger & Kundi 1990 (men: asbestos cement factory) 151 151 1 any 2816 54 1.29 0.93 1.80
Olshon et al 1984 (Men: railroad shop workers) 151 151 3442 41 0.57 0.42 0.79
Pang et al 1997 (men) 151 151 1 any 160 5 0.64 7.87    
Pang et al 1997 (women) 151 151 1 any 370 0 0.50 0.00    
Pesch et al 2010 (Men: asbestos screening survey) 151 151 1 any 576 5 1.15 0.46 2.85
Peto et al 1985 (men: asbestos textile workers) 151 151 1 any 3211 29 29.99 1.00    
151 151 27 duration >10 yrs, 
>20 yrs since 1st 3211 9 5.00 1.80    
Peto et al 1985 (women: asbestos textile workers) 151 151 1 any 283 2 1.08 1.85    
Pira et al 2005 (men + women: asbestos texiles) 151 151 1 any 1966 15  1.20 0.67 1.98 95
151 151 7 duration >10 yrs 1966 2  0.57   p>0.05
Puntoni et al 2001 (men: shipyard workers) 151 151 1 any 3984 67 58.60 1.14 0.86 1.45 95
Raffn et al 1989 (men, incidence: asbestos cement factory) 151 151 1 any 7996 43 30.09 1.43 1.03 1.93 95
151 151 14 duration >5 yrs 1884 15 11.83 1.27 0.70 2.07 95
151 151 14 first employed 
1928-1940 269 8 4.73 1.69 0.73 3.33 95
Reid et al 2004 (men: crocidolite miners) 151 151 1 any 5685 21 15.00 1.39 0.91 2.14 95
Reid et al 2004 (men, incidence: crodidolite miners) C16.0 C16.9 1 any 5685 27 22.00 1.31 0.82 1.75 95
Sanden & Jarvholm 1987 (men, incidence: shipyard workers) 151 151 1 any 3787 3 3.40 0.88 0.18 2.60  
151 151 1 any 
(with 20 yrs latency) 3787 3 2.80 1.07    
151 151 31 heavy 
(with 20 yrs latency) 3787 1 1.30 0.77    
Seidman et al 1986 (men:  producers of shipyard insulation) 151 151 1 any 820 11 5.78 1.90   p<0.05
Selikoff et al 1979 (male insulators starting 1943-1962) 151 151 1 any 632 19 5.40 3.52    
151 151 33 From 1st expo   
>35yrs 632 13 3.80 3.42    
Selikoff & Seidman 1991 (male members insulation unions 1967) 151 151 1 any 17800 38 29.36 1.29   p>0.05
Smailyte et al 2004 (men, incidence: asbestos cement factory) 151 151 1 any 1285 14  0.90 0.50 1.50 95
151 151 7 duration 
>10 yrs 1285 3  0.60 0.20 1.90 95
151 151 21 from 1st expo 
(>25 yrs) 1285 4  0.60    
Smailyte et al 2004 (women, incidence: asbestos cement factory) 151 151 1 any 602 4  1.20 0.40 3.20 95
Szeszenia-Dabrowska et al 2000 (men: asbestos cement factory) 151 151 1 any 2525 16 1.07 0.63 1.81
Szeszenia-Dabrowska et al 2002 (men compensated 
for asbestosis)
151 151 1
any 902 5  0.70 0.23 1.63 95
Tola et al 1988 (men, incidence: shipyard workers) 151 151 15 shipyard pipefitters 608 2 6.10 0.33 0.04 1.18 95
Zhu & Wang 1993 (men + women: asbestos factory) 151 151 1 any 5893 28  2.50   p<0.01
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Table 6. Ventilatory impairment in longitudinal studies of asbestos exposure cohorts
Reference Subjects Follow Up Average Exposure 
Duration / Amount
Prevalence 
Interstitial Changes
Prevalence
Pleural Changes
Summary of Lung Function Findings
Bader et al 1965 17 asbestos factory 
workers at baseline, 13 
followed over time
10 yr (Initial PFT 
1954-55, 1-3 studies 
over next 10 yr)
11.5 yr 100% N.R. VC fell significantly in 12 of 13; correlated with pulmonary compliance. In half, change not 
associated with worsening of CXR or symptoms. VC felt to be sensitive index of progression
Murphy et al 
1978
101 asbestos-exposed 
shipyard pipe-coverers. 
Also, 95 controls (ship-
fitters and pipefitters)
approx 6 yr (1965-66 
and 1972)
N.R. small opacities 
> 1/0: 31/77
 pipe-coverers
pleural thick-
ening 17/73 
pipe-coverers
Asbestos coverers: Baseline - FVC 101% predicted, FEV1/FVC 73.9%, DLCO 104% predicted; 
6 yr follow up - FVC 93% predicted, FEV1/FVC 71.4%, DLCO 96% predicted. 
Jones et al 1980 204 asbestos cement 
workers (145/204 
had both CXR & PFT 
followed)
3 yr (1973 and 1976) 21 yr; cum. exp. 289 
mppcf * yr
12% > 1/0 21% with any 
pleural thick-
ening
Over the 3 years, cumulative dust exposure was a significant predictor of decline in FEV1 and 
FVC and approached significance for TLC. Significantly larger declines in FEV1 and FVC were 
seen in those with progression of pleural thickening. Progression of irregular small opacities 
was associated with significantly greater decline in FEV1, FVC, and FEF25-75 (MMEF).
Becklake et al 
1982
1015 Quebec chrysotile 
asbestos miners and 
millers 
approx 8 yr (1967-68 
and 1974)
those with follow up 
PFT: 23.3 yr, cum. exp. 
343 mpcf*yr; those 
with follow up PFT & 
CXR: 13.9 yr, cum. exp. 
115 mpcf* yr
Follow up PFT: 
9.4% > 1/0; 
Follow up 
PFT & CXR: 4.2%
N.R. Level of asbestos exposure was significantly associated with progression of breathlessness. 
FVC and MMEF on follow up were treated as categorical variables with a change < 10% con-
sidered unchanged, 10%-20% doubtful change, and > 20% definite change. Age and smoking 
had significant impacts proportion of workers changing categories, but cumulative exposure 
history did not.
Siracusa et al 
1984
Workers in a plant that 
manufactured asbestos 
cement and polyvinyl 
chloride (PVC) starting 
in 1963. Asbestos use 
progressively decreased 
after 1974 and ended in 
1978.
7 yr - 65 asbestos 
workers and 30 PVC 
workers were studied 
in 1973 and again in 
1980 (76 asbestos 
workers and 51 PVC 
workers total in 1980)
mean duration of 
exposure/time since 
exposure 1980 group: 
asbestos low exposure - 
10.4 yr/15.7 yr, asbestos 
high exposure 10.6 
yr/14.9 yr (low and high 
based on working in 
mixing/grinding or not)
N.R. N.R. Observed yearly decline for entire asbestos exposed group: FVC 48 ml/yr, FEV1 49 ml/yr. 
Decline appeared to accelerate with time since first exposure:  < 15 yr: FVC 24.3 ml/yr, FEV1 
37.6 ml/yr;  > 15 yr FVC 52.5 ml/yr, FEV1 50.9 ml/yr. In evaluation of cross-sectional data 
from 1980, number of years since first asbestos exposure was signficantly associated with 
values for FVC and FEV1, and pack-yr smoking signfiicantly associated with FEV1 but not 
FVC. The effect of smoking and asbestos exposure on pulmonary function was reported as 
less than additive in this study.
Ohlson et al 
1985
75 Swedish former as-
bestos cement workers 
and a referent group of 
56 workers at nearby 
industrial plants without 
asbestos exposure
4 yr (1976 and 1980) inclusion criteria of at 
least 10 yr employment; 
median cumulative 
exposure 17.5 fiber-yr
0% 32% PP on follow 
up exam
Four-year decrements in FEV1 and FVC were greater in the exposed group than in referents.  
When evaluated by exposure terciles (< 14 fiber-years, 15-22 fiber-years, > 23 fiber-years), 
the linear trend for FEV1 decline was statistically significant (-4.56, -8.2, and -8.7%, respec-
tively). The linear trend for FVC nearly achieved significance (-4.5, -7.3, and -8.2%, respec-
tively). Multivariate analysis of variance showed cumulative asbestos exposure and smoking 
to be independent risk factors for lung function decline. Presence of pleural plaques (PP) 
was not a risk factor.
Siracusa et al 
1988
Workers in a plant that 
manufactured asbestos 
cement and polyvinyl 
chloride (PVC) starting 
in 1963. Asbestos use 
decreased and ended 
between 1974 and 
1978. Workers in a 
cement plant were also 
studied.
11 yr (1973, 1980, 
1984).  Workers stud-
ied at all times: 61 
exposed to asbestos 
(13 heavy based on 
history of working in 
mixing and grinding 
areas), 29 to PVC, 36 
to cement. 
Total dust, asbes-
tos cement working 
area, 1973: 10.9 mg/
m3 (geometric mean, 
6 samples). Mean 
employment duration, 
heavy exposure group, 
7.6 yr
N.R. N.R. Asbestos workers had faster declines in FEV1 and FVC than the other groups. Particularly for 
the heavy-exposure group, decline was not linear and accelerated over time. Lung function 
decline continued despite cessation of asbestos exposure. In models predicting decline of 
FEV1 and FVC over 20 years, both declined together. The effect of asbestos exposure and 
smoking on lung function decline was noted to be additive and, in this population, the im-
pact of smoking was felt to be minor relative to the impact of asbestos exposure.
Jones et al 1989 167 asbestos cement 
workers 
Mean of 9.75 yr 
(initial evaluation in 
1973)
Initial group of 244 
workers in 1973: du-
ration 21.3 yr, average 
exposure 12.8 mppcf
8% small opacities 
> 1/0 alone; 9% 
also had pleural 
abnormalities
15% pleural 
abnormalities 
alone; 9% also 
had small opac-
ities
In multivariate analyses, smoking history was significantly associated with lower baseline 
FEV1, MMEF, TLC and diffusing capacity, and with higher RV and TLC. Presence of small opac-
ities ILO classification 1/0 or greater was significantly associated at baseline with lower FVC, 
FEV1 and RV and higher diffusing capacity. Presence of pleural thickening or calcification 
was associated with lower FVC, FEV1, MMEF and RV. Average exposure was associated with 
lower FVC, FEV1, and MMEF. During follow up, rates of decline of FVC and FEV1 across the 
studied population were small at 17 ml/year and 20 ml/year, respectively. Although smoking 
and progression of pleural thickening or calcifications were significantly associated with 
worsening pulmonary function during follow up, presence of small opacities and exposure 
level were not.
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Table 6. Ventilatory impairment in longitudinal studies of asbestos exposure cohorts
Reference Subjects Follow Up Average Exposure 
Duration / Amount
Prevalence 
Interstitial Changes
Prevalence
Pleural Changes
Summary of Lung Function Findings
Bader et al 1965 17 asbestos factory 
workers at baseline, 13 
followed over time
10 yr (Initial PFT 
1954-55, 1-3 studies 
over next 10 yr)
11.5 yr 100% N.R. VC fell significantly in 12 of 13; correlated with pulmonary compliance. In half, change not 
associated with worsening of CXR or symptoms. VC felt to be sensitive index of progression
Murphy et al 
1978
101 asbestos-exposed 
shipyard pipe-coverers. 
Also, 95 controls (ship-
fitters and pipefitters)
approx 6 yr (1965-66 
and 1972)
N.R. small opacities 
> 1/0: 31/77
 pipe-coverers
pleural thick-
ening 17/73 
pipe-coverers
Asbestos coverers: Baseline - FVC 101% predicted, FEV1/FVC 73.9%, DLCO 104% predicted; 
6 yr follow up - FVC 93% predicted, FEV1/FVC 71.4%, DLCO 96% predicted. 
Jones et al 1980 204 asbestos cement 
workers (145/204 
had both CXR & PFT 
followed)
3 yr (1973 and 1976) 21 yr; cum. exp. 289 
mppcf * yr
12% > 1/0 21% with any 
pleural thick-
ening
Over the 3 years, cumulative dust exposure was a significant predictor of decline in FEV1 and 
FVC and approached significance for TLC. Significantly larger declines in FEV1 and FVC were 
seen in those with progression of pleural thickening. Progression of irregular small opacities 
was associated with significantly greater decline in FEV1, FVC, and FEF25-75 (MMEF).
Becklake et al 
1982
1015 Quebec chrysotile 
asbestos miners and 
millers 
approx 8 yr (1967-68 
and 1974)
those with follow up 
PFT: 23.3 yr, cum. exp. 
343 mpcf*yr; those 
with follow up PFT & 
CXR: 13.9 yr, cum. exp. 
115 mpcf* yr
Follow up PFT: 
9.4% > 1/0; 
Follow up 
PFT & CXR: 4.2%
N.R. Level of asbestos exposure was significantly associated with progression of breathlessness. 
FVC and MMEF on follow up were treated as categorical variables with a change < 10% con-
sidered unchanged, 10%-20% doubtful change, and > 20% definite change. Age and smoking 
had significant impacts proportion of workers changing categories, but cumulative exposure 
history did not.
Siracusa et al 
1984
Workers in a plant that 
manufactured asbestos 
cement and polyvinyl 
chloride (PVC) starting 
in 1963. Asbestos use 
progressively decreased 
after 1974 and ended in 
1978.
7 yr - 65 asbestos 
workers and 30 PVC 
workers were studied 
in 1973 and again in 
1980 (76 asbestos 
workers and 51 PVC 
workers total in 1980)
mean duration of 
exposure/time since 
exposure 1980 group: 
asbestos low exposure - 
10.4 yr/15.7 yr, asbestos 
high exposure 10.6 
yr/14.9 yr (low and high 
based on working in 
mixing/grinding or not)
N.R. N.R. Observed yearly decline for entire asbestos exposed group: FVC 48 ml/yr, FEV1 49 ml/yr. 
Decline appeared to accelerate with time since first exposure:  < 15 yr: FVC 24.3 ml/yr, FEV1 
37.6 ml/yr;  > 15 yr FVC 52.5 ml/yr, FEV1 50.9 ml/yr. In evaluation of cross-sectional data 
from 1980, number of years since first asbestos exposure was signficantly associated with 
values for FVC and FEV1, and pack-yr smoking signfiicantly associated with FEV1 but not 
FVC. The effect of smoking and asbestos exposure on pulmonary function was reported as 
less than additive in this study.
Ohlson et al 
1985
75 Swedish former as-
bestos cement workers 
and a referent group of 
56 workers at nearby 
industrial plants without 
asbestos exposure
4 yr (1976 and 1980) inclusion criteria of at 
least 10 yr employment; 
median cumulative 
exposure 17.5 fiber-yr
0% 32% PP on follow 
up exam
Four-year decrements in FEV1 and FVC were greater in the exposed group than in referents.  
When evaluated by exposure terciles (< 14 fiber-years, 15-22 fiber-years, > 23 fiber-years), 
the linear trend for FEV1 decline was statistically significant (-4.56, -8.2, and -8.7%, respec-
tively). The linear trend for FVC nearly achieved significance (-4.5, -7.3, and -8.2%, respec-
tively). Multivariate analysis of variance showed cumulative asbestos exposure and smoking 
to be independent risk factors for lung function decline. Presence of pleural plaques (PP) 
was not a risk factor.
Siracusa et al 
1988
Workers in a plant that 
manufactured asbestos 
cement and polyvinyl 
chloride (PVC) starting 
in 1963. Asbestos use 
decreased and ended 
between 1974 and 
1978. Workers in a 
cement plant were also 
studied.
11 yr (1973, 1980, 
1984).  Workers stud-
ied at all times: 61 
exposed to asbestos 
(13 heavy based on 
history of working in 
mixing and grinding 
areas), 29 to PVC, 36 
to cement. 
Total dust, asbes-
tos cement working 
area, 1973: 10.9 mg/
m3 (geometric mean, 
6 samples). Mean 
employment duration, 
heavy exposure group, 
7.6 yr
N.R. N.R. Asbestos workers had faster declines in FEV1 and FVC than the other groups. Particularly for 
the heavy-exposure group, decline was not linear and accelerated over time. Lung function 
decline continued despite cessation of asbestos exposure. In models predicting decline of 
FEV1 and FVC over 20 years, both declined together. The effect of asbestos exposure and 
smoking on lung function decline was noted to be additive and, in this population, the im-
pact of smoking was felt to be minor relative to the impact of asbestos exposure.
Jones et al 1989 167 asbestos cement 
workers 
Mean of 9.75 yr 
(initial evaluation in 
1973)
Initial group of 244 
workers in 1973: du-
ration 21.3 yr, average 
exposure 12.8 mppcf
8% small opacities 
> 1/0 alone; 9% 
also had pleural 
abnormalities
15% pleural 
abnormalities 
alone; 9% also 
had small opac-
ities
In multivariate analyses, smoking history was significantly associated with lower baseline 
FEV1, MMEF, TLC and diffusing capacity, and with higher RV and TLC. Presence of small opac-
ities ILO classification 1/0 or greater was significantly associated at baseline with lower FVC, 
FEV1 and RV and higher diffusing capacity. Presence of pleural thickening or calcification 
was associated with lower FVC, FEV1, MMEF and RV. Average exposure was associated with 
lower FVC, FEV1, and MMEF. During follow up, rates of decline of FVC and FEV1 across the 
studied population were small at 17 ml/year and 20 ml/year, respectively. Although smoking 
and progression of pleural thickening or calcifications were significantly associated with 
worsening pulmonary function during follow up, presence of small opacities and exposure 
level were not.
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Reference Subjects Follow Up Average Exposure 
Duration / Amount
Prevalence 
Interstitial Changes
Prevalence
Pleural Changes
Summary of Lung Function Findings
Rom et al 1992 96 heavily exposed U.S. 
white male insulators 
and boilermakers. 77 
had > 1 PFT (32 smokers 
and 45 ex-smokers)
Mean of 3 visits over 
a mean of 30 months 
for those with > 1 PFT 
mean 31 yr exposure 100% 
opacities 
graded > 1/0
Bilateral PP in 
49/96; DPT in 
23/96
Across all 77 individuals, mean decline in FVC: 92 ml/year, FEV1: 66 ml/year, and TLC: 14 ml/
year. Individuals with reduced lung function at their initial visit had markedly less decline in 
FEV1 and FVC. Nonsmokers had mean decline in FVC of -131 ml/year and FEV1 of -52 ml/
year. Ex-smokers had decline in FVC of -65 ml/year and FEV1 of -76 ml/year. In nonsmokers, 
TLC declined by -50 ml/year, while for ex-smokers it increased by 10 ml/year, consistent with 
a developing obstructive defect. Multivariate analysis showed cigarette smoking to be more 
strongly associated with decline in FEV1 than FVC. Radiographic irregular opacities and rales 
were associated with more rapid declines in FEV1, FVC, and TLC. Among those with pleural 
findings, DPT was associated with significantly lower values of FEV1, FVC, and TLC than PP.
Schwartz et al 
1994
115 asbestos-exposed 
workers identified in a 
survey of sheet metal 
workers or from the 
University of Iowa 
clinics
followed for an aver-
age of 2 yr
mean duration 31.7 
yr, mean yr since last 
exposure 10.5
HRCT chest: 27% 
IS changes alone, 
26% both IS changes 
and pleural fibrosis
HRCT chest: 7% 
pleural fibrosis 
alone, 26% both 
IS changes and 
pleural fibrosis
During follow up, average decline of 1.5% in TLC and 2.5% DLCO. Lower measures of TLC 
independently related to moderate to severe dyspnea, DPT, and higher concentrations of 
fibronectin in BAL. Lower measures of DLCO independently related to moderate to severe 
dyspnea , increased pack-years cigarette smoking , honeycombing on HRCT scan, and higher 
levels of inflammatory markers in BAL.
Nakadate 1995 242 middle aged work-
ers from two Japanese 
asbestos-product 
factories that produced 
calcium silicate boards 
and joint materials 
including asbestos
6 years of annual 
follow up
Exposure categorized 
as present in those who 
had worked for > 1 yr in 
areas where asbestos 
was processed and 
absent in others. 
> 1/0 and < 2/1: 
”negative exposure”
 group 109/199; 
”positive exposure” 
group 27/43
N.R. In multivariate analyses, pre-existing pneumoconiosis was significantly associated with more 
negative FEV1/height2 slope. A similar trend was noted for FVC/height2, but it was not 
significant. Smoking only affected FEV1/height2 slope.
Ostiguy et al 
1995
494 long term workers 
in a copper refinery 
with mixed exposures 
including asbestos; 
396 of these had been 
previously studied 
(evaluations in 1983-4 
and 1991)
7 years between eval-
uations. Most data 
presented in paper 
are for the cross-sec-
tional data from 1991
Mean time at plant for 
all 494 workers was 
20.6 yr. Mean time at 
plant for those at least 
50 years old was 28.5 yr
Chest radiograph: 
1/0 – 8 of 494 workers; 
1/1 or greater
 – 4 of workers 
Chest radio-
graph: pleural 
plaques 54 of 
494 workers. Of 
those at least 50 
years old, 44 of 
208 had pleural 
plaques
In the cross-sectional evaluation of all workers, circumscribed pleural plaques of low grade 
width or extent had no significant influence on FVC, FEV1, or MMEF. In a case-control lon-
gitudinal evaluation, the presence of these plaques was associated with a difference in loss 
of FVC in ml/yr reported to not achieve statistical significance (data shown as mean + SEM): 
pleural plaques present – 31 + 12 (54 workers); pleural plaques absent – 15 + 6 (247 workers)
Brodkin et al 
1996
446 asbestos-exposed 
men enrolled in Seattle 
Asbestos Lung Cancer 
Chemoprevention Trial
Mean follow-up of 
3.7 yr
N.R. 13% > 1/0 only; 23%  
both parenchymal 
and pleural 
abnormalities
28% pleural 
thickening > 
3mm bilaterally 
or 5mm unilat-
erally; 23% both 
parenchymal and 
pleural
Decline in entire group: FVC 49 ml/yr; FEV1 50 ml/yr; FEV1/FVC 0.4% loss in ratio/yr. Never 
smokers (n=71): FVC 54 ml/yr; FEV1 54 ml/yr; FEV1/FVC 0.4% loss in ratio/yr. Current smok-
ers (n=74): FVC 56 ml/yr; FEV1 68 ml/yr; FEV1/FVC 0.8% loss in ratio/yr. Development of a 
new respiratory symptom, or to a lesser extent persistence of symptoms during follow up, 
were associated with significantly greater ventilatory losses as compared with asymptomatic 
individuals. 
Yates et al 1996 64 men with asbes-
tos-related DPT recruit-
ed from the London 
Medical Boarding 
Centre for Respiratory 
Diseases
36 subjects had 
longitudinal PFT data 
over a mean period 
of 8.9 yr
Mean = 15 yr of asbes-
tos exposure
asbestosis was an 
exclusion criteria
100% with DPT; 
discrete PP with-
out DPT excluded
Restriction at baseline. In those with longitudinal PFTs, rate of decline in FEV1 (35 ml/year) 
and FVC (39 ml/year), but not FEV1/FVC percent, were significantly different from predicted. 
Rate of decline was more marked in smokers and ex-smokers than in nonsmokers.
Rui et al 2004 103 workers exposed 
to asbestos primarily 
in ship building and 
repairing
mean follow up of 
3.7 yr
mean duration asbestos 
exposure = 25 years
asbestosis was an 
exclusion criteria
36/103 had PP Multivariate analyses showed that a history of occupational exposure to asbestos exposure 
was significantly associated with predicted 10-year declines in FEV1 and FVC. Trends were 
also present for association with 10-year declines in FEV1/VC and TLC, but these did not 
attain statistical significance. There was no association between the presence of PP and 
decline in pulmonary function. 
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Rom et al 1992 96 heavily exposed U.S. 
white male insulators 
and boilermakers. 77 
had > 1 PFT (32 smokers 
and 45 ex-smokers)
Mean of 3 visits over 
a mean of 30 months 
for those with > 1 PFT 
mean 31 yr exposure 100% 
opacities 
graded > 1/0
Bilateral PP in 
49/96; DPT in 
23/96
Across all 77 individuals, mean decline in FVC: 92 ml/year, FEV1: 66 ml/year, and TLC: 14 ml/
year. Individuals with reduced lung function at their initial visit had markedly less decline in 
FEV1 and FVC. Nonsmokers had mean decline in FVC of -131 ml/year and FEV1 of -52 ml/
year. Ex-smokers had decline in FVC of -65 ml/year and FEV1 of -76 ml/year. In nonsmokers, 
TLC declined by -50 ml/year, while for ex-smokers it increased by 10 ml/year, consistent with 
a developing obstructive defect. Multivariate analysis showed cigarette smoking to be more 
strongly associated with decline in FEV1 than FVC. Radiographic irregular opacities and rales 
were associated with more rapid declines in FEV1, FVC, and TLC. Among those with pleural 
findings, DPT was associated with significantly lower values of FEV1, FVC, and TLC than PP.
Schwartz et al 
1994
115 asbestos-exposed 
workers identified in a 
survey of sheet metal 
workers or from the 
University of Iowa 
clinics
followed for an aver-
age of 2 yr
mean duration 31.7 
yr, mean yr since last 
exposure 10.5
HRCT chest: 27% 
IS changes alone, 
26% both IS changes 
and pleural fibrosis
HRCT chest: 7% 
pleural fibrosis 
alone, 26% both 
IS changes and 
pleural fibrosis
During follow up, average decline of 1.5% in TLC and 2.5% DLCO. Lower measures of TLC 
independently related to moderate to severe dyspnea, DPT, and higher concentrations of 
fibronectin in BAL. Lower measures of DLCO independently related to moderate to severe 
dyspnea , increased pack-years cigarette smoking , honeycombing on HRCT scan, and higher 
levels of inflammatory markers in BAL.
Nakadate 1995 242 middle aged work-
ers from two Japanese 
asbestos-product 
factories that produced 
calcium silicate boards 
and joint materials 
including asbestos
6 years of annual 
follow up
Exposure categorized 
as present in those who 
had worked for > 1 yr in 
areas where asbestos 
was processed and 
absent in others. 
> 1/0 and < 2/1: 
”negative exposure”
 group 109/199; 
”positive exposure” 
group 27/43
N.R. In multivariate analyses, pre-existing pneumoconiosis was significantly associated with more 
negative FEV1/height2 slope. A similar trend was noted for FVC/height2, but it was not 
significant. Smoking only affected FEV1/height2 slope.
Ostiguy et al 
1995
494 long term workers 
in a copper refinery 
with mixed exposures 
including asbestos; 
396 of these had been 
previously studied 
(evaluations in 1983-4 
and 1991)
7 years between eval-
uations. Most data 
presented in paper 
are for the cross-sec-
tional data from 1991
Mean time at plant for 
all 494 workers was 
20.6 yr. Mean time at 
plant for those at least 
50 years old was 28.5 yr
Chest radiograph: 
1/0 – 8 of 494 workers; 
1/1 or greater
 – 4 of workers 
Chest radio-
graph: pleural 
plaques 54 of 
494 workers. Of 
those at least 50 
years old, 44 of 
208 had pleural 
plaques
In the cross-sectional evaluation of all workers, circumscribed pleural plaques of low grade 
width or extent had no significant influence on FVC, FEV1, or MMEF. In a case-control lon-
gitudinal evaluation, the presence of these plaques was associated with a difference in loss 
of FVC in ml/yr reported to not achieve statistical significance (data shown as mean + SEM): 
pleural plaques present – 31 + 12 (54 workers); pleural plaques absent – 15 + 6 (247 workers)
Brodkin et al 
1996
446 asbestos-exposed 
men enrolled in Seattle 
Asbestos Lung Cancer 
Chemoprevention Trial
Mean follow-up of 
3.7 yr
N.R. 13% > 1/0 only; 23%  
both parenchymal 
and pleural 
abnormalities
28% pleural 
thickening > 
3mm bilaterally 
or 5mm unilat-
erally; 23% both 
parenchymal and 
pleural
Decline in entire group: FVC 49 ml/yr; FEV1 50 ml/yr; FEV1/FVC 0.4% loss in ratio/yr. Never 
smokers (n=71): FVC 54 ml/yr; FEV1 54 ml/yr; FEV1/FVC 0.4% loss in ratio/yr. Current smok-
ers (n=74): FVC 56 ml/yr; FEV1 68 ml/yr; FEV1/FVC 0.8% loss in ratio/yr. Development of a 
new respiratory symptom, or to a lesser extent persistence of symptoms during follow up, 
were associated with significantly greater ventilatory losses as compared with asymptomatic 
individuals. 
Yates et al 1996 64 men with asbes-
tos-related DPT recruit-
ed from the London 
Medical Boarding 
Centre for Respiratory 
Diseases
36 subjects had 
longitudinal PFT data 
over a mean period 
of 8.9 yr
Mean = 15 yr of asbes-
tos exposure
asbestosis was an 
exclusion criteria
100% with DPT; 
discrete PP with-
out DPT excluded
Restriction at baseline. In those with longitudinal PFTs, rate of decline in FEV1 (35 ml/year) 
and FVC (39 ml/year), but not FEV1/FVC percent, were significantly different from predicted. 
Rate of decline was more marked in smokers and ex-smokers than in nonsmokers.
Rui et al 2004 103 workers exposed 
to asbestos primarily 
in ship building and 
repairing
mean follow up of 
3.7 yr
mean duration asbestos 
exposure = 25 years
asbestosis was an 
exclusion criteria
36/103 had PP Multivariate analyses showed that a history of occupational exposure to asbestos exposure 
was significantly associated with predicted 10-year declines in FEV1 and FVC. Trends were 
also present for association with 10-year declines in FEV1/VC and TLC, but these did not 
attain statistical significance. There was no association between the presence of PP and 
decline in pulmonary function. 
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Alfonso et al 
2004
1392 former workers 
and residents of Wite-
noom, Australia 
819 workers fol-
lowed a mean of 3.3 
years, 573 residents 
followed a mean of 
5.7 years
Mean cumulative f/ml 
-year: residents - 6.9; 
workers - 24.7.  Mean yr 
since last asbestos ex-
posure: residents - 32.4 
yr; workers - 33.1 yr
Small opacities > 1/0: 
residents - 1.4%; 
workers - 17.6%
N.R. At baseline, cumulative dose of asbestos was associated on average with 0.9 ml lower FEV1 
per fiber/ml-year and over time with a 0.08 ml/year decline per fiber/ml-year.  Values for FVC 
were 1.5 ml and -0.1 ml/year respectively. In contrast, radiographic asbestosis was associ-
ated with an average 313 ml lower baseline FEV1 and -13 ml/year decline in FEV1 over time. 
Values for FVC were 381 ml and -20 ml/year, respectively. Cumulative asbestos exposure and 
radiographic asbestosis were not significantly associated with changes in FEV1/FVC percent 
at baseline or during follow up. Current smoking was associated with an average decrease 
in baseline FEV1 of 350 ml and decline over time of -13 ml/year. Respective values for FVC 
were -283 ml and -3.3 ml/year. Current smoking significantly decreased baseline FEV1/FVC 
percent and increased its decline over time. Ex-smoking status did not significantly affect 
baseline FEV1 or FVC or their decline over time, but did have a small statistically significant 
effect on FEV1/FVC percent. There was no significant interaction between asbestos expo-
sure and smoking on the baseline levels or rates of change of lung function.
Sichletidis et al 
2006
198 residents of North-
ern Greece with pleural 
plaques related to 
environmental asbestos 
exposure, particularly 
chrysotile and tremolite
23 subjects had lung 
function testing in 
1988-1990. 18 sur-
vivors had follow up 
testing in 2003.
Other studies evalu-
ating local exposures 
cited in paper. Regional 
prevalence of pleural 
plaques in people at 
least 40 years cited as 
5.2 – 39.6%. 
Chest radiographs: 
No interstitial disease 
found by 2 experienced 
physicians separately 
(ILO system not cited)
In 18 survivors, 
mean + SD 
plaque sur-
face area (cm2) 
increased: 1988: 
11.27 + 12.98; 
2003: 18.06 + 
15.71
In the overall cohort, out of 72 deaths, 11 were from malignant lung neoplasm and 4 from 
mesothelioma. In those with longitudinal lung function, mean % predicted values fell as 
follows: TLC: 95.65% to 76.48%; FVC: 94.74% to 80.12%; FEV1: 93.43% to 89.1%. FEV1/FVC 
percent increased from 79.84% to 84.95%. A significant linear relationship was found be-
tween expansion in plaque surface area and loss of TLC (r = -0.486, p = 0.041). It is concluded 
that the study shows evidence that, over the years, pleural plaques due to environmental 
asbestos expand and respiratory function deteriorates. 
Moshammer & 
Neuberger 2009
309 Austrian asbestos 
cement workers
Followed in screening 
program for a mean 
of 14.9 yr
Mean cumulative f/ml 
-year: 72.6; median - 
40.4
Irregular small 
opacities 112/301; 
rounded small 
opacities 111/301; l
arge opacities 3/301 
pleural thicken-
ing 34/301
Significant predictors of longitudinal FEV1 decline (in order of magnitude) were DPT, smok-
ing, presence of irregular small opacities, and > 70 fibers x years/cm3 cumulative asbestos 
exposure. Significant predictors of FVC decline (in order of magnitude) were DPT, presence 
of irregular small opacities, smoking, and > 70 fibers x years/cm3 cumulative asbestos expo-
sure.  This level of asbestos exposure was significantly related to maximum expiratory flow 
rate at 25% FVC, but not at 50% or 75% FVC. Reductions in all of these lung function values 
were significantly associated with mortality, so the authors recommended monitoring lung 
function as an indication of need for more intensive care.
Wang et al 2010 243 male workers of an 
asbestos plant in China 
that had produced 
asbestos textiles and 
asbestos building mate-
rials such as cement and 
tiles since the 1950s
174 workers were 
tested at least twice 
over 10 years (125 
had 5-year data and 
124 had 10-year data)
Personal samples 
exceeded 3 fibers/
ml during the years of 
operation. Mean expo-
sure duration 13.6 yr 
in those with baseline 
data and 21.6 yr in 
those with 10-yr data
27% at at baseline, 
no new cases during 
follow up
N.R. DLCO was the most rapidly declining measure in the population, with an annual decline of 
5% over 5 years after adjustment for age, height and smoking. Workers with asbestosis had 
more rapid declines. Workers with greater cumulative exposure also tended to have greater 
decline after adjustment for age, height, smoking and presence of asbestosis. The adjusted 
annual decline in FVC was 3% and FEV1 was 2.7% at 5 years, with slightly lower declines at 
10 years.  In a multivariate analysis, FVC and FEV1 fell more in those with heavier asbestos 
exposures (in the 3rd and 4th quartiles of cumulative exposure). This was only statistically 
significant for FVC in the 4th quartile of exposure. In this analysis, asbestosis was also associ-
ated with a markedly increased decline in FVC, but not FEV1.
Algranti et al 
2013
502 former asbestos 
cement workers with 
at least 2 spirometry 
tests performed 4 years 
apart
mean follow up of 9.1 
yr, mean # PFTs = 3.5
Mean duration of ex-
posure = 13.5 yr; used 
a semiquantititve index 
to evaluate cumulative 
exposure. Mean latency 
at study entry = 25.6 yr
8.6% at baseline, 
12.7% at last follow up
pleural thicken-
ing 33.9% at last 
follow up (based 
on HRCT)
FEV1 was significantly related to cumulative asbestos exposure at entry, pack-years of smok-
ing at entry and during follow-up, and the presence of asbestosis at follow-up. FVC level 
was significantly related to cumulative asbestos exposure and body mass index at entry, and 
smoking pack-years, asbestosis and pleural thickening at follow-up. Mean group rate of FEV1 
decline was -38 ml/year. Asbestos exposure was not associated with increasing rates of FEV1 
and FVC decline. Small but statistically significant differences were found in FEV1 regression 
slopes with age, estimated by terciles of cumulative exposure.  Heavy smokers in the heavi-
est asbestos exposure tercile had accelerated FEV1 decline when compared to nonsmokers 
in the lowest asbestos exposure tercile . The authors concluded that the impact of exposure 
on pulmonary function in these asbestos-cement workers was largely during the working 
period and that smoking and asbestos exposure were synergistic.
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Prevalence 
Interstitial Changes
Prevalence
Pleural Changes
Summary of Lung Function Findings
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1392 former workers 
and residents of Wite-
noom, Australia 
819 workers fol-
lowed a mean of 3.3 
years, 573 residents 
followed a mean of 
5.7 years
Mean cumulative f/ml 
-year: residents - 6.9; 
workers - 24.7.  Mean yr 
since last asbestos ex-
posure: residents - 32.4 
yr; workers - 33.1 yr
Small opacities > 1/0: 
residents - 1.4%; 
workers - 17.6%
N.R. At baseline, cumulative dose of asbestos was associated on average with 0.9 ml lower FEV1 
per fiber/ml-year and over time with a 0.08 ml/year decline per fiber/ml-year.  Values for FVC 
were 1.5 ml and -0.1 ml/year respectively. In contrast, radiographic asbestosis was associ-
ated with an average 313 ml lower baseline FEV1 and -13 ml/year decline in FEV1 over time. 
Values for FVC were 381 ml and -20 ml/year, respectively. Cumulative asbestos exposure and 
radiographic asbestosis were not significantly associated with changes in FEV1/FVC percent 
at baseline or during follow up. Current smoking was associated with an average decrease 
in baseline FEV1 of 350 ml and decline over time of -13 ml/year. Respective values for FVC 
were -283 ml and -3.3 ml/year. Current smoking significantly decreased baseline FEV1/FVC 
percent and increased its decline over time. Ex-smoking status did not significantly affect 
baseline FEV1 or FVC or their decline over time, but did have a small statistically significant 
effect on FEV1/FVC percent. There was no significant interaction between asbestos expo-
sure and smoking on the baseline levels or rates of change of lung function.
Sichletidis et al 
2006
198 residents of North-
ern Greece with pleural 
plaques related to 
environmental asbestos 
exposure, particularly 
chrysotile and tremolite
23 subjects had lung 
function testing in 
1988-1990. 18 sur-
vivors had follow up 
testing in 2003.
Other studies evalu-
ating local exposures 
cited in paper. Regional 
prevalence of pleural 
plaques in people at 
least 40 years cited as 
5.2 – 39.6%. 
Chest radiographs: 
No interstitial disease 
found by 2 experienced 
physicians separately 
(ILO system not cited)
In 18 survivors, 
mean + SD 
plaque sur-
face area (cm2) 
increased: 1988: 
11.27 + 12.98; 
2003: 18.06 + 
15.71
In the overall cohort, out of 72 deaths, 11 were from malignant lung neoplasm and 4 from 
mesothelioma. In those with longitudinal lung function, mean % predicted values fell as 
follows: TLC: 95.65% to 76.48%; FVC: 94.74% to 80.12%; FEV1: 93.43% to 89.1%. FEV1/FVC 
percent increased from 79.84% to 84.95%. A significant linear relationship was found be-
tween expansion in plaque surface area and loss of TLC (r = -0.486, p = 0.041). It is concluded 
that the study shows evidence that, over the years, pleural plaques due to environmental 
asbestos expand and respiratory function deteriorates. 
Moshammer & 
Neuberger 2009
309 Austrian asbestos 
cement workers
Followed in screening 
program for a mean 
of 14.9 yr
Mean cumulative f/ml 
-year: 72.6; median - 
40.4
Irregular small 
opacities 112/301; 
rounded small 
opacities 111/301; l
arge opacities 3/301 
pleural thicken-
ing 34/301
Significant predictors of longitudinal FEV1 decline (in order of magnitude) were DPT, smok-
ing, presence of irregular small opacities, and > 70 fibers x years/cm3 cumulative asbestos 
exposure. Significant predictors of FVC decline (in order of magnitude) were DPT, presence 
of irregular small opacities, smoking, and > 70 fibers x years/cm3 cumulative asbestos expo-
sure.  This level of asbestos exposure was significantly related to maximum expiratory flow 
rate at 25% FVC, but not at 50% or 75% FVC. Reductions in all of these lung function values 
were significantly associated with mortality, so the authors recommended monitoring lung 
function as an indication of need for more intensive care.
Wang et al 2010 243 male workers of an 
asbestos plant in China 
that had produced 
asbestos textiles and 
asbestos building mate-
rials such as cement and 
tiles since the 1950s
174 workers were 
tested at least twice 
over 10 years (125 
had 5-year data and 
124 had 10-year data)
Personal samples 
exceeded 3 fibers/
ml during the years of 
operation. Mean expo-
sure duration 13.6 yr 
in those with baseline 
data and 21.6 yr in 
those with 10-yr data
27% at at baseline, 
no new cases during 
follow up
N.R. DLCO was the most rapidly declining measure in the population, with an annual decline of 
5% over 5 years after adjustment for age, height and smoking. Workers with asbestosis had 
more rapid declines. Workers with greater cumulative exposure also tended to have greater 
decline after adjustment for age, height, smoking and presence of asbestosis. The adjusted 
annual decline in FVC was 3% and FEV1 was 2.7% at 5 years, with slightly lower declines at 
10 years.  In a multivariate analysis, FVC and FEV1 fell more in those with heavier asbestos 
exposures (in the 3rd and 4th quartiles of cumulative exposure). This was only statistically 
significant for FVC in the 4th quartile of exposure. In this analysis, asbestosis was also associ-
ated with a markedly increased decline in FVC, but not FEV1.
Algranti et al 
2013
502 former asbestos 
cement workers with 
at least 2 spirometry 
tests performed 4 years 
apart
mean follow up of 9.1 
yr, mean # PFTs = 3.5
Mean duration of ex-
posure = 13.5 yr; used 
a semiquantititve index 
to evaluate cumulative 
exposure. Mean latency 
at study entry = 25.6 yr
8.6% at baseline, 
12.7% at last follow up
pleural thicken-
ing 33.9% at last 
follow up (based 
on HRCT)
FEV1 was significantly related to cumulative asbestos exposure at entry, pack-years of smok-
ing at entry and during follow-up, and the presence of asbestosis at follow-up. FVC level 
was significantly related to cumulative asbestos exposure and body mass index at entry, and 
smoking pack-years, asbestosis and pleural thickening at follow-up. Mean group rate of FEV1 
decline was -38 ml/year. Asbestos exposure was not associated with increasing rates of FEV1 
and FVC decline. Small but statistically significant differences were found in FEV1 regression 
slopes with age, estimated by terciles of cumulative exposure.  Heavy smokers in the heavi-
est asbestos exposure tercile had accelerated FEV1 decline when compared to nonsmokers 
in the lowest asbestos exposure tercile . The authors concluded that the impact of exposure 
on pulmonary function in these asbestos-cement workers was largely during the working 
period and that smoking and asbestos exposure were synergistic.
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Introduction
Since the publication of the 1997 Helsinki criteria for diagnosis and attribution 
of asbestosis and asbestos-related cancers (1), there have been a number of ad-
vances in our understanding of the pathology of these disorders and the identi-
fication of biomarkers for asbestos-related diseases. 
The World Health Organization has included additional histological patterns in 
the major categories of lung cancer, and the classification of adenocarcinomas 
of the lung has undergone extensive revisions. In addition, there have been 
advancements in the classification of interstitial lung disorders from which as-
bestosis must be distinguished. A wide variety of immunohistochemical markers 
have been developed to assist in the characterization and diagnosis of malig-
nant mesothelioma and its distinction from other malignancies. Furthermore, 
the separation of benign mesothelial reactions from mesothelioma, which has 
implications for the early diagnosis of mesothelioma, has improved. There have 
also been advances with respect to the use of biomarkers and molecular stud-
ies for the early diagnosis of mesothelioma, which has the potential to improve 
the sensitivity and specificity of current imaging modalities. Finally, a number 
of molecular markers have been examined for their utility in identifying asbes-
tos-related lung cancers. It is the purpose of this study to review the advances 
that have been made in this area since the publication of the 1997 Helsinki 
document.  
Histological types of lung cancer associated with    
asbestos exposure
The World Health Organization (WHO) defines six major types of lung cancer: 
adenocarcinoma, squamous cell carcinoma, small cell carcinoma, large cell 
carcinoma, sarcomatoid carcinoma, and adenosquamous carcinoma. (2, 3) 
4
124
The histological classification of lung cancer, especially adenocarcinoma, has 
undergone substantial revision in recent years, in part driven by clinical studies 
showing remarkable responses among cancers with certain molecular profiles 
to specific chemotherapeutic agents. (4) Although histological classification 
may be most accurately applied to resection specimens with generous sam-
plings of tumor, guidelines have been published for the classification of lung 
cancers in small biopsy specimens. (5, 6)
In the author’s experience (VLR) of the 1051 lung cancer specimens for which 
smoking history was available, the distribution of the six histological types was 
as follows: adenocarcinoma – 39.4%; squamous cell carcinoma – 27.5%; small 
cell carcinoma – 12.4%; large cell carcinoma – 12.4%; sarcomatoid carcinoma 
– 6.2%; and adenosquamous carcinoma – 2.2%. Over 90% of these cancers 
occurred in smokers or ex-smokers, ranging from about 90% of adenocarcino-
mas, to 98% of squamous cell carcinomas, and 100% of small cell carcinomas. 
The histological types are described below in more detail.
Adenocarcinoma: The WHO recognizes several patterns of adenocarcinoma 
of the lung, including acinar, papillary, bronchioloalveolar cell carcinoma and 
solid variants with mucous production. (2, 3) More recent studies have indi-
cated that the micropapillary pattern should be considered a specific variant, 
as this pattern often implies a poor prognosis clinically. (4) Furthermore, the 
International Association for the Study of Lung Cancer, the American Thoracic 
Society and the European Respiratory Society have recommended that the 
term bronchioloalveolar cell carcinoma be dropped, because in the literature, 
this term has been applied to lung cancers with vastly different clinical behav-
iors and outcomes. (4) Most mucinous bronchiloalveolar cell carcinomas have 
been reclassified as invasive mucinous adenocarcinoma, since there is nearly 
always an invasive component in adequately sampled tumors. Some variants 
with nearly 100% five-year disease-free survival have also been recognized, in-
cluding adenocarcinoma in situ and minimally invasive adenocarcinoma. Most 
non-mucinous bronchioloalveolar cell carcinomas have been reclassified into 
one of these two categories. (4) Less common variants of pulmonary adenocar-
cinoma recognized by the WHO include fetal adenocarcinoma and colloid ad-
enocarcinoma. (2, 3) Pulmonary adenocarcinomas with enteric differentiation 
have also been recognized more recently. (4, 7)
Squamous cell carcinoma: The second most common of the histologic pat-
terns recognized by WHO, squamous cell carcinoma, is characterized by tumor 
growth as sheets or nests which demonstrate one or more of the following: 
keratin pearl formation, intercellular bridges, and individual cell keratinization. 
(2, 3) Basaloid carcinoma and lymphoepithelioma-like carcinoma are recog-
nized variants. Some cases may also occur with an endobronchial papillary 
growth pattern. One should use caution not to confuse apoptotic cells with 
hypereosinophilic cytoplasm, and pyknotic nuclei with individual cell keratini-
zation.
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Small cell carcinoma: This variant is considered a high grade neuroendocrine 
carcinoma, which is frequently widespread at the time of diagnosis, often 
manifested by bulky mediastinal lymph node metastases. Small cell carcinoma 
is characterized by cells with a high nuclear to cytoplasmic ratio, scant cyto-
plasm, and frequent nuclear molding. Mitotic figures are frequent and nucleoli 
inconspicuous. Chromatin is described as showing a salt and pepper distribu-
tion. Rosettes may be present and focal necrosis is a frequent finding. Crush 
artifact is often seen in small biopsy specimens. When a small cell carcinoma 
pattern is present in a tumor that also displays large cell, squamous or ade-
nocarcinoma differentiation, the tumor is referred to as combined small cell 
carcinoma. (2, 3)
Large cell carcinoma: With the advent of sensitive and specific immunohis-
tochemical markers for adenocarcinoma and squamous cell carcinoma, this 
category continues to shrink as a percentage of lung cancers in general. These 
tumors form sheets and nests of cells with large nuclei and typically prominent 
nucleoli; mitotic figures are usually readily identified. (2, 3) The term large cell 
carcinoma should probably only be used on resection specimens where the 
tumor is extensively sampled and no evidence of adeno- or squamous differ-
entiation is apparent. Recognized variants include large cell neuroendocrine 
carcinoma and rhabdoid phenotype. (3)
Sarcomatoid carcinoma: This category was newly proposed after the original 
1997 Helsinki document and includes variants that were previously included in 
the squamous, large cell or adenocarcinoma categories. (1, 3) Variants of sar-
comatoid carcinoma include pleomorphic carcinoma, spindle cell carcinoma, 
giant cell carcinoma, carcinosarcoma and pulmonary blastoma. These tumors 
typically include a spindle cell or mesenchymal element that may be confused 
with soft tissue sarcomas. Carcinomas including sarcomatoid, giant cell, ade-
nocarcinoma or squamous cell carcinoma mixtures are referred to as pleomor-
phic carcinoma. If the sarcomatoid component includes heterologous elements 
(osteosarcomatoid, chondrosarcomatoid or rhabdomyosarcomatoid differenti-
ation) the term carcinosarcoma is preferred. 
Adenosquamous carcinoma: Lung carcinomas that contain both adenocarcino-
ma and squamous cell carcinoma components are referred to as adenosqua-
mous carcinoma. Conventionally, at least 10% of each component should be 
present in the tumor. This diagnosis is difficult or impossible to make on small 
biopsy specimens and should be reserved for resection specimens. (5, 6)
One of the authors (VLR) has studied 76 primary lung cancers in patients with 
asbestosis as defined by the recent 2010 classification (8) who also underwent 
fiber analyses. (9) The distribution of histological types using the recent WHO 
classification is shown in Table 1. The distribution of histological types is 
similar for patients with asbestosis, pleural plaques without asbestosis, and 
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lung cancer patients with neither plaques nor asbestosis. Hence, the histolog-
ical type of a lung cancer has no value in either proving or disproving a rela-
tionship with asbestos. Any of the six major histological categories mentioned 
above may occur as a consequence of asbestos exposure.
Table 1. Histological Typing of Lung Cancer in 76 Cases of Asbestosis 
with Fiber Analysis
Histological Type Number Percentage
Adenocarcinoma 31 40.8
Squamous cell carcinoma 17 22.4
Small cell carcinoma* 12 15.8
Large cell carcinoma**  5   6.6
Sarcomatoid carcinoma  5   6.6
Adenosquamous carcinoma  6 7.9
TOTAL 76 100 
*Includes two combined small cell carcinomas (one squamous, one large cell)
**Includes one large cell neuroendocrine carcinoma
 
A number of far less common primary lung malignancies are recognized by 
WHO, including primary pulmonary sarcomas, lymphomas, salivary gland-like 
carcinomas, melanomas, intrapulmonary thymomas, teratomas, clear cell 
tumors, and carcinoid tumors. (2, 3) Clin et al. have reported that there is an 
association between pulmonary carcinoid tumors and asbestos exposure. (10) 
For the remaining tumors, there is no evidence that these primary pulmonary 
malignancies are asbestos related. The same is true for pulmonary blastoma, a 
rare variant of sarcomatoid carcinoma.
There is no major difference in the proportion of peripheral versus central 
cancers in patients who were exposed to asbestos in comparison to those who 
were not. Thus the central versus peripheral distribution of lung cancer among 
asbestos workers is similar to that of lung cancer patients with no background 
of asbestos exposure. (9, 11)
Some studies have recorded a predominance of lower lobe carcinomas among 
asbestos-exposed workers (12–20), whereas others have not. (9, 21–24) Never-
theless, the overlap is great enough that the lobar distribution is hardly suffi-
cient to assign attribution to asbestos exposure in an individual case. (11)
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Asbestosis: Histological criteria for diagnosis
Asbestos bodies are the hallmark of asbestos exposure. They are golden brown, 
beaded, segmented or dumbbell shaped structures that are formed when 
macrophages deposit an iron-rich protein and mucopolysaccharide coating on 
the surface of asbestos fibers that have been deposited in the lung parenchy-
ma. They may also be found in regional lymph nodes. This coating is typically 
deposited on fibers that are at least 20 microns in length. Other mineral fibers 
may also be coated with similar material to form non-asbestos ferruginous 
bodies or pseudoasbestos bodies. Many of these have black or broad yellow 
sheet silicate type cores so that they can be readily distinguished from true as-
bestos bodies at the light microscopic level. However, some such as erionite or 
refractory ceramic fibers, may have thin translucent cores similar to asbestos. 
These ferruginous bodies can only be distinguished from true asbestos bodies 
by analytical electron microscopic techniques. (25, 26)
Only a small percentage of asbestos fibers in the lungs become coated to form 
asbestos bodies. Nonetheless, there is a strong statistical correlation between 
asbestos bodies and amphibole fibers that are 5 µm or greater in length. Dif-
ferent amphibole asbestos types have a varying ability to form asbestos bodies 
probably due to their length distribution; e.g., the relation of asbestos bodies 
to asbestos fibers was significantly higher in the lung tissue of workers who 
were principally exposed to commercial anthophyllite, as compared to those 
who were exposed to crocidolite or amosite. (27) There is also individual vari-
ability with respect to the efficiency of the coating process. Finally, there is a 
poor correlation between asbestos body concentrations and chrysotile fibre 
burdens. (25)
Within the lung, asbestos bodies occur in both the interstitium and within the 
alveolar spaces. The latter are the likely source of asbestos bodies (and fibers) 
found in sputum or in bronchoalveolar lavage (BAL) specimens. There is a rea-
sonably good correlation between the concentrations of asbestos bodies in 
lung parenchyma as compared with sputum or BAL fluid. (25, 27)
When sensitive quantitative techniques are employed, asbestos bodies may 
be found in the lungs of most individuals from industrialized nations. Asbestos 
bodies may also be found in low levels in BAL fluid of some individuals from 
the general population. They are not observed in sputum samples from indi-
viduals in the general population. In the interpretation of quantitative asbestos 
analyses, it is important that laboratories determine an appropriate reference 
range. (25, 28) Furthermore, laboratories should employ techniques which en-
able the detection of the asbestos type or mixtures of fiber types that workers 
in their region have been exposed to. For example, if several asbestos fiber 
types with different coating efficiency have been used, fiber analyses using an-
alytical electron microscopy rather than the analysis of asbestos body counts 
may be necessary.
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Asbestos bodies, asbestos fibers and asbestosis
In 1982, the Asbestos Committee of the College of American Pathologists 
defined minimal histological criteria for a diagnosis of asbestosis as discrete 
foci of fibrosis in the walls of respiratory bronchioles in association with the 
accumulations of asbestos bodies in histological sections. In 1997, the Helsinki 
criteria took this one step further by requiring at least two asbestos bodies 
per cm2 of lung parenchyma. More recently, this approach was adopted by the 
Asbestosis Committee of the College of American Pathologists and Pulmonary 
Pathology Society. This latter group further determined that diffuse alveolar 
septal fibrosis should also be present before a diagnosis of asbestosis is ren-
dered histologically. In cases where the fibrosis is confined to the walls of bron-
chioles, the term ‘asbestos airways disease’ is preferred. These criteria apply to 
the histological diagnosis of asbestosis, irrespective of fiber type. (1, 8, 29) 
Studies have shown a good correlation between asbestos fiber concentra-
tions in lung parenchyma and the severity of interstitial fibrosis. Furthermore, 
regression studies show a threshold for fibrosis when fiber concentrations 
are compared to a reference population. The best correlation was with the 
concentration of commercial amphibole fibers that were 5 µm or greater in 
length. Similar observations were made for cases with asbestosis associated 
with non-commercial amphiboles, although the number of cases in this latter 
category was small. (25, 30)
By constructing 95% confidence intervals around the regression line for fibrosis 
and commercial amphibole concentration, Schneider et al. showed that there 
was almost no overlap between bona fide asbestosis cases and cases of diffuse 
interstitial lung disease that did not meet the histological criteria for asbesto-
sis, despite some asbestos exposure history. The vast majority of these cases 
were patients with lung samples, demonstrating a typical usual interstitial 
pneumonia (UIP) pattern with peripheral and lower lobe accentuation, hon-
eycomb changes, and readily identified fibroblast foci. It was concluded that 
a fiber analysis was not necessary in cases with a typical UIP pattern and no 
asbestos bodies upon careful examination of an iron-stained section. However, 
in cases with a UIP pattern in which pleural plaques are present and/or some 
asbestos bodies are present in histological sections (but fewer than 2 AB/cm2), 
a fiber analysis by an experienced laboratory is recommended. In such cases 
with a fiber burden compatible with asbestosis, then a diagnosis of asbestosis 
is likely. (30, 31)
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Biomarkers for the histopathological diagnosis of malignant 
mesothelioma
Mesothelioma diagnosis
Malignant mesothelioma is a cancer that may involve any of the serosal 
membranes, which include the pleura, peritoneum and pericardium.   
The most common location is the pleura. A variety of cancers may arise in  
or metastasize to the pleura, and thus be confused with mesothelioma.  
Furthermore, mesothelioma may assume any of a number of histological  
patterns with significant overlap with other malignancies that may involve 
the serosal membranes. Consequently, the diagnosis of mesothelioma can  
be challenging.
The World Health Organization recognizes four major histological patterns of 
malignant mesothelioma: epithelioid, sarcomatoid, desmoplastic and bipha-
sic. Less common variants of mesothelioma include well-differentiated papil-
lary mesothelioma, localized malignant mesothelioma, and adenomatoid tu-
mors of the pleura or peritoneum. (3) Because of the differential diagnostic 
considerations mentioned above, the diagnosis of malignant mesothelioma is 
best made with knowledge of the gross distribution of tumor, either from im-
aging studies or observations of the surgeon at the time of surgical sampling 
(or both). (32, 33) Even armed with this information, the diagnosis may be 
difficult for the pathologist, especially when dealing with small biopsy speci-
mens. Therefore, a variety of biomarkers have been developed to assist with 
the more common differential diagnostic considerations. (34)
General guidelines
There are no known markers with 100% specificity and sensitivity for me-
sothelioma, so a panel of antibodies is typically used to assist in diagnosing 
mesothelioma. It is recommended that at least two positive (mesothelial) 
and two negative (carcinomatous) markers be used for making a histopatho-
logical diagnosis of malignant mesothelioma. Because the usage of these 
markers has not yet been standardized, it is recommended that each labora-
tory performing immunohistochemical studies determine which positive and 
negative markers best fit its needs. It is further recommended that markers 
used should have at least 80% sensitivity and specificity. (34) Furthermore, 
different markers work best for pleural and peritoneal tumors.
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Mesothelial positive biomarkers
Several immunohistochemical markers have been reported with specificity 
for mesothelioma. These include calretinin, cytokeratins 5/6, WT-1, D2-40, 
thrombomodulin, HBME-1 and mesothelin. Calretinin has been recognized as a 
specific mesothelial marker for the longest duration (since 1996) and has stood 
the test of time. (3, 32‒35) Nuclear staining is the most specific, although in the 
typical case, both nuclear and cytoplasmic staining is observed. In one of the 
authors’ (VLR) the experience with over 200 cases of epithelial pleural or peri-
toneal mesotheliomas, calretinin was positive in 98% of cases, usually showing 
diffuse strong staining. As tumors become more poorly differentiated, the 
percentage of cases staining for the marker drops off. For example, in 84 cases 
of biphasic pleural or peritoneal mesotheliomas, calretinin was positive in 92%, 
and more cases were observed with weak or focal staining. Finally, in 36 cases 
of sarcomatoid mesothelioma, only 47% showed positive staining, which was 
usually focal.
Similar considerations apply to the other positive markers. Cytokeratins 5/6 
(cytoplasmic staining), WT-1 (nuclear staining) and D2-40 (membranous stain-
ing) stain a high percentage of epithelial mesotheliomas but do not stain the 
great majority of pulmonary adenocarcinomas. In the experience of one of the 
authors (VLR), these markers are positive in 89–92% of epithelial pleural or 
peritoneal mesotheliomas. For biphasic pleural mesotheliomas, the percentage 
of positive staining drops down to 78‒83%, and for biphasic peritoneal meso-
theliomas, 50‒75%. For sarcomatoid mesotheliomas, staining for cytokeratins 
5/6 and WT-1 is so infrequent that these markers are not useful in this setting. 
Interestingly, D2-40 stains a substantial proportion of sarcomatoid mesothelio-
mas (in our hands, 55% of cases).
The single most useful marker for sarcomatoid or desmoplastic mesotheliomas 
is broad spectrum staining for cytokeratins. Over 90% of sarcomatoid me-
sotheliomas are keratin positive, and the staining is diffuse and moderate to 
strong in the majority of cases. Most soft tissue sarcomas, on the other hand, 
stain negative for cytokeratins. It should be noted that staining for cytokeratins 
is not useful for distinguishing sarcomatoid mesothelioma from sarcomatoid 
carcinoma of the lung. (36) Although cytokeratins will stain both malignant and 
reactive mesothelial spindle cells (as for example in cases of fibrous pleurisy), 
such staining is still useful for highlighting the invasion of adipose tissue by ker-
atin positive spindle cells, a reliable marker for malignancy. (37, 38)
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Mesothelial negative biomarkers
Just as there are markers that stain mesotheliomas but not tumors with which 
it may be confused, there are markers that stain a variety of adenocarcinomas 
(with which mesothelioma is most likely to be confused) but not mesothelio-
mas. Some of these negative markers include carcinoembryonic antigen (CEA), 
CD15 (Leu M-1), BerEP4, B72.3, MOC-31, Bg8, and TTF-1. The markers chosen 
depend both upon the tumor site (pleural vs. peritoneal) and tumor morphol-
ogy. For pleural tumors, a useful negative pair of markers would include CEA 
and TTF-1, since a high percentage (greater than 90% in our hands) of pulmo-
nary adenocarcinomas (with which pleural epithelial mesotheliomas may be 
confused) stain positive with these two markers. In contrast, epithelial pleural 
mesotheliomas stain in only 10% of cases for CEA, typically with only focal pos-
itivity. Only 0.5% of pleural mesotheliomas show nuclear positivity for TTF-1 
(focal staining). 
For peritoneal tumors, pulmonary adenocarcinoma is less likely to be in the 
differential diagnosis, so a more useful pair of negative markers is BerEP4 and 
B72.3. Only 9% of peritoneal mesotheliomas stain for BerEP4 (typically with 
only focal positivity) and none stain for B72.3 (0%). Peritoneal mesotheliomas 
in women must be distinguished from serous papillary carcinomas of the peri-
toneum and ovary, and many of these tumors will stain positive for mesothelial 
markers. Therefore, it is recommended that for peritoneal malignancies in 
women, stains for estrogen (ER) and progesterone (PR) receptors be added to 
the panel, since these are positive in a substantial percentage of serous papil-
lary carcinomas, but only rarely so in mesotheliomas. (34)
Biomarkers in the distinction between malignant and reactive 
mesothelial cells
A variety of diseases and injuries to the serosal membranes may result in 
proliferation of mesothelial cells as a response to injury. In some cases, such 
proliferations may be florid and difficult to distinguish from mesothelioma. The 
positive and negative markers described above are of no use in this differential 
diagnosis, since both benign and malignant mesothelial cells stain for positive 
markers and neither stain for negative markers. 
A variety of biomarkers have been proposed to aid in the distinction between 
benign and malignant mesothelial cells. These include glucose transporter-1 
(GLUT-1), epithelial membrane antigen (EMA), p53, and desmin. Some studies 
have reported that mesotheliomas will stain positive for GLUT-1, EMA and p53, 
whereas reactive mesothelium tends to be negative for these markers. Simi-
larly, reactive mesothelium stains positive for desmin, whereas mesothelioma 
tends to be negative for this marker. Although a panel using these four markers 
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has been proposed, their specificity and sensitivity are not sufficient to incor-
porate them into routine practice at this time. (34) More recent studies have 
suggested that homozygous loss of P16/INK2A may be a reliable marker for the 
separation of benign and malignant mesothelial proliferations (see Ref. 34 and 
discussion below).
Biomarkers for screening and early diagnosis of malignant  
mesothelioma
Sensitive and specific biomarkers for malignant mesothelioma (MM) are ur-
gently needed for screening of asbestos-exposed workers in order to diagnose 
this aggressive tumor at an earlier stage when surgical resection combined 
with radiation and chemotherapy may be more effective in prolonging survival 
(39). Malignant mesothelioma in the general population is a rare disease (~1–2 
cases per million) and screening should be limited to high-risk populations 
with a history of exposure to asbestos fibers or erionite. Ideally, the screening 
procedure should be noninvasive, cost-effective, and beneficial for treating 
patients at an earlier stage of the disease. These benefits must outweigh 
the risks, expenses, and physical and psychological stress associated with 
false-positive tests and extensive follow-up to establish a definitive diagnosis 
(39, 40). 
This section will review the current rationale for screening for malignant meso-
thelioma, limitations of current imaging techniques, and the pleural fluid and 
serum biomarkers that have been evaluated for sensitivity and specificity in 
the early diagnosis of malignant mesothelioma.
Rationale for screening and early detection
In the 20th century, worldwide commercial production of asbestos reached a 
peak of greater than 5 million tons in 1975 and WHO estimates that 125 million 
workers are exposed to asbestos (41). Although commercial production of as-
bestos ended in Europe, Australia, South Africa, and the United States between 
1983 and 2002, asbestos production continues in Canada, Russia, Kazakhstan, 
Brazil, and China. Continued production and consumption of asbestos-contain-
ing products in developing countries including Russia, China, Brazil, India, and 
Thailand raises concern about the ongoing and future burden of asbestos-re-
lated diseases worldwide (42). 
In addition to occupational exposures, the presence of asbestos in homes, 
workplaces, and public buildings, as well as exposure to naturally-occurring 
asbestos fibers and persistent environmental contamination from abandoned 
mining sites contribute to ongoing residential and environmental exposures 
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(43‒45). Mortality associated with pleural malignant mesothelioma is estimat-
ed to be highest in Europe, Australia, and New Zealand, with increasing mortal-
ity predicted for Asia, South America, and Eastern and Southern Europe (46). 
Significant occupational, residential, and environmental exposure to asbestos 
fibers and erionite are strong risk factors for the development of malignant me-
sothelioma (41). Familial clusters of MM have been reported (reviewed in 47) al-
though some of these cases may be due to a shared exposure to asbestos fibers. 
Polymorphisms in DNA repair genes have been associated with malignant meso-
thelioma in residents of Casale Monferrato, an area of Italy with high asbestos 
exposure (48). Familial BAP1 mutations in the gene encoding BRCA1-associated 
protein 1 have been identified in two families predisposed to development of 
malignant mesothelioma, as well as in 2 of 26 patients with both uveal melano-
mas and malignant mesothelioma (49). A variety of genetic and chromosomal 
alterations have been identified in malignant mesothelioma, for example, dele-
tion in the CDKN2A tumor suppressor gene locus and mutations or deletions in 
the NF2 locus (50). 
Although these alterations are not unique to malignant mesothelioma, fluores-
cence in situ hybridization to detect homozygous deletion at the CDKN2A gene 
locus may be useful as an early diagnostic marker for malignant mesothelioma 
(50). No specific gene expression signature has been associated with asbestos 
exposure or malignant mesothelioma, and variability in gene expression profiles 
in individual cases or in limited case series is common due to differences in mi-
croarray platforms, instability of RNA extracted from patient samples, and con-
tamination of tumor samples with host tissue (51). Newer molecular techniques 
to investigate molecular alterations in malignant mesothelioma may provide 
more insight into the pathogenesis and progression of this rare tumor.
The natural history of malignant mesothelioma is characterized by a long latent 
period following asbestos exposure (usually 30–40 years) and diagnosis at ear-
ly, noninvasive stages is uncommon because the symptoms, including dyspnea, 
weight loss, and chest pain, are nonspecific (52). In a combined series of 3400 
patients, the median survival period was 6–12 months (33) because malignant 
mesothelioma is usually diagnosed at advanced stages when the tumor has 
already spread diffusely on the pleural surfaces and extension into the chest 
wall, mediastinum, and pericardium prevents complete surgical resection. 
In a series of 176 selected patients diagnosed at earlier stages and treated with 
extrapleural pneumonectomy followed by radiation and chemotherapy, sur-
vival rates were 38% after 2 years and 15% after 5 years (53). It is hoped that 
a sensitive and specific serum or pleural fluid biomarker will be identified to 
improve detection and treatment of malignant mesothelioma at early clinical 
stages.
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Limitations of imaging techniques for screening malignant  
pleural mesothelioma 
Asbestos exposure can lead to nonmalignant pleural lesions including pleural 
plaques, diffuse pleural fibrosis, rounded atelectasis, and benign asbestos 
pleurisy (54). These nonmalignant lesions can occur as early as 10 years after 
asbestos exposure, and bilateral pleural plaques are a marker of exposure to 
asbestos or erionite. These individuals are at an increased risk of developing 
asbestos-related malignancy, although not all individuals exposed to asbestos 
develop pleural plaques or other nonmalignant pleural lesions (reviewed in 55). 
Pleural effusion can be an initial manifestation of malignant mesothelioma; 
however, nonmalignant conditions including pneumonia, pulmonary embo-
lism, heart or renal failure, and other malignancies including lung cancer and 
metastatic carcinoma are the most common causes of fluid accumulation in 
the pleural space (55). Numerous noninvasive imaging techniques can detect 
pleural effusions as well as pleural lesions; however, there are advantages and 
disadvantages to each of these techniques for the early diagnosis of malignant 
mesothelioma (40, 56). Computed tomography (CT scanning) is more sensitive 
than chest radiography for the detection of pleural thickening and effusions; 
however, radiation exposure is a major concern for repeated screening of as-
bestos-exposed populations. The screening of asbestos-exposed workers in 
the United Kingdom using chest radiography was ineffective in screening for 
malignant mesothelioma (57). Low-dose CT scanning of asbestos workers in 
Europe and Canada was also ineffective in detecting early disease (58, 59). 
Although ultrasound examinations are highly sensitive in detecting pleural ef-
fusions and malignancies (60) they are not widely used. Positron-emission to-
mography (PET) combined with CT scanning is used in the staging of lung can-
cer; however, this is not useful as a screening tool for malignant mesothelioma 
because inflammatory lesions can produce false positive results (61). Magnetic 
resonance imaging (MRI) currently has limited spatial resolution and is subject 
to artifacts due to motion. Adverse reactions to contrast media limit its use for 
repeated screening (62). 
Novel optical imaging techniques are under development using biolumines-
cent, fluorescent, or multifunctional probes based on nanotechnology (63). 
These probes may provide safer, less expensive tools for non-invasive screen-
ing for malignant mesothelioma and diagnosis at earlier stages in asbestos-ex-
posed populations.
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Pleural fluid biomarkers for early diagnosis of malignant   
mesothelioma
The current algorithm proposed for the diagnosis of pleural effusion includes 
thoracentesis and examination of the pleural fluid in all patients except those 
with heart, liver, or chronic renal failure (64). Pleural fluid cytology is a simple 
screening tool for diagnosis of malignancy; unfortunately, in two large series of 
556 and 815 patients, the sensitivity of cytology for diagnosis of malignant me-
sothelioma was only 56–68% (56). 
Newer techniques in flow cytometry (65) and fluorescence in situ hybridization 
for detecting the deletion of the P16/INK2A gene locus in combination with cy-
tology (66–68) may improve sensitivity and specificity for the early diagnosis of 
malignant mesotheliomas using pleural fluids. However, not all cases of malig-
nant mesothelioma are accompanied by pleural effusions, and malignant cells 
in the sarcomatoid subtype are usually not exfoliated. The International Me-
sothelioma Interest Group recommends that cytologic diagnoses be confirmed 
histopathologically on tissue biopsy in conjunction with clinical and radiologic 
findings (34).  
Soluble biomarkers in pleural effusions have been evaluated for the early di-
agnosis of malignant mesothelioma. Several studies were conducted between 
1999 and 2007 that evaluated the effectiveness of pleural fluid biomarkers for 
the early diagnosis of malignant mesothelioma and discrimination from nonma-
lignant pleural effusions or metastatic pleural disease (reviewed by 39). These 
biomarkers included cytokeratin fragment 21-1, tissue polypeptide antigen (rep-
resenting fragments of cytokeratins), cell surface antigens (CA 15-3, CA 19-9), 
carcinoembryonic antigens (CEA), and hyaluronic acid. None of these biomark-
ers, applied to pleural fluid or serum, had sufficient sensitivity and specificity for 
the diagnosis of malignant mesothelioma. 
Gueugnon et al. (69) conducted microarray analysis in 101 patients with non-
malignant effusions, metastatic adenocarcinoma, or a recent histopathological 
diagnosis of malignant mesothelioma and identified an elevated expression of 
C-C motif chemokine (CCL2) and a reduced expression of galectin-3 as potential 
biomarkers. CCL2 or monocyte chemoattractant protein 1 is a protumorigenic 
chemokine and levels in pleural effusions from patients with three major sub-
types of malignant mesothelioma were significantly higher than levels in pa-
tients with metastatic adenocarcinoma or malignant pleural effusions. Howev-
er, at a sensitivity of 96%, the specificity of CCL2 was less than 50%. 
Galectin-3 is the gene product of LGALS3, a multifunctional protein involved in 
tumor invasion and metastases. Galectin-3 levels are significantly lower in pa-
tients with malignant mesothelioma in comparison with patients with metastat-
ic adenocarcinoma. At 100% sensitivity for this biomarker, specificity is 67%. 
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Blanquart et al. (70) recently reported improved diagnosis of malignant meso-
thelioma using a combination of CCL2, galectin-3, and soluble mesothelin-re-
lated peptides (SMRP) in discriminating between malignant mesothelioma pa-
tients and patients with metastatic adenocarcinoma or nonmalignant pleural 
effusions. In this series of 106 cases, only one sample was classified as false 
positive and six samples classified as false negative. 
A recent series of 275 patients with pleural effusions was evaluated using cy-
tology and SMRP levels to differentiate between malignant mesothelioma and 
nonmalignant effusions or pleural metastases. A combination of both pleural 
markers improved diagnosis of malignant mesothelioma (71). Future studies 
are needed to evaluate whether these pleural fluid markers can provide similar 
sensitivity and specificity for early diagnosis of malignant mesothelioma using 
serum samples.
Serum biomarkers for screening and early diagnosis of malignant 
mesothelioma
Since the most recent meeting of international experts on the advances in the 
screening of asbestos-related diseases held in 2000 (72), several serum bio-
markers have been evaluated as candidates for screening and early diagnosis of 
malignant mesothelioma (summarized in Table 2).  A recent review of serum and 
cytological markers for early, non-invasive diagnosis of malignant mesothelio-
ma concluded that soluble mesothelin-related protein (SMRP) has most widely 
been evaluated (73). However, these authors do not consider its diagnostic per-
formance to be adequate for early diagnosis. 
Mesothelin is expressed by normal mesothelial cells and only 50–60% of pa-
tients with the epithelioid subtype of malignant mesothelioma have elevated 
SMRP levels (74). The mesothelin gene promoter is methylated in normal pleural 
mesothelial cells, as well as in a subset of malignant mesotheliomas, which may 
account for the poor sensitivity of SMRP as a serum biomarker for malignant 
mesothelioma (75). In addition, mesothelin is also overexpressed in some ovar-
ian and pancreatic carcinomas (74). Longitudinal screening of asbestos-exposed 
individuals may be more useful than a single baseline assessment of SMRP level, 
although it has been noted that SMRP levels increase with age and in patients 
with diminished renal function (74, 76). Serum or plasma SMRP levels may be 
useful to detect disease recurrence following surgical resection of epithelioid 
malignant mesothelioma (77, 78).
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Table 2. Serum and plasma biomarkers for early diagnosis of malignant pleural mesothelioma
Biomarker Description Sensitivity/
specificity
Selected 
References
Soluble mesothe-
lin-related proteins 
(SMRP)
Soluble protein similar 
to mesothelin, a mem-
brane-anchored glycopro-
tein expressed on meso-
thelial cells
73/95%
lacks sensitivity for non-epithelial 
subtypes
89, 90
Megakaryocyte 
potentiating factor 
(MPF)
Cleaved from mesothelin 
anchored to cell surface
34/95%
lacks sensitivity for non-epithelial 
subtypes
74, 90, 91
Osteopontin Secreted glycoprotein 
involved in cell migration, 
cell-matrix interactions, 
and inflammation
need to use plasma, not 
serum
47/95.5%
lacks specificity for malignant 
mesothelioma
76–81, 90
Fibulin-3 extracellular glycoprotein 
encoded by epidermal 
growth factor – containing 
fibulin-like extracellular 
matrix protein 1 (EFEMP1) 
gene 
96.7/95.5% 
100/94.1% for stage I or II
82
MicroRNA’s plasma miR-625-3P 
peripheral blood cells 
miR-103
serum miR-126
not assessed
78–83/71–76%
80/60% - better correlation with 
mesothelioma in combination with 
SMRP
83, 92–94
Proteomics profiling 259 cases; 64 candidates
protein biomarkers includ-
ing markers of inflamma-
tion and cell proliferation
91/94%; 77% of stage I
superior to SMRP (68/88%) in this 
series
95
Megakaryocyte potentiating factor (MPF) is a cytokine derived from mesothelin 
and elevated serum levels are detected in 50–70% of patients with the epitheli-
oid subtype of malignant mesothelioma. Serum levels of MPF are also elevated 
in patients with other pleural or lung diseases, including lung cancer. This bio-
marker requires further validation in larger asbestos-exposed populations (78). 
Combining both SMRP and MRP did not improve diagnostic performance in a 
recent prospective study (74).
Osteopontin is an extracellular cell adhesion protein that also functions as a cy-
tokine and in promotion of tumor metastasis. Serum osteopontin levels are ele-
vated in asbestos-exposed patients with pleural plaques and pulmonary fibrosis 
with even higher levels in patients with malignant mesothelioma (79). 
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However, osteopontin is susceptible to cleavage by thrombin in serum and plas-
ma, and osteopontin levels are elevated in patients with chronic inflammation, 
nonmalignant pleural effusions, and lung, breast, ovarian, gastrointestinal, and 
prostate cancer (76, 80, 81).
Most recently, elevated levels of fibulin-3 were detected in plasma and pleural 
effusions in three patient cohorts with malignant mesothelioma (82). This new 
biomarker appears to have high sensitivity and specificity for detection of ma-
lignant mesothelioma at early stages (Table 2); however, this study must be val-
idated in prospective longitudinal studies and confirmed in asbestos-exposed 
individuals with nonmalignant pleural effusions.
Emerging biomarkers
Microarray profiling of microRNA (miRNA) expression in peripheral blood 
cells and proteomics-based screening of serum from asbestos-exposed and 
malignant mesothelioma patients have identified new potential biomarkers 
for the early diagnosis of malignant mesothelioma (Table 2). A circulating mi-
croRNA was also found to be elevated in the plasma of patients with malignant 
mesothelioma (83). Quantitation of microRNA levels in plasma and serum is 
technically challenging and is compromised by hemolysis (84). Additional inves-
tigation of these novel biomarkers in larger asbestos-exposed populations is 
required. 
Proteomic analysis of N-glycosylated proteins expressed on the surface of 
malignant mesothelial cells may identify additional novel protein biomarkers 
for malignant mesothelioma (85). A new electrochemical surface-imprinting 
method was recently developed as a substitute for ELISA assays using hyaluro-
nan-linked protein 1 (HAPLN1) as a model serum biomarker for malignant me-
sothelioma (86). HAPLN1 or cartilage link protein (CRTL1) is highly expressed in 
malignant mesothelioma and may be important in host-tumor interactions and 
in promoting tumor cell proliferation and invasion (87). This serum protein has 
potential for developing multifunctional diagnostic and therapeutic (theranos-
tic) probes based on biocompatible, biodegradable polymeric nanoparticles to 
enable highly sensitive imaging of early malignant mesothelioma, and targeted 
delivery of antitumorigenic drugs to treat these tumors at earlier stages (88).
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Markers of asbestos attribution in lung cancer
Development of techniques for rapid and simultaneous screening of alterations 
in tens of thousands of genes and proteins as regards expression levels, gene 
copy numbers and DNA sequence, as well as epigenetic changes, have made it 
possible to discover previously unknown asbestos-related molecular changes 
in cancer. The use of these techniques in research requires careful planning of 
the initial test settings as regards exposure assessment and standardization of 
all other patient characteristics, and subsequent epidemiological validation of 
the findings in a larger patient population. The sizes of study populations are 
restricted by the facts that suitable patient materials are not readily available, 
and all molecular techniques are still relatively time-consuming and expensive. 
The development of markers for clinical practice requires the validation and 
standardization of detection methods and the combination of different mark-
ers in molecular assays. Experimental studies using cell lines and animal data 
are necessary to give mechanistic and supporting information. 
The calculation of the sensitivity and specificity of a molecular assay for asbes-
tos relation is not so obvious, because it is not known which of the individual 
cancer cases are truly asbestos-related. Furthermore, determination of the 
dose-response requires that detailed exposure history and/or pulmonary as-
bestos body or fiber counts are available. The only means to evaluate a test is 
by comparison with the present criteria of attribution preferably in prospective 
international multicenter studies. However, when such a molecular assay has 
successfully passed all the study phases, it could remarkably enhance the rec-
ognition of asbestos-related lung cancer. In addition, it could possibly pick up 
some asbestos-related cancers which cannot be conventionally recognized, for 
example lung cancer in a smoker or non-smoker with low-level exposure, or 
exclude the asbestos effect in the lung cancer of a smoker. 
A number of molecular alterations in lung cancer have been associated with 
asbestos exposure. In the following, those markers are reviewed in detail with 
evidence of the specific asbestos effect in lung cancer and preferably at least 
preliminary information about sensitivity and specificity and dose-response 
in relation to asbestos exposure. Several investigators have found increased 
prevalence of TP53 and KRAS mutations as well as LOH at 3p14 and 3p21 in 
asbestos-exposed smokers, but it has not been possible to separate the effects 
of the two carcinogens (see Table 3 for references). In addition, some recently 
described alterations are not yet properly validated, such as asbestos-related 
changes in microRNA and gene expression, such as ADAM28 (96-98). 
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Table 3. Asbestos-related molecular alterations in lung cancer
Alteration Putative consequence or 
carcinogenic association
Type of study References
AI and loss at 
2p16
Lung cancer of asbestos-ex-
posed individuals
105
LOH at 3p14 FHIT exon loss Lung cancer of asbestos-ex-
posed individuals
115, 116 
LOH  at 3p21 Possible down-regulation 
of tumor suppressors
Lung cancer of asbestos-ex-
posed individuals
99, 117
LOH/homozy-
gous deletion at 
9p21.3 
Loss of P16/CDKN2A Lung cancer of asbestos-ex-
posed individuals
108, 109
CNA at 9q33.1 Loss of DBC1 Lung cancer of asbestos-ex-
posed individuals
111
AI and loss at 
19p13
Possible down-regulation 
of tumor suppressors, e.g. 
KEAP1
In vitro; lung cancer of as-
bestos-exposed individuals
100, 112
Polyploidy Aneuploidy and chromo-
somal instability
In vitro; lung cancer of as-
bestos-exposed individuals
111, 118
Up-regulation 
of TP53
Decreased  or abnormal 
tumor suppressor activity 
possibly due to mutations
In vitro; lung cancer of as-
bestos-exposed individuals 119, 120
Serum Ras (p21) Up-regulation due to 
mutations
Asbestos-exposed lung can-
cer patients.
121
KRAS Specific mutations Lung cancer of asbestos-ex-
posed individuals
122, 123
AI and loss at 2p16
The chromosomal region 2p21-p16.3 was originally described as one of the 18 
asbestos-related alterations in lung cancer, detected by genome wide gene 
copy number and gene expression profiling (99, 100). Furthermore, in an ex-
perimental study applying gene expression arrays on A549 and Beas-2B lung 
cell lines, treatment with crocidolite asbestos was shown to induce altered 
gene expression at 2p22 (101). Several other alterations of chromosome 2 have 
been detected in lung cancer, such as the amplification of the MYCN locus at 
2p24 (102, 103), and the fusion gene, EML4-ALK, resulting from inversion at 
2p21.1-p14 (104). No information is available on the possible association of 
these changes with asbestos exposure. 
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Kettunen et al. (105) studied the 2p22-2p16 region further in order to localize 
the specific asbestos-targeted core region and to assess the frequency of the 
alterations of this region among 205 lung cancers of asbestos-exposed and 
non-exposed individuals. They showed that low copy number loss and allelic 
imbalance (AI) at 2p16 in lung cancer were significantly associated with high 
pulmonary asbestos fiber counts (> 5 million/g dry-weight tissue, P=0.02 and 
P=0.003, respectively). Lost DNA at 2p16 was demonstrated by FISH in 22% of 
lung tumors of the highly exposed (> 5 million fibers/g d-w), in 17% of the ex-
posed (1– <5 million fibers/g d-w), and in 9% of the non-exposed cases. 
The association was seen in all histological lung cancer types, although quite 
small numbers of each type were studied. A subsequent study with a larger 
number of cases, determined the sensitivity and specificity of AI and loss at 
2p16 in the detection of the patients’ past asbestos exposure. The sensitivity of 
AI in the detection of moderate and high exposure was 50–69% and 56–75%, 
respectively, depending on the microsatellite marker (106). Loss at 2p16 was 
detected by FISH with a sensitivity of 8–10%. However, a specificity of 54–63% 
was obtained for AI, and 99% for loss at 2p16 determined by FISH (probe RP11-
703K23) (106). To conclude, loss at 2p16 in lung cancer is more specific than AI 
of the same region to the patients’ past asbestos exposure.  Because loss at 
2p16, determined by FISH, is a rare event in lung cancer, the sensitivity of this 
alteration for asbestos exposure is quite low, whereas the specificity is very 
high. 
Loss at 9p21.3/P16
The P16/CDKN2A tumor suppressor gene, located in the 9p21.3 region, may be 
silenced in lung cancer by promoter methylation and the point mutation of the 
gene, and by homozygous deletion or LOH (AI), in combination with another 
alteration at 9p21.3. Homozygous deletion at 9p21.3 is a frequent aberration in 
malignant mesothelioma, and it has been suggested as a marker of malignan-
cy in mesothelial proliferations, as well as a prognostic marker (see molecular 
markers of MM). 
In lung cancer, promoter hypermethylation of P16/CDKN2A associates strongly 
with tobacco smoking, whereas homozygous deletion has been shown to be 
more common in never smokers than in smokers and ex-smokers (107, 108). 
Point mutations have been detected solely in tobacco smokers (108). Kraunz 
et al. found a higher frequency of homozygous deletions in the asbestos-ex-
posed than in the non-exposed among 171 consecutive lung cancer cases with 
smoking and exposure information collected by questionnaires. However, the 
difference was not statistically significant. Andujar et al. (109) studied 75 lung 
cancer cases, with detailed information of smoking habits and asbestos expo-
sure (including pulmonary asbestos body counts), for the mechanisms of inac-
tivation of P16/CDKN2A. They demonstrated a higher incidence of homozygous 
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deletion and LOH in the asbestos-exposed than in the non-exposed after ad-
justment for age and cumulative tobacco consumption (P=0.0062). 
The lung cancers of the asbestos-exposed showed similar frequencies of ho-
mozygous deletion (50%) and methylation (24%) as malignant mesotheliomas 
(40% and 19%, respectively), while lung cancers of the non-exposed showed 
opposite frequencies (24% and 49%). To our knowledge, no attempts have 
been made to estimate the sensitivity and specificity of homozygous deletion 
and LOH (AI) at 9p21.3 for asbestos-related lung cancer. This could perhaps be 
achieved by combining of the data from several studies and adding the deter-
mination of asbestos exposure by using similar methods throughout, prefera-
bly quantitative pulmonary asbestos fiber or body counting.
Copy number alterations at 9q33.1
The differential gene copy numbers at 9q33.1-34.3 between asbestos-ex-
posed and non-exposed patients’ lung tumors were originally detected in a 
profiling study on two groups of lung cancer patients, exposed and non-ex-
posed, matched for age, gender, smoking, and distribution of histological 
cancer types (99). The 9q33.1 region harbors a tumor suppressor ‘deleted 
in bladder cancer 1’ (DBC1), which has been shown to be frequently silenced 
by homozygous deletion or methylation in non-small cell lung cancer (110). 
Aberrations at 9q have also been described in malignant mesothelioma, 
where losses have often been found to initiate at 9q33.1. This may indicate 
that this region contains a potential breakpoint hotspot for asbestos-induced 
DNA damage (106).
Nymark et al. (109) further studied allelic imbalance (AI) at 9q33.1-34.3 with 
15 microsatellite markers in 52 lung tumors and copy number alterations 
in this same region by FISH in 95 lung tumors from asbestos-exposed and 
non-exposed patients. Asbestos exposure was classified according to pul-
monary fiber counts into three groups: from 0 to 0.5 million, from 1 to 9.99 
million, and 10 million or more per gram dry-weight lung. AI at 9q33.1-q34.3 
was observed in 100% (17/17) of asbestos-exposed and in 64% (14/22) of 
non-exposed patients’ lung tumors and the most significant difference was 
found at 9q33.1 (P=0.002). Copy number alterations at 9q33.1 studied by 
FISH were also more frequent among the asbestos-exposed, and a dose-
response trend was observed (P=0.03). The association between 9q33.1 
alterations and asbestos exposure was observed for all main histological 
lung cancer types. However, losses were more common than gains in non-
small cell lung cancer, whereas losses and gains occurred equally in small 
cell lung cancer (111). This study, also found more frequent polyploidy in 
asbestos-exposed than in non-exposed patients’ lung tumors. 
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Nymark et al. (106) expanded the patient material in order to assess the 
specificity and sensitivity of 9q33.1 alterations as regards asbestos rela-
tion in lung cancer. The best microsatellite markers at this region detected 
asbestos exposure with a sensitivity of 60–63% and a specificity of 63%, 
whereas with a FISH probe RP11-440N22 a sensitivity of 28–35% and a 
specificity of 80% was reached.
Loss at 19p13
Of all genomic regions, loss at 19p13 in lung cancer associated most signifi-
cantly with asbestos exposure in the genome-wide gene copy number and 
expression profiling studies (99, 100). While allelic imbalance (AI) in this 
region correlated with asbestos exposure in other histological cancer types, 
except in adenocarcinomas, losses at 19p13 determined by FISH associated 
with asbestos in all histological cancer types (100, 112). The AI site in which 
the most significant asbestos-association was observed (D19S216) co-local-
izes with the border of minimal-deleted region at 19p13 in lung cancer (100, 
113), which suggests that this region contains a breakpoint hotspot possibly 
targeted by asbestos fibers (106).  Ruosaari et al. (112) showed, in vitro, 
using BEAS-2B cells, that crocidolite induced centromere-negative micronu-
clei that harbored chromosomal fragments, and furthermore, an increased 
frequency of rare 19p fragments was observed. The 19p13 region contains a 
tumor suppressor KEAP1, which is an important regulator of the redox-sen-
sitive NRF2 -mediated signaling pathway (114). 
Nymark et al. (106) further studied 118 lung tumors for losses and over 100 
tumor and normal tissues for AI at 9p13. They were able to detect asbestos 
exposure by AI at 9p13 with a sensitivity of 61–68%, depending on the mi-
crosatellite marker and exposure level, and with a specificity of 60–62%. By 
using FISH probe RP11-333F10, sensitivity was 22–24% and specificity 96%. 
The sensitivity with almost all markers tested at 19p13, 9q33.1, and 2p16 
was higher in the patient group with pulmonary fiber counts of five million or 
more as compared to the group with lower fiber counts, possibly indicating 
a smaller role of asbestos in the pathogenesis of lung cancer in those with 
lower exposure (106). When Nymark et al. (106) combined the results from 
the three regions, they found a clear dose-dependency between pulmonary 
fiber count and either AI or copy number alteration or both, in at least two 
of the three regions (P<0.001).  By combining FISH results from the three 
regions, a specificity of 100% was reached, whereas sensitivity remained 
low. AI from all regions gave a sensitivity of 74–76% and a specificity of 
89% (106).
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The asbestos epidemic is far from over. WHO estimates that over 107 000 
people die each year from asbestos-related lung cancer, mesothelioma and 
asbestosis resulting from exposure at work.
The first ‘Asbestos, asbestosis, and cancer´ expert meeting convened in 
Helsinki in 1997. Since then, a considerable amount of new knowledge 
regarding the diagnosis and screening of asbestos diseases has accumulated.  
The Finnish Institute of Occupational Health therefore decided to integrate 
this new data into the Helsinki Criteria. The Helsinki Criteria was updated with 
the help of international experts over a period of two years, culminating in 
a final meeting in Espoo, Finland, in February 2014. 
The Consensus Report: Asbestos, Asbestosis, and Cancer: Helsinki Criteria for 
Diagnosis and Attribution 2014 summarizes the current, up-to-date informa-
tion on the methods for managing and eliminating asbestos-related diseases. 
The newly updated Helsinki Criteria are recommended for use in programs 
and practices for the detection, diagnosis and attribution of asbestos-related 
diseases.
